<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00048568</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-102</org_study_id>
    <nct_id>NCT00048568</nct_id>
  </id_info>
  <brief_title>A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate</brief_title>
  <official_title>A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy With Methotrexate Versus Methotrexate Alone in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      Short Term: The purpose of this clinical research study is to learn if abatacept (BMS-188667)
      in combination with methotrexate is better than methotrexate alone in participants that have
      active rheumatoid arthritis and are not responding to methotrexate. The safety of this
      treatment will also be studied.

      Long Term Extension: The purpose of this amendment is to provide participants who have
      completed the initial 12-month double-blind treatment period the opportunity to receive open
      label treatment with active drug treatment until abatacept is approved in the local country
      or until clinical development has been discontinued.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of American College of Rheumatology 20 (ACR 20) Responders at Day 169</measure>
    <time_frame>Day 169</time_frame>
    <description>ACR 20 response requires a patient to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in Health Assessment Questionnaire (HAQ) score. A participant achieved a sustained ACR 20 response if the participant had ACR 20 observed for at least 2 consecutive study visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Achieving Clinically Meaningful Improvement in Health Assessment Questionnaire (HAQ) at Day 365</measure>
    <time_frame>Day 365</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline and Mean Change From Baseline (BL) in Radiographic Erosion Score Results at Day 365</measure>
    <time_frame>BL (Day 0), Day 365</time_frame>
    <description>To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions. The erosion score range is 0 (no radiographic damage) to 145 (worst possible radiographic damage). Change from baseline = Post-baseline - Baseline value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Deaths, Adverse Events (AEs) and SAEs in the Open-Label (OL) Period</measure>
    <time_frame>Day 365 to Day 2,185</time_frame>
    <description>AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE was defined as any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Hematology Values Meeting the Marked Abnormality Criteria in the OL Period</measure>
    <time_frame>Day 365 to Day 2,185</time_frame>
    <description>Marked abnormality criteria are: Hemoglobin (HGB): &gt;3 g/dL decrease from BL; Hematocrit: &lt;0.75 * BL; Erythrocytes: &lt;0.75 * BL; Platelets (PLT): &lt;0.67 * LLN/&gt;1.5 * ULN, or if BL &lt; LLN then use &lt;0.5 * BL and &lt;100,000 mm^3; Leukocytes: &lt;0.75 * LLN/ &gt;1.25 * ULN, or if BL&lt;LLN then use &lt;0.8 * BL or &gt;ULN, or if BL&gt;ULN then use &gt;1.2 * BL or &lt;LLN; neutrophils+bands: &lt;1.0 * 10^3 c/uL; eosinophils: &gt;0.750 * 10^3 c/uL; basophils: &gt; 400 mm^3; monocytes: &gt;2000 mm^3; lymphocytes: &lt;0.750 * 10^3 c/uL/ &gt;7.50 * 10^3 c/uL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria in the OL Period</measure>
    <time_frame>Day 365 to Day 2,185</time_frame>
    <description>Marked abnormality criteria are: Hemoglobin (HGB): &gt;3 g/dL decrease from BL; Hematocrit: &lt;0.75 * BL; Erythrocytes: &lt;0.75 * BL; Platelets (PLT): &lt;0.67 * LLN/&gt;1.5 * ULN, or if BL &lt; LLN then use &lt;0.5 * BL and &lt;100,000 mm^3; Leukocytes: &lt;0.75 * LLN/ &gt;1.25 * ULN, or if BL&lt;LLN then use &lt;0.8 * BL or &gt;ULN, or if BL&gt;ULN then use &gt;1.2 * BL or &lt;LLN; neutrophils+bands: &lt;1.0 * 10^3 c/uL; eosinophils: &gt;0.750 * 10^3 c/uL; basophils: &gt; 400 mm^3; monocytes: &gt;2000 mm^3; lymphocytes: &lt;0.750 * 10^3 c/uL/ &gt;7.50 * 10^3 c/uL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Electrolyte Values Meeting the Marked Abnormality Criteria in the OL Period</measure>
    <time_frame>Day 365 to Day 2,185</time_frame>
    <description>Sodium &lt; 0.9 * LLN or &gt; 1.05 * ULN or if BL &lt; LLN then use &lt; 0.95 * BL or &gt; ULN or if BL &gt; ULN then use &gt;1.05 *BL or &lt; LLN; Potassium: &lt; 0.9 * LLN or &gt; 1.1 * ULN or if BL &lt; LLN then use &lt; 0.9 * BL or &gt; ULN or if BL &gt; ULN then use 1.1 * BL or &lt; LLN; Chloride: &lt; 0.9 * LLN or &gt; 1.1 * ULN or if BL &lt; LLN then use &lt;0.9 * BL or &gt;ULN or if BL &gt; ULN then use &gt; 1.1 * BL or &lt; LLN; Calcium &lt;0.8 * LLN or &gt; 1.2 * ULN or if BL &lt; LLN then use &lt;0.67 * BL or &gt; ULN or if BL &gt; ULN then use &gt; 1.3 * BL or &lt; LLN.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Glucose, Protein, Metabolites, and Urinalysis Values Meeting the Marked Abnormality Criteria in the OL Period</measure>
    <time_frame>Day 365 to Day 2,185</time_frame>
    <description>Glucose: &lt; 65 mg/dL or &gt; 220 mg/dL; Fasting Glucose: &lt;0.8 * LLN or &gt; 1.5 * ULN or if BL &lt; LLN then use &lt; 0.8 * BL or &gt; ULN or if BL &gt; ULN then use 1.1 * BL or &lt; LLN; Total protein: &lt; 0.9 * LLN or 1.1 * ULN or if BL &lt; LLN then use 0.9 * BL or &gt; ULN or if BL &gt; ULN then use 1.1 * BL or &lt; LLN; Albumin: &lt; 0.9 * LLN or if BL &lt; LLN then use 0.75 * BL; Uric acid: &gt; 1.5 * ULN or if BL &gt; ULN then use &gt; 2.0 * BL. All urinalysis abnormalities were defined as: if missing BL then use &gt;= 2 or if value &gt;=4, or if BL = 0 or 0.5 then use &gt;= 2, or if BL = 1.0 then use &gt;= 3, or if BL = 2.0 then use &gt;=4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean BL Immunoglobulins Over Time in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093</time_frame>
    <description>Mean baseline values are those that are reported for each cohort at each time point on Day 365, Day 729, and Day 1,093.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From BL in Immunoglobulins in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Immunogenicity to Abatacept in the Cumulative DB + OL Period</measure>
    <time_frame>Day 1 to Day 1,821</time_frame>
    <description>Participants with titers to abatacept in the DB and OL periods. Serum samples from abatacept-treated adult participants with active Rheumatoid Arthritis (RA) were screened for the presence of drug-specific antibodies using two validated direct-format enzyme-linked immunosorbent assays (ELISAs) to determine the presence of antibodies to abatacept and or CTLA4-T.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing Clinically Significant Changes in Vital Signs in the OL Period</measure>
    <time_frame>Day 365 to Day 1,821. All changes in participant vital signs were monitored on each day of study drug administration prior to dosing and 60 minutes after dosing.</time_frame>
    <description>Vital signs included body temperature, heart rate, and seated blood pressure. Clinically significant changes were defined as those that were not within the normal range for the participant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing AEs of Special Interest in the OL Period</measure>
    <time_frame>Day 365 to Day 2,185</time_frame>
    <description>AEs were defined as any new untoward medical occurrence or worsening of a pre- existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest have been identified to be those which may be associated with the use of immunomodulatory agents or infusion of therapeutic proteins. Acute infusional AEs were defined as those that occurred within 1 hour after the start of the infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean BL Hematocrit in the OL Period</measure>
    <time_frame>Baseline (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
    <description>Mean baseline values are those that are reported for each cohort at each time point on Day 365 to Day 2,185.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From BL in Participant Hematocrit in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
    <description>All changes in participant laboratory parameters were monitored on each day of study drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean BL Platelet Count in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
    <description>Mean baseline values are those that are reported for each cohort at each time point on Day 365 to Day 2,185.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From BL in Participant Platelet Count in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
    <description>All changes in participant laboratory parameters were monitored on each day of study drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean BL Hemoglobin, Total Protein, and Albumin in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
    <description>Mean baseline values are those that are reported for each cohort at each time point on Day 365 to Day 2,185.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From BL in Hemoglobin, Total Protein, and Albumin in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
    <description>All changes in participant laboratory parameters were monitored on each day of study drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean BL White Blood Cells in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
    <description>Mean baseline values are those that are reported for each cohort at each time point on Day 365 to Day 2,185.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From BL in White Blood Cells in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
    <description>All changes in participant laboratory parameters were monitored on each day of study drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean BL Liver Function Parameters in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
    <description>Mean baseline values are those that are reported for each cohort at each time point on Day 365 to Day 2,185.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From BL in Liver Function Parameters in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
    <description>All changes in participant laboratory parameters were monitored on each day of study drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean BL Select Laboratory Parameters in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
    <description>Mean baseline values are those that are reported for each cohort at each time point on Day 365 to Day 2,185.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From BL in Select Laboratory Parameters in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
    <description>All changes in participant laboratory parameters were monitored on each day of study drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean BL Serum Electrolytes in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
    <description>Mean baseline values are those that are reported for each cohort at each time point on Day 365 to Day 2,185.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From BL in Serum Electrolytes in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
    <description>All changes in participant laboratory parameters were monitored on each day of study drug administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Tender Joints and Swollen Joints at DB BL</measure>
    <time_frame>BL (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean DB BL Participant Physical Pain Assessment, Participant Global Assessment, and Physician Global Assessment</measure>
    <time_frame>BL (Day 0)</time_frame>
    <description>Participant physical pain assessment was determined at baseline on the Visual Analog Scale (VAS) of 0 mm to 100 mm where 0mm is no pain and 100mm is worst pain possible. The mean participant global assessment is a measure of overall disease burden and is a component of the ACR and evaluated using the VAS 100 mm. The physician global assessment is a measure of overall disease burden and is a component of the ACR and evaluated using the VAS 0mm to 100 mm with 0mm indicating no disease burden and 100mm indicating worse disease burden possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BL Rheumatoid Factor (RF) Status for Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 365)</time_frame>
    <description>This analysis determined whether participants in the OL period were RF positive or RF negative based on serum samples. A positive value for RF was &gt; 20 IU/ml; a negative value for RF was ≤ 20 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR 20 Responders at Day 365</measure>
    <time_frame>Day 365</time_frame>
    <description>ACR 20 response requires a patient to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 20 response if the participant had ACR 20 observed for at least 2 consecutive study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR 20 Responders in the Double-Blind (DB) Period</measure>
    <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365</time_frame>
    <description>ACR 20 response requires a patient to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR 50 Responders at Day 169</measure>
    <time_frame>Day 169</time_frame>
    <description>ACR 50 response requires a patient to have a 50% reduction in the number of swollen and tender joints, and a reduction of 50% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 50 response if the participant had ACR 50 observed for at least 2 consecutive study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR 50 Responders at Day 365</measure>
    <time_frame>Day 365</time_frame>
    <description>ACR 50 response requires a patient to have a 50% reduction in the number of swollen and tender joints, and a reduction of 50% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR 50 Responders in the DB Period</measure>
    <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365</time_frame>
    <description>ACR 50 response requires a patient to have a 50% reduction in the number of swollen and tender joints, and a reduction of 50% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 50 response if the participant had ACR 50 observed for at least 2 consecutive study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR 70 Responders at Day 169</measure>
    <time_frame>Day 169</time_frame>
    <description>ACR 70 response requires a patient to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR 70 Responders at Day 365</measure>
    <time_frame>Day 365</time_frame>
    <description>ACR 70 response requires a patient to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR 70 Responders in the DB Period</measure>
    <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365</time_frame>
    <description>ACR 70 response requires a patient to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Major Clinical Response By Day 365</measure>
    <time_frame>Day 1 to Day 365. Data were collected monthly during the first 6 months and then every other month (with the exception of Day 337) during the second 6 months of the DB period.</time_frame>
    <description>A Major Clinical Response (MCR) is defined as maintenance of an ACR 70 response over a continuous 6-month period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL and Disease Activity Score 28 (DAS-28; Erythrocyte Sedimentation Rate [ESR]) at Day 169 and Day 365</measure>
    <time_frame>BL (Day 0), Day 169, Day 365, Day 169, Day 365</time_frame>
    <description>The DAS 28 is an assessment of disease activity measured on a visual analog scale (VAS)of 100 mm. The scale reports from 1 to 10, with increasing number indicating increasing extent of disease progression. Scores for disease activity are defined as high (&gt;5.1); low (≤3.2); remission (&lt;2.6). Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, Discontinuation Due to SAEs, AEs, Related AEs, or Discontinued Due to AEs in the DB Period</measure>
    <time_frame>Day 1 to Day 365</time_frame>
    <description>AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE was defined as any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean DB BL and Mean Change From BL in Joint Space Narrowing (JSN) and Total Score (TS)</measure>
    <time_frame>BL (Day 0), Day 365</time_frame>
    <description>To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and joint space narrowing (JSN). The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage. Change from baseline = Post-baseline - Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean DB BL Physical Component Summary of Health-Related Quality of Life (SF-36)</measure>
    <time_frame>BL (Day 0), Day 169, Day 365</time_frame>
    <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From BL in the Physical Component Summary of Health-Related Quality of Life (SF-36) in the DB Period</measure>
    <time_frame>BL (Day 0), Day 169, Day 365</time_frame>
    <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants in the DB Period Achieving an Extended Major Clinical Response</measure>
    <time_frame>Day 1 to Day 365</time_frame>
    <description>An extended major clinical response (MCR) was defined as a continuous ACR 70 response over any nine month treatment period with study medications. ACR 70 response criteria requires a patient to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL DAS-28 C-Reactive Protein (CRP) and ESR in the DB Period</measure>
    <time_frame>BL (Day 0), Day 169, Day 365</time_frame>
    <description>The mean baseline CRP and ESR in the DB period on Day 169 and Day 365 was evaluated for all treated participants. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From BL in DAS-28 CRP and ESR in the DB Period</measure>
    <time_frame>BL (Day 0), Day 169, Day 365</time_frame>
    <description>The mean change from baseline in CRP and ESR in the DB period was evaluated for all treated participants. Adjustment based on ANCOVA model with treatment as factor and baseline value as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL Soluble Interleukin-2 Receptors (sIL2-r) in the DB Period</measure>
    <time_frame>BL (Day 0), Day 169, Day 365</time_frame>
    <description>The mean baseline sIL2-r in the DB period was evaluated from serum samples for all treated participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in Soluble Interleukin-2 Receptors (sIL2-r) in the DB Period</measure>
    <time_frame>BL (Day 0), Day 169, Day 365</time_frame>
    <description>The mean change from baseline in sIL2-r in the DB period was evaluated for all treated participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR Core Component: Mean Number of Tender Joints at All Post-BL Visits in the DB Period</measure>
    <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365</time_frame>
    <description>Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR Core Component: Mean Number of Swollen Joints at All Post-BL Visits in the DB Period</measure>
    <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365</time_frame>
    <description>The mean number of swollen joints in the DB period was evaluated based on the swollen joint core component of the ACR scoring system where increasing score indicates increasing level of severity. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR Core Component: Mean Participant Pain Assessment at All Post-BL Visits in the DB Period</measure>
    <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365</time_frame>
    <description>Participant self-reported pain assessment core component of the ACR scoring system where increasing score indicates increasing level of severity as indicated on a 100mm Visual Analog Scale (VAS) with 0mm representing no pain and 100mm representing the most pain possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR Core Component: Mean Participant Physical Function Assessment at All Post-BL Visits in the DB Period</measure>
    <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR Core Component: Mean Participant Global Assessment at All Post-BL Visits in the DB Period</measure>
    <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365</time_frame>
    <description>Participant self-reported global RA assessment core component of the ACR scoring system where increasing score indicates increasing level of severity as indicated on a 100mm Visual Analog Scale (VAS) with 0mm representing no pain and 100mm representing the most pain possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR Core Component: Mean Physician Global Assessment at All Post-BL Visits in the DB Period</measure>
    <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365</time_frame>
    <description>Physician global RA assessment core component of the ACR scoring system where increasing score indicates increasing level of severity as indicated on a 100mm Visual Analog Scale (VAS) with 0mm representing very good global RA assessment and 100mm representing very poor global RA assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR Core Component: Mean CRP at All Post-BL Visits in the DB Period</measure>
    <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365</time_frame>
    <description>CRP core component of the ACR scoring system was evaluated from serum samples in which increasing levels indicate increasing level of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Discontinuing in the DB Period</measure>
    <time_frame>Day 1 to Day 169, Day 170 to Day 365</time_frame>
    <description>Participants that discontinued treatment during the DB period for any reason were evaluated after 6 months and 1 year of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From BL in Joint Narrowing Score (JSN), Erosion Score (ES), and Total Score (TS) by Category in the DB Period</measure>
    <time_frame>BL (Day 0), Day 365</time_frame>
    <description>To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and joint space narrowing (JSN). The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage. Improvement=decreases from BL, stable=same as BL, worsening=increases from BL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Experiencing Clinically Significant Changes in Vital Signs in the DB Period</measure>
    <time_frame>Day 1 to Day 365</time_frame>
    <description>All changes in participant vital signs were monitored on each day of study drug administration prior to dosing and 60 minutes after dosing. Vital signs included body temperature, heart rate, and seated blood pressure. Clinical significance was defined as any change from baseline that resulted in a value outside the normal limits for the participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Experiencing AEs of Special Interest in the DB Period</measure>
    <time_frame>Day 1 to Day 365</time_frame>
    <description>AEs were defined as any new untoward medical occurrence or worsening of a pre- existing medical condition which does not necessarily have a causal relationship with this treatment. AEs were identified as those which may be associated with the use of immunomodulatory agents or infusion of therapeutic proteins. Acute infusional AEs were defined as those that occurred within 1 hour after the start of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL Individual Components of the HAQ DI at Day 169 and Day 365</measure>
    <time_frame>BL (Day 0), Day 169, Day 365</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From BL in Individual Components of the HAQ DI at Day 169</measure>
    <time_frame>Day 169</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From BL in Individual Components of the HAQ DI at Day 365</measure>
    <time_frame>Day 365</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Immunogenicity to Abatacept in the DB Period</measure>
    <time_frame>Day 1 to Day 365</time_frame>
    <description>Participants with titers to abatacept in the DB period. Serum samples from abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using two validated direct-format enzyme-linked immunosorbent assays (ELISAs) to determine the presence of antibodies to abatacept and/or CTLA4-T.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of New Tender Joints and Number of New Swollen Joints in the DB Period</measure>
    <time_frame>Day 169, Day 365</time_frame>
    <description>Tender joints and swollen joints are core components of the ACR 20, 50, and 70. The incidences of new tender joints and new swollen joints were evaluated in the DB period after 6 months and 1 year of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing a 100% Reduction in Tender Joints or 100% Reduction in Swollen Joints in the DB Period</measure>
    <time_frame>Day 169, Day 365</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hematology Laboratories Meeting Marked Abnormality Criteria in the DB Period</measure>
    <time_frame>Day 1 to Day 365</time_frame>
    <description>Marked abnormality criteria were: Hemoglobin (HGB): &gt;3 g/dL decrease from BL; Hematocrit: &lt;0.75 * BL; Erythrocytes: &lt;0.75 * BL; Platelets (PLT): &lt;0.67 * LLN/&gt;1.5 * ULN, or if BL &lt; LLN then use &lt;0.5 * BL and &lt;100,000 mm^3; Leukocytes: &lt;0.75 * LLN/ &gt;1.25 * ULN, or if BL&lt;LLN then use &lt;0.8 * BL or &gt;ULN, or if BL&gt;ULN then use &gt;1.2 * BL or &lt;LLN; neutrophils+bands: &lt;1.0 * 10^3 c/uL; eosinophils: &gt;0.750 * 10^3 c/uL; basophils: &gt; 400 mm^3; monocytes: &gt;2000 mm^3; lymphocytes: &lt;0.750 * 10^3 c/uL/ &gt;7.50 * 10^3 c/uL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Liver and Kidney Function Tests Meeting Marked Abnormality Criteria in the DB Period</measure>
    <time_frame>Day 1 to Day 365</time_frame>
    <description>Marked abnormality criteria were: Aspartate Aminotransferase (AST) &gt;3 * ULN or if BL &gt; ULN then use &gt;4 *BL; Alanine Aminotransferase (ALT) &gt;3 * ULN or if BL &gt; ULN then use &gt; 4 * BL; Creatinine &gt; 1.5 * BL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL ESR and CRP Levels in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>Mean baseline values are reported for each cohort at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in ESR in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>Serum samples were evaluated from study participants to determine the mean change from baseline in ESR values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant RF Seroconversion in the OL Period</measure>
    <time_frame>Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 2,185</time_frame>
    <description>This analysis determined participant RF status (positive or RF negative) based on serum samples at each specified timepoint. A positive value for RF was &gt; 20 IU/ml; a negative value for RF was ≤ 20 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ACR 20 Responders in the DB and OL Periods</measure>
    <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,083, Day 1,177, Day 1,261, Day 1,345, Day 1,497, Day 1,625, Day 1,821</time_frame>
    <description>ACR 20 response requires a patient to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, CRP or ESR, and degree of disability in HAQ score. A participant achieved a sustained ACR 20 response if the participant had ACR 20 observed for at least 2 consecutive study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ACR 50 Responders in the DB and OL Periods</measure>
    <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,083, Day 1,177, Day 1,261, Day 1,345, Day 1,497, Day 1,625, Day 1,821</time_frame>
    <description>ACR 50 response requires a patient to have a 50% reduction in the number of swollen and tender joints, and a reduction of 50% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, CRP or ESR, and degree of disability in HAQ score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ACR 70 Responders in the DB and OL Periods</measure>
    <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,083, Day 1,177, Day 1,261, Day 1,345, Day 1,497, Day 1,625, Day 1,821</time_frame>
    <description>ACR 70 response requires a patient to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, CRP or ESR, and degree of disability in HAQ score. A participant achieved a sustained ACR 70 response if the participant had ACR 70 observed for at least 2 consecutive study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Continuing in the OL Period With DAS-28 Remission or Low DAS-28 Activity Over Time</measure>
    <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,083, Day 1,177, Day 1,261, Day 1,345, Day 1,497, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>The DAS 28 is a continuous measure evaluating extent of disease activity in RA, and is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, erythrocyte sedimentation rate (ESR) and participant assessment of disease activity measure on a visual analog scale (VAS) of 100 mm. The scale reports from 1 to 10, with increasing number indicating increasing extent of disease progression. Scores for disease activity are defined as high (&gt; 5.1); low (≤ 3.2); remission (&lt; 2.6).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL DAS-28 CRP Over Time for Participants Continuing in the OL Period</measure>
    <time_frame>BL(Day 0), Day 15, Day 29,Day 57,Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,083, Day 1,177, Day 1,261, Day 1,345, Day 1,497, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in DAS-28 CRP Over Time for Participants Continuing in the OL Period</measure>
    <time_frame>BL(Day 0),Day 15,Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,083, Day 1,177, Day 1,261, Day 1,345, Day 1,497, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>Change from baseline in participant were calculated at all study visits in the DB and OL periods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL DAS-28 ESR Over Time in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,083, Day 1,177, Day 1,261, Day 1,345, Day 1,497, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>Mean baseline values are reported for each cohort at each time point. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in DAS-28 ESR Over Time in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,083, Day 1,177, Day 1,261, Day 1,345, Day 1,497, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>Change from baseline in participant serum values of ESR were calculated at all study visits in the OL period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving HAQ Response Over Time for Participants Continuing in the OL Period</measure>
    <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,083, Day 1,177, Day 1,261, Day 1,345, Day 1,497, Day 1,625, Day 1,821</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BL and Mean Change From BL in Radiographic Erosion, Joint Space Narrowing (JSN), and Total Scores (TS) in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821</time_frame>
    <description>Change from baseline in the Genant-modified Sharp erosion score, JSN, TS were evaluated for all participants at the end of the OL period. The total Genant-modified Sharp score (TS) ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145).Higher scores indicated more damage. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL Physical Component Summary of the SF-36 by Visit in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 14,57, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL by Visit in the Physical Component Summary of the SF-36 in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 14,57, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL Mental Component Summary of the SF-36 by Visit in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL by Visit in the Mental Component Summary of the SF-36 in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL Physical Function Component of the SF-36 by Visit in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL by Visit in the Physical Function Component of the SF-36 in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL Role-Physical Component of the SF-36 by Visit in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL by Visit in the Role-Physical Component of the SF-36 in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL Bodily Pain Component of the SF-36 by Visit in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL by Visit in the Bodily Pain Component of the SF-36 in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL General Health Component of the SF-36 by Visit in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL by Visit in the General Health Component of the SF-36 in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL Social Functioning Component of the SF-36 by Visit in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL by Visit in the Social Functioning Component of the SF-36 in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL Role-Emotional Component of the SF-36 by Visit in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL by Visit in the Role-Emotional Component of the SF-36 in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL Vitality Component of the SF-36 by Visit in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL by Visit in the Vitality Component of the SF-36 in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL Mental Health Component of the SF-36 by Visit in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL by Visit in the Mental Health Component of the SF-36 in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL Fatigue in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>Mean baseline values are reported for each cohort at each time point using the VAS 100 mm where 0= no fatigue to 100 = the worst fatigue imaginable. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in Fatigue in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>The mean change from baseline in fatigue was measured on the VAS 100 mm where 0= no fatigue to 100 = the worst fatigue imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL Sleep Quality in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>Mean baseline values are reported for each cohort at each time point using the Medical Outcomes Study Sleep scale (MOS-sleep [assesses the extent of sleep problems and measures six dimensions of sleep on a 12-item participant-reported measure]). An overall Sleep Problems Index (SPI) was generated as a summary measure of different types of sleep problems (sleep disturbance, sleep quantity, sleep adequacy, etc.). The score ranges from 0 to 100, with 0 = no problems with sleep and 100 = the most severe problems with sleep. The mean score of the SPI in a population with chronic conditions is 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in Sleep Quality in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
    <description>The mean change from baseline in sleep quality was assessed on the Medical Outcomes Study Sleep scale (MOS-sleep [assesses the extent of sleep problems and measures six dimensions of sleep on a 12-item participant-reported measure]). An overall Sleep Problems Index (SPI) was generated as a summary measure of different types of sleep problems (sleep disturbance, sleep quantity, sleep adequacy, etc.). The score ranges from 0 to 100, with 0 = no problems with sleep and 100 = the most severe problems with sleep. The mean score of the SPI in a population with chronic conditions is 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL Limitations on Activities of Daily Living in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457</time_frame>
    <description>Mean baseline values are reported for each cohort at each time point. Activity limitation was measured by the number of days in the past 30 days a participant was unable to perform usual activities due to RA. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in Limitations on Activities of Daily Living in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457</time_frame>
    <description>The mean change from baseline in limitations on activities of daily living in the OL period. Activity limitation was measured by the number of days in the past 30 days a participant was unable to perform usual activities due to RA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL Interleukin-6 (IL-6), SIL-2R, and Tumor Necrosis Alpha (TNF-Alpha) in the DB Period</measure>
    <time_frame>BL (Day 0), Day 169, Day 365</time_frame>
    <description>Mean baseline values are reported for each cohort at each time point. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in Interleukin-6 (IL-6), SIL-2R, and Tumor Necrosis Alpha (TNF-Alpha) in the DB Period</measure>
    <time_frame>BL (Day 0), Day 169, Day 365</time_frame>
    <description>The mean change from baseline in potential biomarkers of disease (IL-6, SIL-3R, and TNF-Alpha were determined for all participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in RF in the DB Period</measure>
    <time_frame>BL (Day 0), Day 169, Day 365</time_frame>
    <description>The mean change from baseline in participant rheumatoid factor was determined after 6 months and 1 year of treatment relative to baseline. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL E-Selectin, SICAM-1, and MMP3 in the DB Period</measure>
    <time_frame>BL (Day 0), Day 169, Day 365</time_frame>
    <description>Mean baseline values are reported for each cohort at each time point. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in E-Selectin, SICAM-1, and MMP3 in the DB Period</measure>
    <time_frame>BL (Day 0), Day 169, Day 365</time_frame>
    <description>The mean change from basline in particpant biomarkers of RA disease (E-Selectin, SICAM-1, and MMP3) after 6 months and 1 year of treatment, relative to baseline, were evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) for the Day 365 Cohort of Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 365 for Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 365</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) for the Day 449 Cohort of Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 449</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 449 for Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 449</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) for the Day 533 Cohort of Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 533</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 533 for Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 533</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 617 Cohort of Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 617</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 617 for Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 617</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 729 Cohort of Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 729</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 729 for Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 729</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 813 Cohort of Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 813</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 813 for Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 813</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 897 Cohort of Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 897</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 897 for Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 897</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 981 Cohort of Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 981</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 981 for Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 981</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 1,093 Cohort of Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 1,093</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 1,093 for Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 1,093</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 1,177 Cohort of Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 1,177</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 1,177 for Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 1,177</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 1,261 Cohort of Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 1,261</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 1,261 for Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 1,261</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 1,345 Cohort of Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 1,345</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 1,345 for Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 1,345</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 1,457 Cohort of Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 1,457</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 1,457 for Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 1,457</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 1,625 Cohort of Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 1,625</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 1,625 for Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 1,625</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 1,821 Cohort of Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 1,821</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 1,821 for Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 1,821</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 1,989 Cohort of Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 1,989</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 1,989 for Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 1,989</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 2,185 Cohort of Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 2,185</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 2,185 for Participants Continuing in the OL Period</measure>
    <time_frame>BL (Day 0), Day 2,185</time_frame>
    <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1250</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Abatacept + Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Short Term: Abatacept was dosed by weight with participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. Participants continued treatment with methotrexate (MTX) either orally or parenterally at a minimum dose of 15 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Short Term: Participants received a placebo solution intravenously and methotrexate at the dose employed prior to study enrollment and a minimum of 15 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abatacept + Methotrexate Open Label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open Label: Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <description>Intravenous (IV) Solution, - Weight Titered (500 mg &lt; 60 kg); (750 mg 60-100 kg), )1 gram &gt; 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 1 year</description>
    <arm_group_label>Abatacept + Methotrexate</arm_group_label>
    <arm_group_label>Abatacept + Methotrexate Open Label</arm_group_label>
    <other_name>BMS-188667</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Tablets, Oral, &gt;= 15 mg, weekly, 1 year</description>
    <arm_group_label>Abatacept + Methotrexate</arm_group_label>
    <arm_group_label>Placebo + Methotrexate</arm_group_label>
    <arm_group_label>Abatacept + Methotrexate Open Label</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 1 year</description>
    <arm_group_label>Placebo + Methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Rheumatoid Arthritis (RA) for greater than 1 year from the time of initial diagnosis
             of RA.

          -  Participants must have been taking methotrexate for at least 3 months with at least a
             weekly dose of 15 mg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sellersville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <results_reference>
    <citation>Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Li T, Ge Z, Becker JC, Westhovens R. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006 Jun 20;144(12):865-76.</citation>
    <PMID>16785475</PMID>
  </results_reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2002</study_first_submitted>
  <study_first_submitted_qc>November 12, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2002</study_first_posted>
  <results_first_submitted>March 28, 2011</results_first_submitted>
  <results_first_submitted_qc>October 26, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 5, 2011</results_first_posted>
  <last_update_submitted>October 26, 2011</last_update_submitted>
  <last_update_submitted_qc>October 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants in this evaluation were enrolled 116 sites worldwide: 31 sites in the United States; 32 sites in Europe, 13 sites in Canada; 4 sites in Australia; 7 sites in Argentina; 7 sites in Brazil; 7 sites in Mexico; 3 sites in Peru; 5 sites in South Africa; 3 sites in Taiwan; and 4 sites in Turkey.</recruitment_details>
      <pre_assignment_details>Of 1250 participants enrolled, 594 participants were not randomized (519 no longer met study criteria, 37 for unknown reasons, 33 withdrew consent, 3 lost to follow-up, 1 administrative reason by sponsor, and 1 adverse event). Four participants (2 per group) were randomized but never treated; 2 no longer met study criteria and 2 withdrew consent.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Abatacept (ABA) + Methotrexate (MTX) DB</title>
          <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of (10-30 mg/wk), although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
        </group>
        <group group_id="P2">
          <title>MTX + Placebo DB</title>
          <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of (10-30 mg/wk), although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo was administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
        </group>
        <group group_id="P3">
          <title>ABA + MTX [Open-label (OL)]</title>
          <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-Blind Period Days 1 to 169</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="433"/>
                <participants group_id="P2" count="219"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="401"/>
                <participants group_id="P2" count="174"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown Reasons</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Double-Blind Period Days 170 to 365</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="401"/>
                <participants group_id="P2" count="174"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="385"/>
                <participants group_id="P2" count="162"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor/Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Longer Met Study Criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-Label Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="539"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="379"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="160"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="49"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Longer Met Study Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Decision By Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown Reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ABA + MTX DB</title>
          <description>Abatacept was dosed by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of (10-30 mg/wk), although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
        </group>
        <group group_id="B2">
          <title>MTX + Placebo DB</title>
          <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of (10-30 mg/wk), although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo was administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="433"/>
            <count group_id="B2" value="219"/>
            <count group_id="B3" value="652"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.5" spread="12.9"/>
                    <measurement group_id="B2" value="50.4" spread="12.4"/>
                    <measurement group_id="B3" value="51.1" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="337"/>
                    <measurement group_id="B2" value="179"/>
                    <measurement group_id="B3" value="516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="379"/>
                    <measurement group_id="B2" value="193"/>
                    <measurement group_id="B3" value="572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Rheumatoid Arthritis (RA) Disease</title>
          <description>Number of participants with RA duration &lt;= 2 years, &gt; 2 years to &lt;= 5 years, &gt; 5 years to &lt;= 10 years, and &gt; 10 years as evaluated at baseline.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;= 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 2 years to &lt;= 5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 5 years to &lt;=10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of American College of Rheumatology 20 (ACR 20) Responders at Day 169</title>
        <description>ACR 20 response requires a patient to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in Health Assessment Questionnaire (HAQ) score. A participant achieved a sustained ACR 20 response if the participant had ACR 20 observed for at least 2 consecutive study visits.</description>
        <time_frame>Day 169</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of American College of Rheumatology 20 (ACR 20) Responders at Day 169</title>
          <description>ACR 20 response requires a patient to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in Health Assessment Questionnaire (HAQ) score. A participant achieved a sustained ACR 20 response if the participant had ACR 20 observed for at least 2 consecutive study visits.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The study had a 99% power to detect a difference of 20% in ACR 20 between the 2 groups at the 5% level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared, Corrected</method>
            <param_type>Estimated Difference</param_type>
            <param_value>28.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19.8</ci_lower_limit>
            <ci_upper_limit>36.7</ci_upper_limit>
            <estimate_desc>Estimated difference between ABA + MTX and MTX + PLA is the estimated difference between ABA+MTX and MTX + PLA in the proportion of participants achieving ACR 20 response.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Achieving Clinically Meaningful Improvement in Health Assessment Questionnaire (HAQ) at Day 365</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>Day 365</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Clinically Meaningful Improvement in Health Assessment Questionnaire (HAQ) at Day 365</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on the hierarchical testing procedure for the co-primary measures, the study had 98% power to detect 18% difference in HAQ response rate between the two arms at the 5% level.</p_value_desc>
            <method>Chi-squared, Corrected</method>
            <method_desc>This model includes treatment as the main factor and baseline value as a covariate.</method_desc>
            <param_type>Estimated Difference</param_type>
            <param_value>24.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.9</ci_lower_limit>
            <ci_upper_limit>32.9</ci_upper_limit>
            <estimate_desc>Estimated difference between ABA + MTX and MTX + PLA is the estimated difference between ABA+MTX and MTX + PLA in the proportion of participants achieving HAQ response at Day 365.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline and Mean Change From Baseline (BL) in Radiographic Erosion Score Results at Day 365</title>
        <description>To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions. The erosion score range is 0 (no radiographic damage) to 145 (worst possible radiographic damage). Change from baseline = Post-baseline - Baseline value</description>
        <time_frame>BL (Day 0), Day 365</time_frame>
        <population>All randomized and treated participants in the DB period with radiographic data available at baseline and Day 365. Due to the compliance issues of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline and Mean Change From Baseline (BL) in Radiographic Erosion Score Results at Day 365</title>
          <description>To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions. The erosion score range is 0 (no radiographic damage) to 145 (worst possible radiographic damage). Change from baseline = Post-baseline - Baseline value</description>
          <population>All randomized and treated participants in the DB period with radiographic data available at baseline and Day 365. Due to the compliance issues of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="391"/>
                <count group_id="O2" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.68" spread="18.07"/>
                    <measurement group_id="O2" value="21.83" spread="18.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Change From BL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="1.77" lower_limit="0.00" upper_limit="1.02"/>
                    <measurement group_id="O2" value="1.14" spread="2.81" lower_limit="0.00" upper_limit="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <method>Nonparametric ANCOVA</method>
            <method_desc>The rank of the change from baseline=dependent variable, treatment=the main factor, rank of baseline value as covariate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Tender Joints and Swollen Joints at DB BL</title>
        <time_frame>BL (Day 0)</time_frame>
        <population>All randomized and treated participants in the DB period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed by weight with participants weighing &lt; 60 kg received 500 mg, subjects weighing 60 kg to 100 kg received 750 mg, and subjects weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of (10-30 mg/wk), although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of (10-30 mg/wk), although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Tender Joints and Swollen Joints at DB BL</title>
          <population>All randomized and treated participants in the DB period.</population>
          <units>Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tender Joints</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" spread="13.2"/>
                    <measurement group_id="O2" value="32.3" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen Joints</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" spread="8.8"/>
                    <measurement group_id="O2" value="22.1" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean DB BL Participant Physical Pain Assessment, Participant Global Assessment, and Physician Global Assessment</title>
        <description>Participant physical pain assessment was determined at baseline on the Visual Analog Scale (VAS) of 0 mm to 100 mm where 0mm is no pain and 100mm is worst pain possible. The mean participant global assessment is a measure of overall disease burden and is a component of the ACR and evaluated using the VAS 100 mm. The physician global assessment is a measure of overall disease burden and is a component of the ACR and evaluated using the VAS 0mm to 100 mm with 0mm indicating no disease burden and 100mm indicating worse disease burden possible.</description>
        <time_frame>BL (Day 0)</time_frame>
        <population>All randomized and treated participants in the DB period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed by weight with participants weighing &lt; 60 kg received 500 mg, subjects weighing 60 kg to 100 kg received 750 mg, and subjects weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of (10-30 mg/wk), although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of (10-30 mg/wk), although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean DB BL Participant Physical Pain Assessment, Participant Global Assessment, and Physician Global Assessment</title>
          <description>Participant physical pain assessment was determined at baseline on the Visual Analog Scale (VAS) of 0 mm to 100 mm where 0mm is no pain and 100mm is worst pain possible. The mean participant global assessment is a measure of overall disease burden and is a component of the ACR and evaluated using the VAS 100 mm. The physician global assessment is a measure of overall disease burden and is a component of the ACR and evaluated using the VAS 0mm to 100 mm with 0mm indicating no disease burden and 100mm indicating worse disease burden possible.</description>
          <population>All randomized and treated participants in the DB period.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participant Physical Pain Assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3" spread="21.1"/>
                    <measurement group_id="O2" value="65.9" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant Global Assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7" spread="21.2"/>
                    <measurement group_id="O2" value="62.8" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physician Global Assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0" spread="16.0"/>
                    <measurement group_id="O2" value="67.4" spread="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BL Rheumatoid Factor (RF) Status for Participants Continuing in the OL Period</title>
        <description>This analysis determined whether participants in the OL period were RF positive or RF negative based on serum samples. A positive value for RF was &gt; 20 IU/ml; a negative value for RF was ≤ 20 IU/mL.</description>
        <time_frame>BL (Day 365)</time_frame>
        <population>All treated participants in the OL period (treatment groups represent treatment received in the DB period).</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>BL Rheumatoid Factor (RF) Status for Participants Continuing in the OL Period</title>
          <description>This analysis determined whether participants in the OL period were RF positive or RF negative based on serum samples. A positive value for RF was &gt; 20 IU/ml; a negative value for RF was ≤ 20 IU/mL.</description>
          <population>All treated participants in the OL period (treatment groups represent treatment received in the DB period).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RF Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RF Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="312"/>
                    <measurement group_id="O2" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR 20 Responders at Day 365</title>
        <description>ACR 20 response requires a patient to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 20 response if the participant had ACR 20 observed for at least 2 consecutive study visits.</description>
        <time_frame>Day 365</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR 20 Responders at Day 365</title>
          <description>ACR 20 response requires a patient to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 20 response if the participant had ACR 20 observed for at least 2 consecutive study visits.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared, Corrected</method>
            <param_type>Estimated Difference</param_type>
            <param_value>33.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>25.1</ci_lower_limit>
            <ci_upper_limit>41.7</ci_upper_limit>
            <estimate_desc>Estimated difference between ABA + MTX and MTX + PLA is the estimated difference between ABA+MTX and MTX + PLA in the proportion of participants achieving ACR 20 response at Day 365.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR 20 Responders in the Double-Blind (DB) Period</title>
        <description>ACR 20 response requires a patient to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score.</description>
        <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR 20 Responders in the Double-Blind (DB) Period</title>
          <description>ACR 20 response requires a patient to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="283"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 225</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="318"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 281</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="312"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR 50 Responders at Day 169</title>
        <description>ACR 50 response requires a patient to have a 50% reduction in the number of swollen and tender joints, and a reduction of 50% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 50 response if the participant had ACR 50 observed for at least 2 consecutive study visits.</description>
        <time_frame>Day 169</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR 50 Responders at Day 169</title>
          <description>ACR 50 response requires a patient to have a 50% reduction in the number of swollen and tender joints, and a reduction of 50% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 50 response if the participant had ACR 50 observed for at least 2 consecutive study visits.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared, Corrected</method>
            <param_type>Estimated Difference</param_type>
            <param_value>23.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.0</ci_lower_limit>
            <ci_upper_limit>31.1</ci_upper_limit>
            <estimate_desc>Estimated difference between ABA + MTX and MTX + PLA is the estimated difference between ABA+MTX and MTX + PLA in the proportion of participants achieving ACR 50 response at Day 169.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR 50 Responders at Day 365</title>
        <description>ACR 50 response requires a patient to have a 50% reduction in the number of swollen and tender joints, and a reduction of 50% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score.</description>
        <time_frame>Day 365</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR 50 Responders at Day 365</title>
          <description>ACR 50 response requires a patient to have a 50% reduction in the number of swollen and tender joints, and a reduction of 50% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared, Corrected</method>
            <param_type>Estimated Difference</param_type>
            <param_value>30.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21.8</ci_lower_limit>
            <ci_upper_limit>38.5</ci_upper_limit>
            <estimate_desc>Estimated difference between ABA + MTX and MTX + PLA is the estimated difference between ABA+MTX and MTX + PLA in the proportion of participants achieving ACR 50 response at Day 365.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR 50 Responders in the DB Period</title>
        <description>ACR 50 response requires a patient to have a 50% reduction in the number of swollen and tender joints, and a reduction of 50% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 50 response if the participant had ACR 50 observed for at least 2 consecutive study visits.</description>
        <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR 50 Responders in the DB Period</title>
          <description>ACR 50 response requires a patient to have a 50% reduction in the number of swollen and tender joints, and a reduction of 50% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 50 response if the participant had ACR 50 observed for at least 2 consecutive study visits.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 225</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 281</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR 70 Responders at Day 169</title>
        <description>ACR 70 response requires a patient to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score.</description>
        <time_frame>Day 169</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR 70 Responders at Day 169</title>
          <description>ACR 70 response requires a patient to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared, Corrected</method>
            <param_type>Estimated Difference</param_type>
            <param_value>13.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.0</ci_lower_limit>
            <ci_upper_limit>19.5</ci_upper_limit>
            <estimate_desc>Estimated difference between ABA + MTX and MTX + PLA is the estimated difference between ABA + MTX and MTX + PLA in the proportion of participants achieving ACR 70 response at Day 169.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR 70 Responders at Day 365</title>
        <description>ACR 70 response requires a patient to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score.</description>
        <time_frame>Day 365</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR 70 Responders at Day 365</title>
          <description>ACR 70 response requires a patient to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared, Corrected</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>22.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.6</ci_lower_limit>
            <ci_upper_limit>29.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR 70 Responders in the DB Period</title>
        <description>ACR 70 response requires a patient to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score.</description>
        <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR 70 Responders in the DB Period</title>
          <description>ACR 70 response requires a patient to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 225</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 281</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Major Clinical Response By Day 365</title>
        <description>A Major Clinical Response (MCR) is defined as maintenance of an ACR 70 response over a continuous 6-month period.</description>
        <time_frame>Day 1 to Day 365. Data were collected monthly during the first 6 months and then every other month (with the exception of Day 337) during the second 6 months of the DB period.</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Major Clinical Response By Day 365</title>
          <description>A Major Clinical Response (MCR) is defined as maintenance of an ACR 70 response over a continuous 6-month period.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared, Corrected</method>
            <param_type>Estimated Difference</param_type>
            <param_value>12.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.3</ci_lower_limit>
            <ci_upper_limit>17.2</ci_upper_limit>
            <estimate_desc>Estimated difference between ABA + MTX and MTX + PLA is the estimated difference between ABA+MTX and MTX + PLA in the proportion of participants achieving MCR.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL and Disease Activity Score 28 (DAS-28; Erythrocyte Sedimentation Rate [ESR]) at Day 169 and Day 365</title>
        <description>The DAS 28 is an assessment of disease activity measured on a visual analog scale (VAS)of 100 mm. The scale reports from 1 to 10, with increasing number indicating increasing extent of disease progression. Scores for disease activity are defined as high (&gt;5.1); low (≤3.2); remission (&lt;2.6). Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
        <time_frame>BL (Day 0), Day 169, Day 365, Day 169, Day 365</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last Observation Carried Forward (LOCF) analysis. N = participants analyzed and n = participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL and Disease Activity Score 28 (DAS-28; Erythrocyte Sedimentation Rate [ESR]) at Day 169 and Day 365</title>
          <description>The DAS 28 is an assessment of disease activity measured on a visual analog scale (VAS)of 100 mm. The scale reports from 1 to 10, with increasing number indicating increasing extent of disease progression. Scores for disease activity are defined as high (&gt;5.1); low (≤3.2); remission (&lt;2.6). Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last Observation Carried Forward (LOCF) analysis. N = participants analyzed and n = participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 169 Cohort (n=366, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.82" spread="0.87"/>
                    <measurement group_id="O2" value="6.84" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 169 Cohort (n=366, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.34" spread="1.38"/>
                    <measurement group_id="O2" value="5.50" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 365 Cohort (n=375, 183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.82" spread="0.87"/>
                    <measurement group_id="O2" value="6.83" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 365 Cohort (n=375, 183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.97" spread="1.40"/>
                    <measurement group_id="O2" value="5.36" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated Difference on Day 169</param_type>
            <param_value>-1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.38</ci_lower_limit>
            <ci_upper_limit>-0.91</ci_upper_limit>
            <estimate_desc>Estimated difference between ABA + MTX and MTX + PLA on Day 169.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Estimated Difference on Day 365</param_type>
            <param_value>-1.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.63</ci_lower_limit>
            <ci_upper_limit>-1.16</ci_upper_limit>
            <estimate_desc>Estimated difference between ABA + MTX and MTX + PLA on Day 365.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, Discontinuation Due to SAEs, AEs, Related AEs, or Discontinued Due to AEs in the DB Period</title>
        <description>AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE was defined as any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
        <time_frame>Day 1 to Day 365</time_frame>
        <population>All treated subjects in the DB period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, Discontinuation Due to SAEs, AEs, Related AEs, or Discontinued Due to AEs in the DB Period</title>
          <description>AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE was defined as any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
          <population>All treated subjects in the DB period.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuations Due to SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="378"/>
                    <measurement group_id="O2" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued Due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean DB BL and Mean Change From BL in Joint Space Narrowing (JSN) and Total Score (TS)</title>
        <description>To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and joint space narrowing (JSN). The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage. Change from baseline = Post-baseline - Baseline value.</description>
        <time_frame>BL (Day 0), Day 365</time_frame>
        <population>All randomized and treated participants in the DB period with radiographic data available at baseline and Day 365. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean DB BL and Mean Change From BL in Joint Space Narrowing (JSN) and Total Score (TS)</title>
          <description>To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and joint space narrowing (JSN). The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage. Change from baseline = Post-baseline - Baseline value.</description>
          <population>All randomized and treated participants in the DB period with radiographic data available at baseline and Day 365. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="391"/>
                <count group_id="O2" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Mean JSN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.79" spread="20.16"/>
                    <measurement group_id="O2" value="23.02" spread="20.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Change From Baseline JSN Day 365</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="1.54"/>
                    <measurement group_id="O2" value="1.18" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Mean TS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.47" spread="37.33"/>
                    <measurement group_id="O2" value="44.85" spread="37.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Change From Baseline TS Day 365</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" spread="2.94"/>
                    <measurement group_id="O2" value="2.32" spread="5.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean DB BL Physical Component Summary of Health-Related Quality of Life (SF-36)</title>
        <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
        <time_frame>BL (Day 0), Day 169, Day 365</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population.Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last Observation Carried Forward (LOCF) analysis. N = participants analyzed and n = participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean DB BL Physical Component Summary of Health-Related Quality of Life (SF-36)</title>
          <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population.Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last Observation Carried Forward (LOCF) analysis. N = participants analyzed and n = participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 169 Cohort (n= 416, 207)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.49" spread="7.18"/>
                    <measurement group_id="O2" value="30.61" spread="7.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 365 Cohort (n=417, 207)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.51" spread="7.17"/>
                    <measurement group_id="O2" value="30.62" spread="7.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From BL in the Physical Component Summary of Health-Related Quality of Life (SF-36) in the DB Period</title>
        <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
        <time_frame>BL (Day 0), Day 169, Day 365</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population.Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last Observation Carried Forward (LOCF) analysis. N = participants analyzed and n = participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From BL in the Physical Component Summary of Health-Related Quality of Life (SF-36) in the DB Period</title>
          <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population.Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last Observation Carried Forward (LOCF) analysis. N = participants analyzed and n = participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 169 (n=416, 207)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.82" spread="0.42"/>
                    <measurement group_id="O2" value="4.77" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 (n=417, 207)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.12" spread="0.43"/>
                    <measurement group_id="O2" value="4.97" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjustment based on ANCOVA model with treatment as factor and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted Mean Difference at Day 169</param_type>
            <param_value>4.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.64</ci_lower_limit>
            <ci_upper_limit>5.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adjustment based on ANCOVA model with treatment as factor and baseline value as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted Mean Difference at Day 365</param_type>
            <param_value>4.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.69</ci_lower_limit>
            <ci_upper_limit>5.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants in the DB Period Achieving an Extended Major Clinical Response</title>
        <description>An extended major clinical response (MCR) was defined as a continuous ACR 70 response over any nine month treatment period with study medications. ACR 70 response criteria requires a patient to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score.</description>
        <time_frame>Day 1 to Day 365</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants in the DB Period Achieving an Extended Major Clinical Response</title>
          <description>An extended major clinical response (MCR) was defined as a continuous ACR 70 response over any nine month treatment period with study medications. ACR 70 response criteria requires a patient to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Chi-squared, Corrected</method>
            <param_type>Estimated Difference</param_type>
            <param_value>5.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.4</ci_lower_limit>
            <ci_upper_limit>9.0</ci_upper_limit>
            <estimate_desc>Estimated difference between ABA + MTX and MTX + PLA is the estimated difference between ABA+MTX and MTX + PLA in the proportion of participants achieving extended MCR.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL DAS-28 C-Reactive Protein (CRP) and ESR in the DB Period</title>
        <description>The mean baseline CRP and ESR in the DB period on Day 169 and Day 365 was evaluated for all treated participants. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
        <time_frame>BL (Day 0), Day 169, Day 365</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population.Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last Observation Carried Forward (LOCF) analysis. N = participants analyzed and n = participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL DAS-28 C-Reactive Protein (CRP) and ESR in the DB Period</title>
          <description>The mean baseline CRP and ESR in the DB period on Day 169 and Day 365 was evaluated for all treated participants. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population.Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last Observation Carried Forward (LOCF) analysis. N = participants analyzed and n = participants with measurements for that time point.</population>
          <units>mg / mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) CRP for Day 169 Cohort (n=418, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.37" spread="0.83"/>
                    <measurement group_id="O2" value="6.36" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) ESR for Day 169 Cohort (n=418, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.82" spread="0.87"/>
                    <measurement group_id="O2" value="6.84" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) CRP for Day 365 Cohort (n=424, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.38" spread="0.83"/>
                    <measurement group_id="O2" value="6.35" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) ESR for Day 365 Cohort (n=424, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.82" spread="0.87"/>
                    <measurement group_id="O2" value="6.83" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From BL in DAS-28 CRP and ESR in the DB Period</title>
        <description>The mean change from baseline in CRP and ESR in the DB period was evaluated for all treated participants. Adjustment based on ANCOVA model with treatment as factor and baseline value as covariate.</description>
        <time_frame>BL (Day 0), Day 169, Day 365</time_frame>
        <population>Due to the closure of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From BL in DAS-28 CRP and ESR in the DB Period</title>
          <description>The mean change from baseline in CRP and ESR in the DB period was evaluated for all treated participants. Adjustment based on ANCOVA model with treatment as factor and baseline value as covariate.</description>
          <population>Due to the closure of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>mg / mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAS-28 CRP Day 169 (n=418, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.38" spread="0.06"/>
                    <measurement group_id="O2" value="-1.29" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS-28 ESR Day 169 (n=418, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.48" spread="0.07"/>
                    <measurement group_id="O2" value="-1.33" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS-28 CRP Day 365 (n=424, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.71" spread="0.06"/>
                    <measurement group_id="O2" value="-1.41" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS-28 ESR Day 365 (n=424, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.85" spread="0.07"/>
                    <measurement group_id="O2" value="-1.46" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL Soluble Interleukin-2 Receptors (sIL2-r) in the DB Period</title>
        <description>The mean baseline sIL2-r in the DB period was evaluated from serum samples for all treated participants.</description>
        <time_frame>BL (Day 0), Day 169, Day 365</time_frame>
        <population>All treated subjects in the DB period. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL Soluble Interleukin-2 Receptors (sIL2-r) in the DB Period</title>
          <description>The mean baseline sIL2-r in the DB period was evaluated from serum samples for all treated participants.</description>
          <population>All treated subjects in the DB period. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>mg / mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 169 (n=370, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1776.0" spread="946.5"/>
                    <measurement group_id="O2" value="1603.0" spread="933.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 (n=235, 106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1674.0" spread="835.1"/>
                    <measurement group_id="O2" value="1601.0" spread="1076.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in Soluble Interleukin-2 Receptors (sIL2-r) in the DB Period</title>
        <description>The mean change from baseline in sIL2-r in the DB period was evaluated for all treated participants.</description>
        <time_frame>BL (Day 0), Day 169, Day 365</time_frame>
        <population>All treated subjects in the DB period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in Soluble Interleukin-2 Receptors (sIL2-r) in the DB Period</title>
          <description>The mean change from baseline in sIL2-r in the DB period was evaluated for all treated participants.</description>
          <population>All treated subjects in the DB period.</population>
          <units>mg / mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 169 (n=370, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-519.00" spread="23.72"/>
                    <measurement group_id="O2" value="-85.50" spread="32.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 (n=235, 106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-562.00" spread="40.82"/>
                    <measurement group_id="O2" value="-290.00" spread="87.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR Core Component: Mean Number of Tender Joints at All Post-BL Visits in the DB Period</title>
        <description>Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
        <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last observation carried forward (LOCF) analysis. N = participants analyzed and n = participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR Core Component: Mean Number of Tender Joints at All Post-BL Visits in the DB Period</title>
          <description>Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last observation carried forward (LOCF) analysis. N = participants analyzed and n = participants with measurements for that time point.</population>
          <units>Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 15 Cohort (n=416, 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.19" spread="14.62"/>
                    <measurement group_id="O2" value="27.93" spread="14.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 29 Cohort (n=419, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.14" spread="14.69"/>
                    <measurement group_id="O2" value="24.11" spread="14.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 57 Cohort (n=421, 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.70" spread="14.06"/>
                    <measurement group_id="O2" value="21.41" spread="14.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 85 Cohort (n=417, 208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.84" spread="13.98"/>
                    <measurement group_id="O2" value="20.58" spread="15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 113 Cohort (n=415, 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.55" spread="13.35"/>
                    <measurement group_id="O2" value="19.83" spread="15.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 141 Cohort (n=420, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.59" spread="13.39"/>
                    <measurement group_id="O2" value="19.78" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 169 Cohort (n=420, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.69" spread="12.37"/>
                    <measurement group_id="O2" value="18.70" spread="15.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 225 Cohort (n=419, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.42" spread="12.04"/>
                    <measurement group_id="O2" value="18.22" spread="15.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 281Cohort (n=419, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.92" spread="11.37"/>
                    <measurement group_id="O2" value="17.10" spread="16.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 365 Cohort (n=424, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.96" spread="11.87"/>
                    <measurement group_id="O2" value="18.31" spread="15.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR Core Component: Mean Number of Swollen Joints at All Post-BL Visits in the DB Period</title>
        <description>The mean number of swollen joints in the DB period was evaluated based on the swollen joint core component of the ACR scoring system where increasing score indicates increasing level of severity. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
        <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last observation carried forward (LOCF) analysis. N = participants analyzed and n = participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR Core Component: Mean Number of Swollen Joints at All Post-BL Visits in the DB Period</title>
          <description>The mean number of swollen joints in the DB period was evaluated based on the swollen joint core component of the ACR scoring system where increasing score indicates increasing level of severity. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last observation carried forward (LOCF) analysis. N = participants analyzed and n = participants with measurements for that time point.</population>
          <units>joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 15 Cohort (n=416, 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.40" spread="8.63"/>
                    <measurement group_id="O2" value="18.49" spread="9.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 29 Cohort (n=419, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.04" spread="9.26"/>
                    <measurement group_id="O2" value="16.03" spread="9.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 57 Cohort (n=421, 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.02" spread="8.64"/>
                    <measurement group_id="O2" value="14.77" spread="9.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 85 Cohort (n=417, 208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.76" spread="8.99"/>
                    <measurement group_id="O2" value="14.56" spread="10.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 113 Cohort (n=415, 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.73" spread="8.64"/>
                    <measurement group_id="O2" value="13.93" spread="10.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 141 Cohort (n=420, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.84" spread="8.10"/>
                    <measurement group_id="O2" value="13.28" spread="10.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 169 Cohort (n=420, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.54" spread="7.77"/>
                    <measurement group_id="O2" value="13.14" spread="11.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 225 Cohort (n=419, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.80" spread="7.57"/>
                    <measurement group_id="O2" value="12.78" spread="11.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 281 Cohort (n=419, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.50" spread="7.52"/>
                    <measurement group_id="O2" value="12.46" spread="10.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 365 Cohort (n=424, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.31" spread="7.16"/>
                    <measurement group_id="O2" value="12.69" spread="10.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR Core Component: Mean Participant Pain Assessment at All Post-BL Visits in the DB Period</title>
        <description>Participant self-reported pain assessment core component of the ACR scoring system where increasing score indicates increasing level of severity as indicated on a 100mm Visual Analog Scale (VAS) with 0mm representing no pain and 100mm representing the most pain possible.</description>
        <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last observation carried forward (LOCF) analysis. N = participants analyzed and n = participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR Core Component: Mean Participant Pain Assessment at All Post-BL Visits in the DB Period</title>
          <description>Participant self-reported pain assessment core component of the ACR scoring system where increasing score indicates increasing level of severity as indicated on a 100mm Visual Analog Scale (VAS) with 0mm representing no pain and 100mm representing the most pain possible.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last observation carried forward (LOCF) analysis. N = participants analyzed and n = participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15 (n=413, 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.39" spread="22.85"/>
                    <measurement group_id="O2" value="60.08" spread="21.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n=418, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.03" spread="23.84"/>
                    <measurement group_id="O2" value="54.69" spread="23.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (n=419, 209)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.34" spread="24.29"/>
                    <measurement group_id="O2" value="50.11" spread="25.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 (n=417, 207)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.97" spread="24.01"/>
                    <measurement group_id="O2" value="48.36" spread="25.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113 (n=418, 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.31" spread="23.61"/>
                    <measurement group_id="O2" value="48.60" spread="26.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141 (n=420, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.93" spread="25.47"/>
                    <measurement group_id="O2" value="48.26" spread="27.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169 (n=421, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.69" spread="24.32"/>
                    <measurement group_id="O2" value="49.21" spread="27.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 225 (n=418, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.39" spread="24.01"/>
                    <measurement group_id="O2" value="47.20" spread="26.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 281 (n=419, 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.06" spread="24.58"/>
                    <measurement group_id="O2" value="46.18" spread="27.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 (n=424, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.78" spread="24.20"/>
                    <measurement group_id="O2" value="48.17" spread="27.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR Core Component: Mean Participant Physical Function Assessment at All Post-BL Visits in the DB Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last observation carried forward (LOCF) analysis. N = participants analyzed and n = participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR Core Component: Mean Participant Physical Function Assessment at All Post-BL Visits in the DB Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last observation carried forward (LOCF) analysis. N = participants analyzed and n = participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15 (n=405, 206)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="0.64"/>
                    <measurement group_id="O2" value="1.58" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n=406, 207)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="0.64"/>
                    <measurement group_id="O2" value="1.47" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (n=412, 205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread="0.65"/>
                    <measurement group_id="O2" value="1.42" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 (n=407, 203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" spread="0.68"/>
                    <measurement group_id="O2" value="1.32" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113 (n=409, 206)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="0.67"/>
                    <measurement group_id="O2" value="1.35" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141 (n=411, 207)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="0.71"/>
                    <measurement group_id="O2" value="1.35" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169 (n=413, 207)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="0.70"/>
                    <measurement group_id="O2" value="1.31" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 225 (n=409, 207)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="0.70"/>
                    <measurement group_id="O2" value="1.35" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 281 (n=408, 207)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="0.70"/>
                    <measurement group_id="O2" value="1.31" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 (n=415, 208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread="0.70"/>
                    <measurement group_id="O2" value="1.34" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR Core Component: Mean Participant Global Assessment at All Post-BL Visits in the DB Period</title>
        <description>Participant self-reported global RA assessment core component of the ACR scoring system where increasing score indicates increasing level of severity as indicated on a 100mm Visual Analog Scale (VAS) with 0mm representing no pain and 100mm representing the most pain possible.</description>
        <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last observation carried forward (LOCF) analysis. N = participants analyzed and n = participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR Core Component: Mean Participant Global Assessment at All Post-BL Visits in the DB Period</title>
          <description>Participant self-reported global RA assessment core component of the ACR scoring system where increasing score indicates increasing level of severity as indicated on a 100mm Visual Analog Scale (VAS) with 0mm representing no pain and 100mm representing the most pain possible.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last observation carried forward (LOCF) analysis. N = participants analyzed and n = participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15 (n=413, 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.90" spread="22.42"/>
                    <measurement group_id="O2" value="56.66" spread="22.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n=418, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.26" spread="22.72"/>
                    <measurement group_id="O2" value="53.11" spread="22.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (n=419, 209)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.78" spread="23.02"/>
                    <measurement group_id="O2" value="49.34" spread="23.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 (n=417, 207)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.07" spread="23.37"/>
                    <measurement group_id="O2" value="46.82" spread="24.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113 (n=418, 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.98" spread="22.59"/>
                    <measurement group_id="O2" value="47.26" spread="25.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141 (n=420, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.52" spread="24.06"/>
                    <measurement group_id="O2" value="47.52" spread="26.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169 (n=421, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.37" spread="23.26"/>
                    <measurement group_id="O2" value="47.93" spread="26.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 225 (n=418, 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.63" spread="22.48"/>
                    <measurement group_id="O2" value="46.06" spread="26.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 281 (n=419, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.98" spread="23.25"/>
                    <measurement group_id="O2" value="44.45" spread="26.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 (n=424, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.95" spread="23.60"/>
                    <measurement group_id="O2" value="45.62" spread="26.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR Core Component: Mean Physician Global Assessment at All Post-BL Visits in the DB Period</title>
        <description>Physician global RA assessment core component of the ACR scoring system where increasing score indicates increasing level of severity as indicated on a 100mm Visual Analog Scale (VAS) with 0mm representing very good global RA assessment and 100mm representing very poor global RA assessment.</description>
        <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last observation carried forward (LOCF) analysis. N = participants analyzed and n = participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR Core Component: Mean Physician Global Assessment at All Post-BL Visits in the DB Period</title>
          <description>Physician global RA assessment core component of the ACR scoring system where increasing score indicates increasing level of severity as indicated on a 100mm Visual Analog Scale (VAS) with 0mm representing very good global RA assessment and 100mm representing very poor global RA assessment.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last observation carried forward (LOCF) analysis. N = participants analyzed and n = participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15 (n=415, 209)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.79" spread="19.24"/>
                    <measurement group_id="O2" value="56.68" spread="18.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n=418, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.24" spread="20.58"/>
                    <measurement group_id="O2" value="51.83" spread="20.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (n=421, 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.89" spread="19.84"/>
                    <measurement group_id="O2" value="45.21" spread="22.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 (n=416, 208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.07" spread="20.12"/>
                    <measurement group_id="O2" value="42.59" spread="23.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113 (n=412, 209)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.01" spread="20.40"/>
                    <measurement group_id="O2" value="42.20" spread="24.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141 (n=420, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.71" spread="20.38"/>
                    <measurement group_id="O2" value="41.22" spread="25.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169 (n=421, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.44" spread="19.65"/>
                    <measurement group_id="O2" value="41.75" spread="25.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 225 (n=418, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.34" spread="19.27"/>
                    <measurement group_id="O2" value="40.68" spread="26.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 281 (n=419, 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.33" spread="19.09"/>
                    <measurement group_id="O2" value="38.76" spread="26.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 (n=424, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.58" spread="19.53"/>
                    <measurement group_id="O2" value="41.04" spread="25.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR Core Component: Mean CRP at All Post-BL Visits in the DB Period</title>
        <description>CRP core component of the ACR scoring system was evaluated from serum samples in which increasing levels indicate increasing level of disease.</description>
        <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last observation carried forward (LOCF) analysis. N = participants analyzed and n = participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>ACR Core Component: Mean CRP at All Post-BL Visits in the DB Period</title>
          <description>CRP core component of the ACR scoring system was evaluated from serum samples in which increasing levels indicate increasing level of disease.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last observation carried forward (LOCF) analysis. N = participants analyzed and n = participants with measurements for that time point.</population>
          <units>IU / mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15 (n=401, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.27" spread="3.13"/>
                    <measurement group_id="O2" value="2.65" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n=410, 208)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="1.99"/>
                    <measurement group_id="O2" value="2.65" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (n=416, 209)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="2.02"/>
                    <measurement group_id="O2" value="2.36" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 (n=412, 203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="1.97"/>
                    <measurement group_id="O2" value="2.53" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113 (n=417, 209)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="1.69"/>
                    <measurement group_id="O2" value="2.55" spread="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141 (n=414, 209)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="1.52"/>
                    <measurement group_id="O2" value="2.48" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169 (n=420, 211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="1.67"/>
                    <measurement group_id="O2" value="2.56" spread="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 225 (n=414, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="1.55"/>
                    <measurement group_id="O2" value="2.46" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 281 (n=412, 210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="1.80"/>
                    <measurement group_id="O2" value="2.60" spread="3.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 (n=424, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="1.63"/>
                    <measurement group_id="O2" value="2.41" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Discontinuing in the DB Period</title>
        <description>Participants that discontinued treatment during the DB period for any reason were evaluated after 6 months and 1 year of treatment.</description>
        <time_frame>Day 1 to Day 169, Day 170 to Day 365</time_frame>
        <population>All randomized and treated participants in the DB period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Discontinuing in the DB Period</title>
          <description>Participants that discontinued treatment during the DB period for any reason were evaluated after 6 months and 1 year of treatment.</description>
          <population>All randomized and treated participants in the DB period.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 to 169 Discontinuations (DC) - All Causes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 to 169 DC Due to Lack of Efficacy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 170 to Day 365 DC - All Causes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 170 to Day 365 DC Due to Lack of Efficacy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From BL in Joint Narrowing Score (JSN), Erosion Score (ES), and Total Score (TS) by Category in the DB Period</title>
        <description>To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and joint space narrowing (JSN). The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage. Improvement=decreases from BL, stable=same as BL, worsening=increases from BL.</description>
        <time_frame>BL (Day 0), Day 365</time_frame>
        <population>This analysis was not completed.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From BL in Joint Narrowing Score (JSN), Erosion Score (ES), and Total Score (TS) by Category in the DB Period</title>
          <description>To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and joint space narrowing (JSN). The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage. Improvement=decreases from BL, stable=same as BL, worsening=increases from BL.</description>
          <population>This analysis was not completed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Deaths, Adverse Events (AEs) and SAEs in the Open-Label (OL) Period</title>
        <description>AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE was defined as any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
        <time_frame>Day 365 to Day 2,185</time_frame>
        <population>All treated participants in the OL period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX OL</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Deaths, Adverse Events (AEs) and SAEs in the Open-Label (OL) Period</title>
          <description>AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE was defined as any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
          <population>All treated participants in the OL period.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="539"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuations Due to SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued Due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Hematology Values Meeting the Marked Abnormality Criteria in the OL Period</title>
        <description>Marked abnormality criteria are: Hemoglobin (HGB): &gt;3 g/dL decrease from BL; Hematocrit: &lt;0.75 * BL; Erythrocytes: &lt;0.75 * BL; Platelets (PLT): &lt;0.67 * LLN/&gt;1.5 * ULN, or if BL &lt; LLN then use &lt;0.5 * BL and &lt;100,000 mm^3; Leukocytes: &lt;0.75 * LLN/ &gt;1.25 * ULN, or if BL&lt;LLN then use &lt;0.8 * BL or &gt;ULN, or if BL&gt;ULN then use &gt;1.2 * BL or &lt;LLN; neutrophils+bands: &lt;1.0 * 10^3 c/uL; eosinophils: &gt;0.750 * 10^3 c/uL; basophils: &gt; 400 mm^3; monocytes: &gt;2000 mm^3; lymphocytes: &lt;0.750 * 10^3 c/uL/ &gt;7.50 * 10^3 c/uL.</description>
        <time_frame>Day 365 to Day 2,185</time_frame>
        <population>All treated participants in the OL period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX OL</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Hematology Values Meeting the Marked Abnormality Criteria in the OL Period</title>
          <description>Marked abnormality criteria are: Hemoglobin (HGB): &gt;3 g/dL decrease from BL; Hematocrit: &lt;0.75 * BL; Erythrocytes: &lt;0.75 * BL; Platelets (PLT): &lt;0.67 * LLN/&gt;1.5 * ULN, or if BL &lt; LLN then use &lt;0.5 * BL and &lt;100,000 mm^3; Leukocytes: &lt;0.75 * LLN/ &gt;1.25 * ULN, or if BL&lt;LLN then use &lt;0.8 * BL or &gt;ULN, or if BL&gt;ULN then use &gt;1.2 * BL or &lt;LLN; neutrophils+bands: &lt;1.0 * 10^3 c/uL; eosinophils: &gt;0.750 * 10^3 c/uL; basophils: &gt; 400 mm^3; monocytes: &gt;2000 mm^3; lymphocytes: &lt;0.750 * 10^3 c/uL/ &gt;7.50 * 10^3 c/uL.</description>
          <population>All treated participants in the OL period.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="536"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low Hemoglobin (LLN 11.5 g/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Hematocrit (LLN 34%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Erythrocytes (LLN 38 x 10^6 c/µL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Platelet Count (LLN 140 x 10^3 c/µL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Platelet Count (ULN 415 x 10^3 c/µL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Leukocytes (LLN 4 x 10^3 c/µL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Leukocytes (ULN 10.5 x 10^3 c/µL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Absolute Neutrophils (LLN 1.8 x 10^3 c/µL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Absolute Lymphocytes (LLN 0.7 x 10^3 c/µL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Absolute Lymphocytes (ULN 4.5 x 10^3 c/µL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Absolute Monocytes (ULN 1.0 x 10^3 c/µL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Absolute Basophils (ULN 0.2 x 10^3 c/µL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Absolute Eosinophils (ULN 0.4 x 10^3 c/µL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria in the OL Period</title>
        <description>Marked abnormality criteria are: Hemoglobin (HGB): &gt;3 g/dL decrease from BL; Hematocrit: &lt;0.75 * BL; Erythrocytes: &lt;0.75 * BL; Platelets (PLT): &lt;0.67 * LLN/&gt;1.5 * ULN, or if BL &lt; LLN then use &lt;0.5 * BL and &lt;100,000 mm^3; Leukocytes: &lt;0.75 * LLN/ &gt;1.25 * ULN, or if BL&lt;LLN then use &lt;0.8 * BL or &gt;ULN, or if BL&gt;ULN then use &gt;1.2 * BL or &lt;LLN; neutrophils+bands: &lt;1.0 * 10^3 c/uL; eosinophils: &gt;0.750 * 10^3 c/uL; basophils: &gt; 400 mm^3; monocytes: &gt;2000 mm^3; lymphocytes: &lt;0.750 * 10^3 c/uL/ &gt;7.50 * 10^3 c/uL.</description>
        <time_frame>Day 365 to Day 2,185</time_frame>
        <population>All treated participants in the OL period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX OL</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria in the OL Period</title>
          <description>Marked abnormality criteria are: Hemoglobin (HGB): &gt;3 g/dL decrease from BL; Hematocrit: &lt;0.75 * BL; Erythrocytes: &lt;0.75 * BL; Platelets (PLT): &lt;0.67 * LLN/&gt;1.5 * ULN, or if BL &lt; LLN then use &lt;0.5 * BL and &lt;100,000 mm^3; Leukocytes: &lt;0.75 * LLN/ &gt;1.25 * ULN, or if BL&lt;LLN then use &lt;0.8 * BL or &gt;ULN, or if BL&gt;ULN then use &gt;1.2 * BL or &lt;LLN; neutrophils+bands: &lt;1.0 * 10^3 c/uL; eosinophils: &gt;0.750 * 10^3 c/uL; basophils: &gt; 400 mm^3; monocytes: &gt;2000 mm^3; lymphocytes: &lt;0.750 * 10^3 c/uL/ &gt;7.50 * 10^3 c/uL.</description>
          <population>All treated participants in the OL period.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="536"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High ALP (ULN 150 U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High AST (ULN 40 U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High ALT (ULN 55 U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High GGT (ULN 65 U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Bilirubin (ULN 1.2 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High BUN (ULN 26 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Creatinine (ULN 1.5 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Electrolyte Values Meeting the Marked Abnormality Criteria in the OL Period</title>
        <description>Sodium &lt; 0.9 * LLN or &gt; 1.05 * ULN or if BL &lt; LLN then use &lt; 0.95 * BL or &gt; ULN or if BL &gt; ULN then use &gt;1.05 *BL or &lt; LLN; Potassium: &lt; 0.9 * LLN or &gt; 1.1 * ULN or if BL &lt; LLN then use &lt; 0.9 * BL or &gt; ULN or if BL &gt; ULN then use 1.1 * BL or &lt; LLN; Chloride: &lt; 0.9 * LLN or &gt; 1.1 * ULN or if BL &lt; LLN then use &lt;0.9 * BL or &gt;ULN or if BL &gt; ULN then use &gt; 1.1 * BL or &lt; LLN; Calcium &lt;0.8 * LLN or &gt; 1.2 * ULN or if BL &lt; LLN then use &lt;0.67 * BL or &gt; ULN or if BL &gt; ULN then use &gt; 1.3 * BL or &lt; LLN.</description>
        <time_frame>Day 365 to Day 2,185</time_frame>
        <population>All treated participants in the OL period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX OL</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Electrolyte Values Meeting the Marked Abnormality Criteria in the OL Period</title>
          <description>Sodium &lt; 0.9 * LLN or &gt; 1.05 * ULN or if BL &lt; LLN then use &lt; 0.95 * BL or &gt; ULN or if BL &gt; ULN then use &gt;1.05 *BL or &lt; LLN; Potassium: &lt; 0.9 * LLN or &gt; 1.1 * ULN or if BL &lt; LLN then use &lt; 0.9 * BL or &gt; ULN or if BL &gt; ULN then use 1.1 * BL or &lt; LLN; Chloride: &lt; 0.9 * LLN or &gt; 1.1 * ULN or if BL &lt; LLN then use &lt;0.9 * BL or &gt;ULN or if BL &gt; ULN then use &gt; 1.1 * BL or &lt; LLN; Calcium &lt;0.8 * LLN or &gt; 1.2 * ULN or if BL &lt; LLN then use &lt;0.67 * BL or &gt; ULN or if BL &gt; ULN then use &gt; 1.3 * BL or &lt; LLN.</description>
          <population>All treated participants in the OL period.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="536"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low Sodium (LLN 135 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Sodium (ULN 148 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Potassium (LLN 3.5 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Potassium (ULN 5.5 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Chloride (LLN 96 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Chloride (ULN 109 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Calcium (LLN 8.5 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Calcium (ULN 10.6 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Phosphorous (LLN 2.5 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Phosphorous (ULN 5.6 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Glucose, Protein, Metabolites, and Urinalysis Values Meeting the Marked Abnormality Criteria in the OL Period</title>
        <description>Glucose: &lt; 65 mg/dL or &gt; 220 mg/dL; Fasting Glucose: &lt;0.8 * LLN or &gt; 1.5 * ULN or if BL &lt; LLN then use &lt; 0.8 * BL or &gt; ULN or if BL &gt; ULN then use 1.1 * BL or &lt; LLN; Total protein: &lt; 0.9 * LLN or 1.1 * ULN or if BL &lt; LLN then use 0.9 * BL or &gt; ULN or if BL &gt; ULN then use 1.1 * BL or &lt; LLN; Albumin: &lt; 0.9 * LLN or if BL &lt; LLN then use 0.75 * BL; Uric acid: &gt; 1.5 * ULN or if BL &gt; ULN then use &gt; 2.0 * BL. All urinalysis abnormalities were defined as: if missing BL then use &gt;= 2 or if value &gt;=4, or if BL = 0 or 0.5 then use &gt;= 2, or if BL = 1.0 then use &gt;= 3, or if BL = 2.0 then use &gt;=4.</description>
        <time_frame>Day 365 to Day 2,185</time_frame>
        <population>All treated participants in the OL period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX OL</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Glucose, Protein, Metabolites, and Urinalysis Values Meeting the Marked Abnormality Criteria in the OL Period</title>
          <description>Glucose: &lt; 65 mg/dL or &gt; 220 mg/dL; Fasting Glucose: &lt;0.8 * LLN or &gt; 1.5 * ULN or if BL &lt; LLN then use &lt; 0.8 * BL or &gt; ULN or if BL &gt; ULN then use 1.1 * BL or &lt; LLN; Total protein: &lt; 0.9 * LLN or 1.1 * ULN or if BL &lt; LLN then use 0.9 * BL or &gt; ULN or if BL &gt; ULN then use 1.1 * BL or &lt; LLN; Albumin: &lt; 0.9 * LLN or if BL &lt; LLN then use 0.75 * BL; Uric acid: &gt; 1.5 * ULN or if BL &gt; ULN then use &gt; 2.0 * BL. All urinalysis abnormalities were defined as: if missing BL then use &gt;= 2 or if value &gt;=4, or if BL = 0 or 0.5 then use &gt;= 2, or if BL = 1.0 then use &gt;= 3, or if BL = 2.0 then use &gt;=4.</description>
          <population>All treated participants in the OL period.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="536"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low Serum Glucose (LLN 64 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Serum Glucose (ULN 140 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Serum Fasting Glucose (LLN 65 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Serum Fasting Glucose (ULN 109 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Total Protein (LLN 6 g/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Total Protein (ULN 8.5 g/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Albumin (LLN 3.5 g/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Uric Acid (ULN 8.7 mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Urine Protein (ULN Trace)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Urine Glucose (ULN Trace)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Urine Ketones (ULN Positive)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Urine Blood (ULN &gt;=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Urine Leukocyte Esterase (ULN &gt;=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Urine White Blood Count (ULN 12 hpf)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Urine Red Blood Count (ULN 8 hpf)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Experiencing Clinically Significant Changes in Vital Signs in the DB Period</title>
        <description>All changes in participant vital signs were monitored on each day of study drug administration prior to dosing and 60 minutes after dosing. Vital signs included body temperature, heart rate, and seated blood pressure. Clinical significance was defined as any change from baseline that resulted in a value outside the normal limits for the participant.</description>
        <time_frame>Day 1 to Day 365</time_frame>
        <population>All randomized and treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Experiencing Clinically Significant Changes in Vital Signs in the DB Period</title>
          <description>All changes in participant vital signs were monitored on each day of study drug administration prior to dosing and 60 minutes after dosing. Vital signs included body temperature, heart rate, and seated blood pressure. Clinical significance was defined as any change from baseline that resulted in a value outside the normal limits for the participant.</description>
          <population>All randomized and treated participants.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Experiencing AEs of Special Interest in the DB Period</title>
        <description>AEs were defined as any new untoward medical occurrence or worsening of a pre- existing medical condition which does not necessarily have a causal relationship with this treatment. AEs were identified as those which may be associated with the use of immunomodulatory agents or infusion of therapeutic proteins. Acute infusional AEs were defined as those that occurred within 1 hour after the start of the infusion.</description>
        <time_frame>Day 1 to Day 365</time_frame>
        <population>All treated participants in the DB period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Experiencing AEs of Special Interest in the DB Period</title>
          <description>AEs were defined as any new untoward medical occurrence or worsening of a pre- existing medical condition which does not necessarily have a causal relationship with this treatment. AEs were identified as those which may be associated with the use of immunomodulatory agents or infusion of therapeutic proteins. Acute infusional AEs were defined as those that occurred within 1 hour after the start of the infusion.</description>
          <population>All treated participants in the DB period.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infections/Infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neoplasms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoimmune Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Infusional AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL Individual Components of the HAQ DI at Day 169 and Day 365</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 169, Day 365</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last observation carried forward (LOCF) analysis. N = participants analyzed and n = participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL Individual Components of the HAQ DI at Day 169 and Day 365</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last observation carried forward (LOCF) analysis. N = participants analyzed and n = participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI Day 169 (n=373, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="0.63"/>
                    <measurement group_id="O2" value="1.70" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ DI Day 365 (n=369, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="0.63"/>
                    <measurement group_id="O2" value="1.70" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming Day 169 (n=374, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="0.75"/>
                    <measurement group_id="O2" value="1.48" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming Day 365 (n=372, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="0.75"/>
                    <measurement group_id="O2" value="1.49" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising Day 169 (n=373, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.83"/>
                    <measurement group_id="O2" value="1.45" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising Day 365 (n=372, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.82"/>
                    <measurement group_id="O2" value="1.46" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating Day 169 (n=374, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.97"/>
                    <measurement group_id="O2" value="1.67" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating Day 365 (n=372, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.97"/>
                    <measurement group_id="O2" value="1.68" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking Day 169 (n=373, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.83"/>
                    <measurement group_id="O2" value="1.36" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking Day 365 (n=372, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.83"/>
                    <measurement group_id="O2" value="1.37" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene Day 169 (n=373, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="0.90"/>
                    <measurement group_id="O2" value="1.91" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene Day 365 (n=370, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="0.90"/>
                    <measurement group_id="O2" value="1.91" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching Day 169 (n=373, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.86"/>
                    <measurement group_id="O2" value="1.97" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching Day 365 (n=370, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.86"/>
                    <measurement group_id="O2" value="1.97" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping Day 169 (n=374, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="0.76"/>
                    <measurement group_id="O2" value="1.90" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping Day 365 (n=371, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="0.76"/>
                    <measurement group_id="O2" value="1.90" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities Day 169 (n=373, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.79"/>
                    <measurement group_id="O2" value="1.86" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities Day 365 (n=369, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.79"/>
                    <measurement group_id="O2" value="1.86" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From BL in Individual Components of the HAQ DI at Day 169</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>Day 169</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last observation carried forward (LOCF) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From BL in Individual Components of the HAQ DI at Day 169</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last observation carried forward (LOCF) analysis.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="0.03"/>
                    <measurement group_id="O2" value="-0.52" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" spread="0.04"/>
                    <measurement group_id="O2" value="-0.55" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="0.03"/>
                    <measurement group_id="O2" value="-0.65" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.04"/>
                    <measurement group_id="O2" value="-0.48" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.04"/>
                    <measurement group_id="O2" value="-0.45" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.05"/>
                    <measurement group_id="O2" value="-0.40" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" spread="0.04"/>
                    <measurement group_id="O2" value="-0.52" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.04"/>
                    <measurement group_id="O2" value="-0.43" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.04"/>
                    <measurement group_id="O2" value="-0.43" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From BL in Individual Components of the HAQ DI at Day 365</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>Day 365</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last observation carried forward (LOCF) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From BL in Individual Components of the HAQ DI at Day 365</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last observation carried forward (LOCF) analysis.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.03"/>
                    <measurement group_id="O2" value="-0.51" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="0.04"/>
                    <measurement group_id="O2" value="-0.61" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.04"/>
                    <measurement group_id="O2" value="-0.58" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" spread="0.04"/>
                    <measurement group_id="O2" value="-0.44" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" spread="0.04"/>
                    <measurement group_id="O2" value="-0.50" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.05"/>
                    <measurement group_id="O2" value="-0.37" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.04"/>
                    <measurement group_id="O2" value="-0.59" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="0.04"/>
                    <measurement group_id="O2" value="-0.44" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="0.44"/>
                    <measurement group_id="O2" value="-0.47" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Immunogenicity to Abatacept in the DB Period</title>
        <description>Participants with titers to abatacept in the DB period. Serum samples from abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using two validated direct-format enzyme-linked immunosorbent assays (ELISAs) to determine the presence of antibodies to abatacept and/or CTLA4-T.</description>
        <time_frame>Day 1 to Day 365</time_frame>
        <population>Participants treated with abatacept in the DB period with at least one immunogenicity sample collected in the DB period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the DB period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; particiapnts ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and particpants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the OL period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Immunogenicity to Abatacept in the DB Period</title>
          <description>Participants with titers to abatacept in the DB period. Serum samples from abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using two validated direct-format enzyme-linked immunosorbent assays (ELISAs) to determine the presence of antibodies to abatacept and/or CTLA4-T.</description>
          <population>Participants treated with abatacept in the DB period with at least one immunogenicity sample collected in the DB period.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="406"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of New Tender Joints and Number of New Swollen Joints in the DB Period</title>
        <description>Tender joints and swollen joints are core components of the ACR 20, 50, and 70. The incidences of new tender joints and new swollen joints were evaluated in the DB period after 6 months and 1 year of treatment.</description>
        <time_frame>Day 169, Day 365</time_frame>
        <population>These data were not summarized as it was determined that no meaningful information would be obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of New Tender Joints and Number of New Swollen Joints in the DB Period</title>
          <description>Tender joints and swollen joints are core components of the ACR 20, 50, and 70. The incidences of new tender joints and new swollen joints were evaluated in the DB period after 6 months and 1 year of treatment.</description>
          <population>These data were not summarized as it was determined that no meaningful information would be obtained.</population>
          <units>Joints</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing a 100% Reduction in Tender Joints or 100% Reduction in Swollen Joints in the DB Period</title>
        <time_frame>Day 169, Day 365</time_frame>
        <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last observation carried forward (LOCF) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing a 100% Reduction in Tender Joints or 100% Reduction in Swollen Joints in the DB Period</title>
          <population>Analyses of efficacy were based on the intent-to-treat population. Due to the non-compliance of a single site, 9 participants in the abatacept group and 5 in the placebo group were not included in this analysis. Last observation carried forward (LOCF) analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>100% Reduction in New Tender Joints Day 169</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100% Reduction in New Swollen Joints Day 169</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100% Reduction in New Tender Joints Day 365</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100% Reduction in New Swollen Joints Day 365</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hematology Laboratories Meeting Marked Abnormality Criteria in the DB Period</title>
        <description>Marked abnormality criteria were: Hemoglobin (HGB): &gt;3 g/dL decrease from BL; Hematocrit: &lt;0.75 * BL; Erythrocytes: &lt;0.75 * BL; Platelets (PLT): &lt;0.67 * LLN/&gt;1.5 * ULN, or if BL &lt; LLN then use &lt;0.5 * BL and &lt;100,000 mm^3; Leukocytes: &lt;0.75 * LLN/ &gt;1.25 * ULN, or if BL&lt;LLN then use &lt;0.8 * BL or &gt;ULN, or if BL&gt;ULN then use &gt;1.2 * BL or &lt;LLN; neutrophils+bands: &lt;1.0 * 10^3 c/uL; eosinophils: &gt;0.750 * 10^3 c/uL; basophils: &gt; 400 mm^3; monocytes: &gt;2000 mm^3; lymphocytes: &lt;0.750 * 10^3 c/uL/ &gt;7.50 * 10^3 c/uL.</description>
        <time_frame>Day 1 to Day 365</time_frame>
        <population>All treated participants in the DB period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hematology Laboratories Meeting Marked Abnormality Criteria in the DB Period</title>
          <description>Marked abnormality criteria were: Hemoglobin (HGB): &gt;3 g/dL decrease from BL; Hematocrit: &lt;0.75 * BL; Erythrocytes: &lt;0.75 * BL; Platelets (PLT): &lt;0.67 * LLN/&gt;1.5 * ULN, or if BL &lt; LLN then use &lt;0.5 * BL and &lt;100,000 mm^3; Leukocytes: &lt;0.75 * LLN/ &gt;1.25 * ULN, or if BL&lt;LLN then use &lt;0.8 * BL or &gt;ULN, or if BL&gt;ULN then use &gt;1.2 * BL or &lt;LLN; neutrophils+bands: &lt;1.0 * 10^3 c/uL; eosinophils: &gt;0.750 * 10^3 c/uL; basophils: &gt; 400 mm^3; monocytes: &gt;2000 mm^3; lymphocytes: &lt;0.750 * 10^3 c/uL/ &gt;7.50 * 10^3 c/uL.</description>
          <population>All treated participants in the DB period.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low Hemoglobin (LLN 11.5 g/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Hematocrit (LLN 34%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Platelet Count (LLN 140 x 10^3 c/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Platelet Count (ULN 415 x 10^3 c/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Leukocytes (LLN 4.0 x 10^3 c/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Leukocytes (ULN 10.5 x 10^3 c/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Absolute Neutrophils (LLN 1.8 x 10^3 c/uL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Liver and Kidney Function Tests Meeting Marked Abnormality Criteria in the DB Period</title>
        <description>Marked abnormality criteria were: Aspartate Aminotransferase (AST) &gt;3 * ULN or if BL &gt; ULN then use &gt;4 *BL; Alanine Aminotransferase (ALT) &gt;3 * ULN or if BL &gt; ULN then use &gt; 4 * BL; Creatinine &gt; 1.5 * BL.</description>
        <time_frame>Day 1 to Day 365</time_frame>
        <population>All treated participants in the DB period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + MTX DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Liver and Kidney Function Tests Meeting Marked Abnormality Criteria in the DB Period</title>
          <description>Marked abnormality criteria were: Aspartate Aminotransferase (AST) &gt;3 * ULN or if BL &gt; ULN then use &gt;4 *BL; Alanine Aminotransferase (ALT) &gt;3 * ULN or if BL &gt; ULN then use &gt; 4 * BL; Creatinine &gt; 1.5 * BL.</description>
          <population>All treated participants in the DB period.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High AST (ULN 40 U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High ALT (ULN 55 U/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Creatinine (ULN 1.5 mg/ dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL ESR and CRP Levels in the OL Period</title>
        <description>Mean baseline values are reported for each cohort at each time point.</description>
        <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period. Treatment groups represent treatment received in the DB period. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; particiapnts ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and particpants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; particiapnts ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and particpants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL ESR and CRP Levels in the OL Period</title>
          <description>Mean baseline values are reported for each cohort at each time point.</description>
          <population>All treated participants in the OL period. Treatment groups represent treatment received in the DB period. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>IU / mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ESR Day 365 (n=343, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.56" spread="22.98"/>
                    <measurement group_id="O2" value="43.61" spread="25.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP Day 365 (n=373, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.48" spread="31.41"/>
                    <measurement group_id="O2" value="24.72" spread="20.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESR Day 729 (n=307, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.74" spread="23.44"/>
                    <measurement group_id="O2" value="41.37" spread="24.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP Day 729 (n=348, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.12" spread="30.99"/>
                    <measurement group_id="O2" value="23.46" spread="19.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESR Day 1,093 (n=283, 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.57" spread="23.34"/>
                    <measurement group_id="O2" value="42.41" spread="25.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP Day 1,093 (n=306, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.96" spread="30.35"/>
                    <measurement group_id="O2" value="24.09" spread="19.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESR Day 1,457 (n=270, 111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.49" spread="23.71"/>
                    <measurement group_id="O2" value="42.87" spread="24.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP Day 1,457 (n=295, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.13" spread="30.14"/>
                    <measurement group_id="O2" value="23.20" spread="19.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESR Day 1,821 (n=257, 109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.03" spread="22.86"/>
                    <measurement group_id="O2" value="41.83" spread="24.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP Day 1,821 (n=275, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.41" spread="29.30"/>
                    <measurement group_id="O2" value="22.14" spread="18.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESR Day 1,989 (n=114, 49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.61" spread="24.00"/>
                    <measurement group_id="O2" value="38.78" spread="19.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP Day 1,989 (n=128, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.22" spread="34.65"/>
                    <measurement group_id="O2" value="20.39" spread="14.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESR Day 2,185 (n=76, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.04" spread="23.46"/>
                    <measurement group_id="O2" value="39.17" spread="21.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP Day 2,185 (n=83, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.73" spread="36.05"/>
                    <measurement group_id="O2" value="22.08" spread="15.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in ESR in the OL Period</title>
        <description>Serum samples were evaluated from study participants to determine the mean change from baseline in ESR values.</description>
        <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period. Treatment groups represent treatment received in the DB period. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; particiapnts ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and particpants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; particiapnts ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and particpants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in ESR in the OL Period</title>
          <description>Serum samples were evaluated from study participants to determine the mean change from baseline in ESR values.</description>
          <population>All treated participants in the OL period. Treatment groups represent treatment received in the DB period. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>IU / mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 (n=343, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.9" spread="1.21"/>
                    <measurement group_id="O2" value="-6.85" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n=307, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.3" spread="1.29"/>
                    <measurement group_id="O2" value="-16.3" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,093 (n=283, 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.2" spread="1.55"/>
                    <measurement group_id="O2" value="-16.6" spread="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,457 (n=270, 111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.7" spread="1.41"/>
                    <measurement group_id="O2" value="-16.3" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,821 (n=257, 109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.7" spread="1.46"/>
                    <measurement group_id="O2" value="-16.6" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,989 (n=114, 49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.3" spread="2.33"/>
                    <measurement group_id="O2" value="-13.3" spread="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,185 (n=76, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.1" spread="2.92"/>
                    <measurement group_id="O2" value="-21.0" spread="4.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant RF Seroconversion in the OL Period</title>
        <description>This analysis determined participant RF status (positive or RF negative) based on serum samples at each specified timepoint. A positive value for RF was &gt; 20 IU/ml; a negative value for RF was ≤ 20 IU/mL.</description>
        <time_frame>Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 2,185</time_frame>
        <population>All treated participants in the OL period. Treatment groups represent treatment received in the DB period. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant RF Seroconversion in the OL Period</title>
          <description>This analysis determined participant RF status (positive or RF negative) based on serum samples at each specified timepoint. A positive value for RF was &gt; 20 IU/ml; a negative value for RF was ≤ 20 IU/mL.</description>
          <population>All treated participants in the OL period. Treatment groups represent treatment received in the DB period. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive Seroconversion Day 365 (n=347, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Seroconversion Day 365 (n=347, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive Seroconversion Day 729 (n=330, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Seroconversion Day 729 (n=330, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive Seroconversion Day 1,093 (n=280, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Seroconversion Day 1,093 (n=280, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive Seroconversion Day 1,457 (n=275, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Seroconversion Day 1,457 (n=275, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive Seroconversion Day 1,821 (n=255, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Seroconversion Day 1,821 (n=255, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive Seroconversion Day 2,185 (n=75, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Seroconversion Day 2,185 (n=75, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of ACR 20 Responders in the DB and OL Periods</title>
        <description>ACR 20 response requires a patient to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, CRP or ESR, and degree of disability in HAQ score. A participant achieved a sustained ACR 20 response if the participant had ACR 20 observed for at least 2 consecutive study visits.</description>
        <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,083, Day 1,177, Day 1,261, Day 1,345, Day 1,497, Day 1,625, Day 1,821</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of ACR 20 Responders in the DB and OL Periods</title>
          <description>ACR 20 response requires a patient to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, CRP or ESR, and degree of disability in HAQ score. A participant achieved a sustained ACR 20 response if the participant had ACR 20 observed for at least 2 consecutive study visits.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15 (n = 370, n = 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n = 368, n=158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (n = 371, n = 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 (n = 367, n = 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113 (n = 367, n = 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141 (n = 368, n = 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="275"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169 (n = 371, n = 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="272"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 225 (n = 369, n = 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 281 (n = 367, n = 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="299"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 (n = 373, n = 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="307"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 (n = 363, n = 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="299"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 (n = 353, n = 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300"/>
                    <measurement group_id="O2" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 (n = 347, n = 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="299"/>
                    <measurement group_id="O2" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n = 337, n = 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="296"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 (n = 322, n = 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273"/>
                    <measurement group_id="O2" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 (n = 311, n = 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 (n = 298, n = 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243"/>
                    <measurement group_id="O2" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,093 (n = 303, n = 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257"/>
                    <measurement group_id="O2" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,177 (n = 265, n = 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228"/>
                    <measurement group_id="O2" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,261 (n = 289, n = 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251"/>
                    <measurement group_id="O2" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,345 (n = 133, n = 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,457 (n = 288, n = 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253"/>
                    <measurement group_id="O2" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,625 (n = 273, n= 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,821 (n = 268, n = 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224"/>
                    <measurement group_id="O2" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,989 (n = 119, n = 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,185 (n = 85, n = 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of ACR 50 Responders in the DB and OL Periods</title>
        <description>ACR 50 response requires a patient to have a 50% reduction in the number of swollen and tender joints, and a reduction of 50% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, CRP or ESR, and degree of disability in HAQ score.</description>
        <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,083, Day 1,177, Day 1,261, Day 1,345, Day 1,497, Day 1,625, Day 1,821</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of ACR 50 Responders in the DB and OL Periods</title>
          <description>ACR 50 response requires a patient to have a 50% reduction in the number of swollen and tender joints, and a reduction of 50% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, CRP or ESR, and degree of disability in HAQ score.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15 (n = 371, n = 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n = 368, n=158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (n = 373, n = 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 (n = 367, n = 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113 (n = 368, n = 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141 (n = 371, n = 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169 (n = 373, n = 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 225 (n = 370, n = 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 281 (n = 369, n = 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 (n = 372, n = 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 (n = 366, n = 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 (n = 348, n = 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 (n = 346, n = 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n = 338, n = 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 (n = 321, n = 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 (n = 314, n = 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 (n = 302, n = 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,093 (n = 306, n = 135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,177 (n = 266, n = 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,261 (n = 289, n = 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,345 (n = 141, n = 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,457 (n = 288, n = 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,625 (n = 274, n= 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,821 (n = 270, n = 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,989 (n = 121, n = 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,185 (n = 83, n = 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of ACR 70 Responders in the DB and OL Periods</title>
        <description>ACR 70 response requires a patient to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, CRP or ESR, and degree of disability in HAQ score. A participant achieved a sustained ACR 70 response if the participant had ACR 70 observed for at least 2 consecutive study visits.</description>
        <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,083, Day 1,177, Day 1,261, Day 1,345, Day 1,497, Day 1,625, Day 1,821</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and particpants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; particiapnts ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and particpants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of ACR 70 Responders in the DB and OL Periods</title>
          <description>ACR 70 response requires a patient to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in three of the following five parameters: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, CRP or ESR, and degree of disability in HAQ score. A participant achieved a sustained ACR 70 response if the participant had ACR 70 observed for at least 2 consecutive study visits.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15 (n = 371, n = 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n = 369, n=159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (n = 374, n = 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 (n = 370, n = 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113 (n = 371, n = 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141 (n = 371, n = 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169 (n = 374, n = 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 225 (n = 369, n = 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 281 (n = 372, n = 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 (n = 374, n = 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 (n = 367, n = 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 (n = 350, n = 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 (n = 347, n = 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n = 340, n = 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 (n = 325, n = 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 (n = 314, n = 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 (n = 306, n = 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,093 (n = 309, n = 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,177 (n = 265, n = 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,261 (n = 289, n = 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,345 (n = 139, n = 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,457 (n = 288, n = 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,625 (n = 278, n= 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,821 (n = 270, n = 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,989 (n = 119, n = 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,185 (n = 83, n = 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Continuing in the OL Period With DAS-28 Remission or Low DAS-28 Activity Over Time</title>
        <description>The DAS 28 is a continuous measure evaluating extent of disease activity in RA, and is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, erythrocyte sedimentation rate (ESR) and participant assessment of disease activity measure on a visual analog scale (VAS) of 100 mm. The scale reports from 1 to 10, with increasing number indicating increasing extent of disease progression. Scores for disease activity are defined as high (&gt; 5.1); low (≤ 3.2); remission (&lt; 2.6).</description>
        <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,083, Day 1,177, Day 1,261, Day 1,345, Day 1,497, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Continuing in the OL Period With DAS-28 Remission or Low DAS-28 Activity Over Time</title>
          <description>The DAS 28 is a continuous measure evaluating extent of disease activity in RA, and is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, erythrocyte sedimentation rate (ESR) and participant assessment of disease activity measure on a visual analog scale (VAS) of 100 mm. The scale reports from 1 to 10, with increasing number indicating increasing extent of disease progression. Scores for disease activity are defined as high (&gt; 5.1); low (≤ 3.2); remission (&lt; 2.6).</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Remission Day 15 (n = 355, n = 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Day 15 (n=355, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Day 29 (n = 362, n =157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Day 29 (n=362, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Day 57 (n = 367, n = 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Day 57 (n=367, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Day 85 (n = 366, n = 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Day 85 (n=366, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Day 113 (n = 367, n = 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Day 113 (n=367, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Day 141 (n = 366, n = 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Day 141 (n=366, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Day 169 (n = 371, n = 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Day 169 (n=371, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Day 225 (n = 366, n = 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Day 225 (n=366, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Day 281 (n = 364, n = 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Day 281 (n=364, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Day 365 (n = 370, n = 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Day 365 (n=370, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Day 449 (n = 357, n = 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Day 449 (n=357, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Day 533 (n = 343, n = 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Day 553 (n=343, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Day 617 (n = 334, n = 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Day 617 (n=334, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Day 729 (n = 337, n = 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Day 729 (n=337, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Day 813 (n = 317, n = 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Day 813 (n=317, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Day 897 (n = 303, n = 135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Day 897 (n=303, 135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Day 981 (n = 297, n = 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Day 981 (n=297, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Day 1,093 (n = 300, n = 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Day 1,093 (n=300, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Day 1,177 (n = 158, n = 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Day 1,177 (n=158, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Day 1,261 (n = 267, n = 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Day 1,261 (n=267, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Day 1,457 (n = 284, n = 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Day 1,457 (n=284, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Day 1,625 (n = 272, n= 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Day 1,625 (n=272, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Day 1,821 (n = 270, n = 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Day 1,821 (n=270, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Day 1,989 (n=118, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Day 1,989 (n=118, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission Day 2,185 (n=82, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Disease Activity Day 2,185 (n=82, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL DAS-28 CRP Over Time for Participants Continuing in the OL Period</title>
        <description>Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
        <time_frame>BL(Day 0), Day 15, Day 29,Day 57,Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,083, Day 1,177, Day 1,261, Day 1,345, Day 1,497, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL DAS-28 CRP Over Time for Participants Continuing in the OL Period</title>
          <description>Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>mg / mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 15 Cohort (n=352, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.36" spread="0.81"/>
                    <measurement group_id="O2" value="6.32" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 29 Cohort (n=357, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.36" spread="0.81"/>
                    <measurement group_id="O2" value="6.35" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 57 Cohort (n=362, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.36" spread="0.81"/>
                    <measurement group_id="O2" value="6.35" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 85 Cohort (n=362, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.35" spread="0.81"/>
                    <measurement group_id="O2" value="6.33" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 113 Cohort (n=362, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.35" spread="0.81"/>
                    <measurement group_id="O2" value="6.34" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 141 Cohort (n=361, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.34" spread="0.80"/>
                    <measurement group_id="O2" value="6.33" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 169 Cohort (n=366, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.35" spread="0.80"/>
                    <measurement group_id="O2" value="6.34" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 225 Cohort (n=361, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.35" spread="0.81"/>
                    <measurement group_id="O2" value="6.33" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 281 Cohort (n=359, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.35" spread="0.81"/>
                    <measurement group_id="O2" value="6.33" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 365 Cohort (n=365, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.36" spread="0.81"/>
                    <measurement group_id="O2" value="6.33" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 449 Cohort (n=352, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.37" spread="0.81"/>
                    <measurement group_id="O2" value="6.34" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 533 Cohort (n=338, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.38" spread="0.81"/>
                    <measurement group_id="O2" value="6.35" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 617 Cohort (n=329, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.37" spread="0.80"/>
                    <measurement group_id="O2" value="6.35" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 729 Cohort (n=333, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.37" spread="0.81"/>
                    <measurement group_id="O2" value="6.36" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 813 Cohort (n=313, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.39" spread="0.82"/>
                    <measurement group_id="O2" value="6.37" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 897 Cohort (n=301, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.38" spread="0.83"/>
                    <measurement group_id="O2" value="6.37" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 981 Cohort (n=294, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.39" spread="0.82"/>
                    <measurement group_id="O2" value="6.37" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,093 Cohort (n=296, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.37" spread="0.83"/>
                    <measurement group_id="O2" value="6.37" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,177 Cohort (n=156, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.43" spread="0.85"/>
                    <measurement group_id="O2" value="6.38" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,261 Cohort (n=267, 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.39" spread="0.80"/>
                    <measurement group_id="O2" value="6.34" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,457 Cohort (n=281, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.40" spread="0.82"/>
                    <measurement group_id="O2" value="6.35" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,625 Cohort (n=269, 121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.39" spread="0.81"/>
                    <measurement group_id="O2" value="6.40" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,821 Cohort (n=267, 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.39" spread="0.81"/>
                    <measurement group_id="O2" value="6.33" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,989 Cohort (n=118, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.53" spread="0.77"/>
                    <measurement group_id="O2" value="6.49" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 2,185 Cohort (n=82, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.41" spread="0.77"/>
                    <measurement group_id="O2" value="6.38" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in DAS-28 CRP Over Time for Participants Continuing in the OL Period</title>
        <description>Change from baseline in participant were calculated at all study visits in the DB and OL periods.</description>
        <time_frame>BL(Day 0),Day 15,Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,083, Day 1,177, Day 1,261, Day 1,345, Day 1,497, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in DAS-28 CRP Over Time for Participants Continuing in the OL Period</title>
          <description>Change from baseline in participant were calculated at all study visits in the DB and OL periods.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>mg / mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15 (n=352, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.04"/>
                    <measurement group_id="O2" value="-0.47" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n=357, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.27" spread="0.05"/>
                    <measurement group_id="O2" value="-0.87" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (n=362, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.80" spread="0.06"/>
                    <measurement group_id="O2" value="-1.17" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 (n=362, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.12" spread="0.06"/>
                    <measurement group_id="O2" value="-1.37" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113 (n=362, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.30" spread="0.06"/>
                    <measurement group_id="O2" value="-1.47" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141 (n=361, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.46" spread="0.07"/>
                    <measurement group_id="O2" value="-1.52" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169 (n=366, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.48" spread="0.07"/>
                    <measurement group_id="O2" value="-1.57" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 225 (n=361, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.72" spread="0.07"/>
                    <measurement group_id="O2" value="-1.70" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 281 (n=359, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.81" spread="0.07"/>
                    <measurement group_id="O2" value="-1.87" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 (n=365, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.83" spread="0.07"/>
                    <measurement group_id="O2" value="-1.68" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 (n=352, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.91" spread="0.07"/>
                    <measurement group_id="O2" value="-2.68" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 (n=338, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.01" spread="0.07"/>
                    <measurement group_id="O2" value="-2.79" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 (n=329, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.00" spread="0.07"/>
                    <measurement group_id="O2" value="-2.92" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n=333, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.10" spread="0.07"/>
                    <measurement group_id="O2" value="-3.02" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 (n=313, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.09" spread="0.07"/>
                    <measurement group_id="O2" value="-3.05" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 (n=301, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.06" spread="0.07"/>
                    <measurement group_id="O2" value="-3.11" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 (n=294, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.21" spread="0.08"/>
                    <measurement group_id="O2" value="-3.14" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,093 (n=296, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.21" spread="0.08"/>
                    <measurement group_id="O2" value="-3.15" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,177 (n=156, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.27" spread="0.11"/>
                    <measurement group_id="O2" value="-3.21" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,261 (n=267, 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.22" spread="0.08"/>
                    <measurement group_id="O2" value="-3.15" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,457 (n=281, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.29" spread="0.08"/>
                    <measurement group_id="O2" value="-3.23" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,625 (n=269, 121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.23" spread="0.08"/>
                    <measurement group_id="O2" value="-3.34" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,821 (n=267, 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.14" spread="0.08"/>
                    <measurement group_id="O2" value="-3.26" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,989 (n=118, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.39" spread="0.12"/>
                    <measurement group_id="O2" value="-3.31" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,185 (n=82, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.04" spread="0.16"/>
                    <measurement group_id="O2" value="-3.30" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL DAS-28 ESR Over Time in the OL Period</title>
        <description>Mean baseline values are reported for each cohort at each time point. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,083, Day 1,177, Day 1,261, Day 1,345, Day 1,497, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL DAS-28 ESR Over Time in the OL Period</title>
          <description>Mean baseline values are reported for each cohort at each time point. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>IU / mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 365 Cohort (n=352, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.82" spread="0.85"/>
                    <measurement group_id="O2" value="6.88" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 449 Cohort (n=345, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.82" spread="0.86"/>
                    <measurement group_id="O2" value="6.89" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 533 Cohort (n=332, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.83" spread="0.86"/>
                    <measurement group_id="O2" value="6.88" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 617 Cohort (n=325, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.85" spread="0.86"/>
                    <measurement group_id="O2" value="6.86" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 729 Cohort (n=315, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.82" spread="0.88"/>
                    <measurement group_id="O2" value="6.87" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 813 Cohort (n=303, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.82" spread="0.87"/>
                    <measurement group_id="O2" value="6.90" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 897 Cohort (n=296, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.83" spread="0.88"/>
                    <measurement group_id="O2" value="6.85" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 981 Cohort (n=282, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.82" spread="0.87"/>
                    <measurement group_id="O2" value="6.88" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,093 Cohort (n=287, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.83" spread="0.88"/>
                    <measurement group_id="O2" value="6.87" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,177 Cohort (n=241, 110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.86" spread="0.87"/>
                    <measurement group_id="O2" value="6.89" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,261 Cohort (n=271, 121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.82" spread="0.87"/>
                    <measurement group_id="O2" value="6.86" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,457 Cohort (n=269, 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.87" spread="0.85"/>
                    <measurement group_id="O2" value="6.88" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,625 Cohort (n=260, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.86" spread="0.85"/>
                    <measurement group_id="O2" value="6.86" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,821 Cohort (n=259, 114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.85" spread="0.86"/>
                    <measurement group_id="O2" value="6.87" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,989 Cohort (n=108, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.95" spread="0.83"/>
                    <measurement group_id="O2" value="7.04" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 2,185 Cohort (n=76, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.90" spread="0.82"/>
                    <measurement group_id="O2" value="6.97" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in DAS-28 ESR Over Time in the OL Period</title>
        <description>Change from baseline in participant serum values of ESR were calculated at all study visits in the OL period.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,083, Day 1,177, Day 1,261, Day 1,345, Day 1,497, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in DAS-28 ESR Over Time in the OL Period</title>
          <description>Change from baseline in participant serum values of ESR were calculated at all study visits in the OL period.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>IU / mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 (n=352, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.96" spread="0.07"/>
                    <measurement group_id="O2" value="-1.76" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 (n=345, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.04" spread="0.08"/>
                    <measurement group_id="O2" value="-2.87" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 (n=332, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.14" spread="0.08"/>
                    <measurement group_id="O2" value="-2.95" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 (n=325, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.17" spread="0.08"/>
                    <measurement group_id="O2" value="-3.02" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n=315, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.27" spread="0.07"/>
                    <measurement group_id="O2" value="-3.20" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 (n=303, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.13" spread="0.08"/>
                    <measurement group_id="O2" value="-3.18" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 (n=296, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.11" spread="0.08"/>
                    <measurement group_id="O2" value="-3.10" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 (n=282, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.26" spread="0.09"/>
                    <measurement group_id="O2" value="-3.19" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,093 (n=287, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.23" spread="0.08"/>
                    <measurement group_id="O2" value="-3.22" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,177 (n=241, 110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.33" spread="0.09"/>
                    <measurement group_id="O2" value="-3.29" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,261 (n=271, 121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.25" spread="0.08"/>
                    <measurement group_id="O2" value="-3.18" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,457 (n=269, 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.32" spread="0.08"/>
                    <measurement group_id="O2" value="-3.23" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,625 (n=260, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.30" spread="0.09"/>
                    <measurement group_id="O2" value="-3.27" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,821 (n=259, 114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.22" spread="0.09"/>
                    <measurement group_id="O2" value="-3.34" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,989 (n=108, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.41" spread="0.13"/>
                    <measurement group_id="O2" value="-3.42" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,185 (n=76, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.25" spread="0.17"/>
                    <measurement group_id="O2" value="-3.66" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean BL Immunoglobulins Over Time in the OL Period</title>
        <description>Mean baseline values are those that are reported for each cohort at each time point on Day 365, Day 729, and Day 1,093.</description>
        <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093</time_frame>
        <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period).</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + MTX DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL Immunoglobulins Over Time in the OL Period</title>
          <description>Mean baseline values are those that are reported for each cohort at each time point on Day 365, Day 729, and Day 1,093.</description>
          <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period).</population>
          <units>mg / mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Immunoglobulin A (IgA) Day 365</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="327.0" spread="135.2"/>
                    <measurement group_id="O2" value="319.2" spread="145.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunoglobulin G (IgG) Day 365</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1278" spread="412.4"/>
                    <measurement group_id="O2" value="1317" spread="425.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunoglobulin M (IgM) Day 365</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.1" spread="86.72"/>
                    <measurement group_id="O2" value="154.3" spread="85.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA Day 729</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="328.0" spread="133.8"/>
                    <measurement group_id="O2" value="317.0" spread="145.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG Day 729</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1280" spread="410.4"/>
                    <measurement group_id="O2" value="1315" spread="425.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM Day 729</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.2" spread="87.34"/>
                    <measurement group_id="O2" value="153.1" spread="85.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA Day 1,093</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="321.8" spread="133.4"/>
                    <measurement group_id="O2" value="318.5" spread="145.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG Day 1,093</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1273" spread="392.3"/>
                    <measurement group_id="O2" value="1319" spread="436.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM Day 1,093</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.6" spread="91.01"/>
                    <measurement group_id="O2" value="153.5" spread="88.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From BL in Immunoglobulins in the OL Period</title>
        <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093</time_frame>
        <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period).</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + MTX DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in Immunoglobulins in the OL Period</title>
          <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period).</population>
          <units>mg / mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IgA Day 365</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.8" spread="3.16"/>
                    <measurement group_id="O2" value="-8.30" spread="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG Day 365</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-212" spread="12.77"/>
                    <measurement group_id="O2" value="-52.7" spread="18.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM Day 365</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.05" spread="1.98"/>
                    <measurement group_id="O2" value="6.95" spread="9.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA Day 729</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.6" spread="4.24"/>
                    <measurement group_id="O2" value="-26.6" spread="9.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG Day 729</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-215" spread="14.10"/>
                    <measurement group_id="O2" value="-206" spread="21.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM Day 729</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.04" spread="3.96"/>
                    <measurement group_id="O2" value="6.49" spread="5.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA Day 1,093</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.8" spread="4.76"/>
                    <measurement group_id="O2" value="-37.9" spread="9.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG Day 1,093</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-236" spread="15.94"/>
                    <measurement group_id="O2" value="-245" spread="25.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM Day 1,093</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38" spread="3.19"/>
                    <measurement group_id="O2" value="6.01" spread="5.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Immunogenicity to Abatacept in the Cumulative DB + OL Period</title>
        <description>Participants with titers to abatacept in the DB and OL periods. Serum samples from abatacept-treated adult participants with active Rheumatoid Arthritis (RA) were screened for the presence of drug-specific antibodies using two validated direct-format enzyme-linked immunosorbent assays (ELISAs) to determine the presence of antibodies to abatacept and or CTLA4-T.</description>
        <time_frame>Day 1 to Day 1,821</time_frame>
        <population>Participants with serum samples available for evaluation of titers to abatacept.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX Cumulative DB + OL Periods</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the DB and OL periods under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; particiapnts ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and particpants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Immunogenicity to Abatacept in the Cumulative DB + OL Period</title>
          <description>Participants with titers to abatacept in the DB and OL periods. Serum samples from abatacept-treated adult participants with active Rheumatoid Arthritis (RA) were screened for the presence of drug-specific antibodies using two validated direct-format enzyme-linked immunosorbent assays (ELISAs) to determine the presence of antibodies to abatacept and or CTLA4-T.</description>
          <population>Participants with serum samples available for evaluation of titers to abatacept.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="586"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving HAQ Response Over Time for Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>Day 15, Day 29, Day 57, Day 85, Day 113, Day 141, Day 169, Day 225, Day 281, Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,083, Day 1,177, Day 1,261, Day 1,345, Day 1,497, Day 1,625, Day 1,821</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving HAQ Response Over Time for Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15 (n = 367, n = 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n = 365, n = 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (n = 372, n = 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 (n = 366, n = 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113 (n = 369, n = 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 141 (n = 370, n = 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 169 (n = 373, n = 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 225 (n = 368, n = 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 281 (n = 368, n = 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 (n = 369, n = 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 (n = 366, n = 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268"/>
                    <measurement group_id="O2" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 (n = 354, n = 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259"/>
                    <measurement group_id="O2" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 (n = 348, n = 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257"/>
                    <measurement group_id="O2" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n = 337, n = 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 (n = 325, n= 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 (n = 318, n = 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232"/>
                    <measurement group_id="O2" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 (n = 312, n = 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,093 (n = 308, n = 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,177 (n = 274, n = 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,261 (n = 292, n = 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,345 (n = 152, n = 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,457 (n = 289, n = 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,625 (n =280, n = 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,821 (n = 271, n = 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,989 (n = 119, n = 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,185 (n = 85, n = 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BL and Mean Change From BL in Radiographic Erosion, Joint Space Narrowing (JSN), and Total Scores (TS) in the OL Period</title>
        <description>Change from baseline in the Genant-modified Sharp erosion score, JSN, TS were evaluated for all participants at the end of the OL period. The total Genant-modified Sharp score (TS) ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145).Higher scores indicated more damage. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
        <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>BL and Mean Change From BL in Radiographic Erosion, Joint Space Narrowing (JSN), and Total Scores (TS) in the OL Period</title>
          <description>Change from baseline in the Genant-modified Sharp erosion score, JSN, TS were evaluated for all participants at the end of the OL period. The total Genant-modified Sharp score (TS) ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145).Higher scores indicated more damage. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 365 Cohort Erosion (n=291, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.65" spread="15.81"/>
                    <measurement group_id="O2" value="18.69" spread="17.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Erosion Change From BL (n=291, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="1.20"/>
                    <measurement group_id="O2" value="0.84" spread="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 365 Cohort JSN (n=291, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.83" spread="14.02"/>
                    <measurement group_id="O2" value="12.02" spread="14.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 JSN Change From BL(n=291, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="1.05"/>
                    <measurement group_id="O2" value="0.64" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 365 Cohort TS (n=291, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.48" spread="29.01"/>
                    <measurement group_id="O2" value="30.71" spread="30.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 TS Change From BL (n=291, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="1.99"/>
                    <measurement group_id="O2" value="1.48" spread="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 729 Cohort Erosion (n=290, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.40" spread="15.41"/>
                    <measurement group_id="O2" value="18.88" spread="17.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Erosion Change From BL (n=291, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="1.67"/>
                    <measurement group_id="O2" value="1.14" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 729 Cohort JSN (n=291, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.65" spread="13.80"/>
                    <measurement group_id="O2" value="12.21" spread="14.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 JSN Change From BL(n=291, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="1.40"/>
                    <measurement group_id="O2" value="1.05" spread="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 729 Cohort TS (n=291, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.05" spread="28.41"/>
                    <measurement group_id="O2" value="31.09" spread="30.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 TS Change From BL(n=291, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread="2.69"/>
                    <measurement group_id="O2" value="2.19" spread="5.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1093 Cohort Erosion (n=293,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.66" spread="15.78"/>
                    <measurement group_id="O2" value="18.69" spread="17.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1093 Erosion Change From BL (n=293, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="2.60"/>
                    <measurement group_id="O2" value="1.48" spread="3.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1093 Cohort JSN (n=293, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.84" spread="13.97"/>
                    <measurement group_id="O2" value="12.02" spread="14.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1093 JSN Change From BL (n=293, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="2.02"/>
                    <measurement group_id="O2" value="1.31" spread="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1093 Cohort TS (n=293, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.50" spread="28.94"/>
                    <measurement group_id="O2" value="30.71" spread="30.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1093 Total Score Change From BL (n=293, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="4.20"/>
                    <measurement group_id="O2" value="2.79" spread="6.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1457 Cohort Erosion (n=290,128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.46" spread="15.46"/>
                    <measurement group_id="O2" value="18.94" spread="17.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1457 Erosion Change From BL (n=290, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="3.14"/>
                    <measurement group_id="O2" value="1.76" spread="4.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1457 Cohort JSN (n=290, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.66" spread="13.71"/>
                    <measurement group_id="O2" value="12.12" spread="14.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1457 JSN Change From BL (n=290, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="2.30"/>
                    <measurement group_id="O2" value="1.51" spread="3.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1457 Cohort TS (n=290, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.12" spread="28.35"/>
                    <measurement group_id="O2" value="31.06" spread="31.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1457 TS Change From BL (n=290, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.01" spread="5.00"/>
                    <measurement group_id="O2" value="3.27" spread="7.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1821 Cohort Erosion (n=233,114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.62" spread="15.62"/>
                    <measurement group_id="O2" value="18.93" spread="17.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1821 Erosion Change From BL (n=233, 114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="2.99"/>
                    <measurement group_id="O2" value="2.05" spread="4.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1821 Cohort JSN (n=233, 114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.77" spread="13.73"/>
                    <measurement group_id="O2" value="12.01" spread="14.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1821 JSN Change From BL (n=233, 114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="2.54"/>
                    <measurement group_id="O2" value="1.73" spread="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1821 Cohort TS (n=233, 114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.39" spread="28.50"/>
                    <measurement group_id="O2" value="30.94" spread="30.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1821 TS Change From BL (n=233, 114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" spread="4.93"/>
                    <measurement group_id="O2" value="3.78" spread="8.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL Physical Component Summary of the SF-36 by Visit in the OL Period</title>
        <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 14,57, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the OL period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA + MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL Physical Component Summary of the SF-36 by Visit in the OL Period</title>
          <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 365 Cohort (n=370, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.69" spread="6.84"/>
                    <measurement group_id="O2" value="30.94" spread="7.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 449 Cohort (n=362, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.55" spread="6.78"/>
                    <measurement group_id="O2" value="30.95" spread="7.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 533 Cohort (n=355, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.64" spread="6.79"/>
                    <measurement group_id="O2" value="30.86" spread="7.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 617 Cohort (n=348, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.70" spread="6.81"/>
                    <measurement group_id="O2" value="30.88" spread="7.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 729 Cohort (n=338, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.75" spread="6.78"/>
                    <measurement group_id="O2" value="30.88" spread="7.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 813 Cohort (n=323, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.58" spread="6.66"/>
                    <measurement group_id="O2" value="31.00" spread="7.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 897 Cohort (n=320, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.52" spread="6.69"/>
                    <measurement group_id="O2" value="30.87" spread="7.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 981 Cohort (n=312, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.49" spread="6.64"/>
                    <measurement group_id="O2" value="30.98" spread="7.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,093 Cohort (n=308, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.51" spread="6.67"/>
                    <measurement group_id="O2" value="30.93" spread="7.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,177 Cohort (n=273, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.58" spread="6.78"/>
                    <measurement group_id="O2" value="30.87" spread="7.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,261 Cohort (n=289, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.64" spread="6.86"/>
                    <measurement group_id="O2" value="31.02" spread="7.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,345 Cohort (n=146, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.40" spread="6.32"/>
                    <measurement group_id="O2" value="29.37" spread="7.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,457 Cohort (n=288, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.51" spread="6.76"/>
                    <measurement group_id="O2" value="31.23" spread="7.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,625 Cohort (n=278, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.70" spread="6.78"/>
                    <measurement group_id="O2" value="30.90" spread="7.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,821 Cohort (n=273, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.54" spread="6.81"/>
                    <measurement group_id="O2" value="31.27" spread="7.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,989 Cohort (n=118, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.80" spread="6.72"/>
                    <measurement group_id="O2" value="30.66" spread="7.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 2,185 Cohort (n=84, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.80" spread="5.77"/>
                    <measurement group_id="O2" value="29.74" spread="5.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL by Visit in the Physical Component Summary of the SF-36 in the OL Period</title>
        <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 14,57, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the OL period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA + MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL by Visit in the Physical Component Summary of the SF-36 in the OL Period</title>
          <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 (n=370, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.70" spread="0.50"/>
                    <measurement group_id="O2" value="6.61" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 (n=362, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.51" spread="0.50"/>
                    <measurement group_id="O2" value="9.91" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 (n=355, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.27" spread="0.51"/>
                    <measurement group_id="O2" value="10.53" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 (n=348, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.46" spread="0.52"/>
                    <measurement group_id="O2" value="10.74" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n=338, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.71" spread="0.53"/>
                    <measurement group_id="O2" value="10.36" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 (n=323, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.79" spread="0.55"/>
                    <measurement group_id="O2" value="10.41" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 (n=320, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.30" spread="0.53"/>
                    <measurement group_id="O2" value="9.87" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 (n=312, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.05" spread="0.58"/>
                    <measurement group_id="O2" value="10.78" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,093 (n=308, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.83" spread="0.55"/>
                    <measurement group_id="O2" value="11.07" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,177 (n=273, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.02" spread="0.61"/>
                    <measurement group_id="O2" value="11.20" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,261 (n=289, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.40" spread="0.60"/>
                    <measurement group_id="O2" value="11.34" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,345 (n=146, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.81" spread="0.87"/>
                    <measurement group_id="O2" value="10.81" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,457 (n=288, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.12" spread="0.58"/>
                    <measurement group_id="O2" value="10.68" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,625 (n=278, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.76" spread="0.61"/>
                    <measurement group_id="O2" value="11.05" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,821 (n=273, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.81" spread="0.63"/>
                    <measurement group_id="O2" value="10.09" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,989 (n=118, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.69" spread="0.93"/>
                    <measurement group_id="O2" value="9.65" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,185 (n=84, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.69" spread="0.99"/>
                    <measurement group_id="O2" value="11.39" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL Mental Component Summary of the SF-36 by Visit in the OL Period</title>
        <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the OL period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA + MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL Mental Component Summary of the SF-36 by Visit in the OL Period</title>
          <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 365 Cohort (n=370, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.40" spread="11.35"/>
                    <measurement group_id="O2" value="40.56" spread="11.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 449 Cohort (n=362, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.20" spread="11.29"/>
                    <measurement group_id="O2" value="40.47" spread="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 533 Cohort (n=355, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.28" spread="11.20"/>
                    <measurement group_id="O2" value="40.53" spread="11.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 617 Cohort (n=348, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.23" spread="11.28"/>
                    <measurement group_id="O2" value="40.67" spread="11.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 729 Cohort (n=338, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.21" spread="11.28"/>
                    <measurement group_id="O2" value="40.24" spread="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 813 Cohort (n=323, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.23" spread="11.34"/>
                    <measurement group_id="O2" value="40.19" spread="11.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 897 Cohort (n=320, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.36" spread="11.41"/>
                    <measurement group_id="O2" value="40.28" spread="11.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 981 Cohort (n=312, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.40" spread="11.39"/>
                    <measurement group_id="O2" value="40.32" spread="11.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,093 Cohort (n=308, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.40" spread="11.25"/>
                    <measurement group_id="O2" value="40.33" spread="11.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,177 Cohort (n=273, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.28" spread="11.47"/>
                    <measurement group_id="O2" value="40.19" spread="11.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,261 Cohort (n=289, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.29" spread="11.45"/>
                    <measurement group_id="O2" value="40.26" spread="11.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,345 Cohort (n=146, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.11" spread="11.81"/>
                    <measurement group_id="O2" value="39.99" spread="10.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,457 Cohort (n=288, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.35" spread="11.45"/>
                    <measurement group_id="O2" value="40.06" spread="11.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,625 Cohort (n=278, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.25" spread="11.60"/>
                    <measurement group_id="O2" value="40.16" spread="11.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,821 Cohort (n=273, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.39" spread="11.60"/>
                    <measurement group_id="O2" value="40.03" spread="11.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,989 Cohort (n=118, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.73" spread="11.58"/>
                    <measurement group_id="O2" value="39.61" spread="9.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 2,185 Cohort (n=84, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.00" spread="11.97"/>
                    <measurement group_id="O2" value="37.55" spread="9.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL by Visit in the Mental Component Summary of the SF-36 in the OL Period</title>
        <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the OL period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA + MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL by Visit in the Mental Component Summary of the SF-36 in the OL Period</title>
          <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 (n=370, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.29" spread="0.60"/>
                    <measurement group_id="O2" value="6.41" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 (n=362, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.84" spread="0.63"/>
                    <measurement group_id="O2" value="7.73" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 (n=355, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.30" spread="0.62"/>
                    <measurement group_id="O2" value="7.20" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 (n=348, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.15" spread="0.64"/>
                    <measurement group_id="O2" value="6.88" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n=338, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.31" spread="0.61"/>
                    <measurement group_id="O2" value="8.07" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 (n=323, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.98" spread="0.67"/>
                    <measurement group_id="O2" value="7.15" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 (n=320, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.26" spread="0.69"/>
                    <measurement group_id="O2" value="8.54" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 (n=312, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.82" spread="0.69"/>
                    <measurement group_id="O2" value="7.76" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,093 (n=308, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.79" spread="0.69"/>
                    <measurement group_id="O2" value="6.09" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,177 (n=273, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.93" spread="0.73"/>
                    <measurement group_id="O2" value="7.65" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,261 (n=289, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.33" spread="0.74"/>
                    <measurement group_id="O2" value="7.04" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,345 (n=146, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.37" spread="1.00"/>
                    <measurement group_id="O2" value="7.42" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,457 (n=288, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.82" spread="0.74"/>
                    <measurement group_id="O2" value="7.19" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,625 (n=278, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.60" spread="0.74"/>
                    <measurement group_id="O2" value="6.99" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,821 (n=273, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.75" spread="0.75"/>
                    <measurement group_id="O2" value="9.08" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,989 (n=118, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.53" spread="1.14"/>
                    <measurement group_id="O2" value="8.74" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,185 (n=84, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.28" spread="1.28"/>
                    <measurement group_id="O2" value="9.91" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL Physical Function Component of the SF-36 by Visit in the OL Period</title>
        <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the OL period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA + MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL Physical Function Component of the SF-36 by Visit in the OL Period</title>
          <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 365 Cohort (n=373, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.79" spread="9.12"/>
                    <measurement group_id="O2" value="28.09" spread="8.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 449 Cohort (n=367, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.62" spread="9.06"/>
                    <measurement group_id="O2" value="28.07" spread="8.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 533 Cohort (n=355, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.63" spread="9.13"/>
                    <measurement group_id="O2" value="28.05" spread="8.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 617 Cohort (n=348, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.71" spread="9.13"/>
                    <measurement group_id="O2" value="28.02" spread="8.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 729 Cohort(n=338, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.68" spread="9.20"/>
                    <measurement group_id="O2" value="28.01" spread="8.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 813 Cohort (n=324, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.41" spread="8.97"/>
                    <measurement group_id="O2" value="28.01" spread="9.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 897 Cohort (n=320, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.36" spread="8.99"/>
                    <measurement group_id="O2" value="27.93" spread="9.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 981 Cohort (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.43" spread="9.01"/>
                    <measurement group_id="O2" value="28.10" spread="9.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,093 Cohort (n=310, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.43" spread="8.98"/>
                    <measurement group_id="O2" value="28.10" spread="9.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,177 Cohort (n=275, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.70" spread="8.95"/>
                    <measurement group_id="O2" value="27.91" spread="8.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,261 Cohort (n=292, 135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.62" spread="9.12"/>
                    <measurement group_id="O2" value="28.17" spread="9.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,345 Cohort (n=147, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.70" spread="8.97"/>
                    <measurement group_id="O2" value="26.49" spread="8.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,457 Cohort (n=290, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.35" spread="9.11"/>
                    <measurement group_id="O2" value="28.24" spread="9.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,625 Cohort (n=279, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.68" spread="9.10"/>
                    <measurement group_id="O2" value="27.98" spread="8.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,821 Cohort (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.50" spread="9.07"/>
                    <measurement group_id="O2" value="28.50" spread="9.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,989 Cohort (n=118, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.78" spread="8.86"/>
                    <measurement group_id="O2" value="27.75" spread="9.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 2,185 Cohort (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.94" spread="7.79"/>
                    <measurement group_id="O2" value="26.25" spread="7.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Clinically Significant Changes in Vital Signs in the OL Period</title>
        <description>Vital signs included body temperature, heart rate, and seated blood pressure. Clinically significant changes were defined as those that were not within the normal range for the participant.</description>
        <time_frame>Day 365 to Day 1,821. All changes in participant vital signs were monitored on each day of study drug administration prior to dosing and 60 minutes after dosing.</time_frame>
        <population>All treated participants entering the OL period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX OL</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Clinically Significant Changes in Vital Signs in the OL Period</title>
          <description>Vital signs included body temperature, heart rate, and seated blood pressure. Clinically significant changes were defined as those that were not within the normal range for the participant.</description>
          <population>All treated participants entering the OL period.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Body Temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing AEs of Special Interest in the OL Period</title>
        <description>AEs were defined as any new untoward medical occurrence or worsening of a pre- existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest have been identified to be those which may be associated with the use of immunomodulatory agents or infusion of therapeutic proteins. Acute infusional AEs were defined as those that occurred within 1 hour after the start of the infusion.</description>
        <time_frame>Day 365 to Day 2,185</time_frame>
        <population>All treated participants in the OL period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX OL</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing AEs of Special Interest in the OL Period</title>
          <description>AEs were defined as any new untoward medical occurrence or worsening of a pre- existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest have been identified to be those which may be associated with the use of immunomodulatory agents or infusion of therapeutic proteins. Acute infusional AEs were defined as those that occurred within 1 hour after the start of the infusion.</description>
          <population>All treated participants in the OL period.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infections/Infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neoplasms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Autoimmune Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Infusional AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peri-Infusional AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean BL Hematocrit in the OL Period</title>
        <description>Mean baseline values are those that are reported for each cohort at each time point on Day 365 to Day 2,185.</description>
        <time_frame>Baseline (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
        <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period). N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL Hematocrit in the OL Period</title>
          <description>Mean baseline values are those that are reported for each cohort at each time point on Day 365 to Day 2,185.</description>
          <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period). N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Percentage of Red Blood Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.79" spread="4.60"/>
                    <measurement group_id="O2" value="39.38" spread="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.72" spread="4.52"/>
                    <measurement group_id="O2" value="39.39" spread="4.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.69" spread="4.57"/>
                    <measurement group_id="O2" value="39.46" spread="4.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.59" spread="4.48"/>
                    <measurement group_id="O2" value="39.40" spread="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.70" spread="4.44"/>
                    <measurement group_id="O2" value="39.48" spread="4.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.11" spread="4.56"/>
                    <measurement group_id="O2" value="39.83" spread="3.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.07" spread="4.78"/>
                    <measurement group_id="O2" value="39.99" spread="4.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.11" spread="3.92"/>
                    <measurement group_id="O2" value="39.12" spread="3.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.25" spread="3.83"/>
                    <measurement group_id="O2" value="39.02" spread="3.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From BL in Participant Hematocrit in the OL Period</title>
        <description>All changes in participant laboratory parameters were monitored on each day of study drug administration.</description>
        <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
        <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period).N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in Participant Hematocrit in the OL Period</title>
          <description>All changes in participant laboratory parameters were monitored on each day of study drug administration.</description>
          <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period).N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Percentage Blood Volume Occupied by RBCs</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.21"/>
                    <measurement group_id="O2" value="-0.04" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.16" spread="0.20"/>
                    <measurement group_id="O2" value="1.36" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="0.20"/>
                    <measurement group_id="O2" value="0.56" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="0.23"/>
                    <measurement group_id="O2" value="1.01" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="0.25"/>
                    <measurement group_id="O2" value="0.78" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.34"/>
                    <measurement group_id="O2" value="0.59" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.38"/>
                    <measurement group_id="O2" value="0.94" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" spread="0.42"/>
                    <measurement group_id="O2" value="0.20" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.37"/>
                    <measurement group_id="O2" value="0.65" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean BL Platelet Count in the OL Period</title>
        <description>Mean baseline values are those that are reported for each cohort at each time point on Day 365 to Day 2,185.</description>
        <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
        <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period).N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL Platelet Count in the OL Period</title>
          <description>Mean baseline values are those that are reported for each cohort at each time point on Day 365 to Day 2,185.</description>
          <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period).N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>10^9 c/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="352.7" spread="108.5"/>
                    <measurement group_id="O2" value="339.2" spread="97.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="351.8" spread="110.4"/>
                    <measurement group_id="O2" value="334.2" spread="91.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="351.7" spread="107.9"/>
                    <measurement group_id="O2" value="334.8" spread="96.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="352.7" spread="106.4"/>
                    <measurement group_id="O2" value="335.0" spread="98.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="351.1" spread="98.28"/>
                    <measurement group_id="O2" value="334.2" spread="97.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="365.7" spread="113.9"/>
                    <measurement group_id="O2" value="333.7" spread="89.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="366.1" spread="115.3"/>
                    <measurement group_id="O2" value="326.6" spread="86.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="375.2" spread="118.6"/>
                    <measurement group_id="O2" value="321.2" spread="90.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380.4" spread="119.7"/>
                    <measurement group_id="O2" value="320.3" spread="91.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From BL in Participant Platelet Count in the OL Period</title>
        <description>All changes in participant laboratory parameters were monitored on each day of study drug administration.</description>
        <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
        <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period). N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in Participant Platelet Count in the OL Period</title>
          <description>All changes in participant laboratory parameters were monitored on each day of study drug administration.</description>
          <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period). N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>10^9 c/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-66.9" spread="4.29"/>
                    <measurement group_id="O2" value="-29.9" spread="5.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-59.5" spread="4.64"/>
                    <measurement group_id="O2" value="-45.4" spread="6.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.5" spread="5.10"/>
                    <measurement group_id="O2" value="-36.8" spread="7.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-59.0" spread="5.64"/>
                    <measurement group_id="O2" value="-48.7" spread="7.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-68.9" spread="4.92"/>
                    <measurement group_id="O2" value="-59.2" spread="7.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-55.1" spread="14.57"/>
                    <measurement group_id="O2" value="-47.5" spread="10.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-63.7" spread="8.33"/>
                    <measurement group_id="O2" value="-50.3" spread="9.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-69.6" spread="10.64"/>
                    <measurement group_id="O2" value="-55.3" spread="11.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-80.5" spread="10.68"/>
                    <measurement group_id="O2" value="-53.9" spread="10.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean BL Hemoglobin, Total Protein, and Albumin in the OL Period</title>
        <description>Mean baseline values are those that are reported for each cohort at each time point on Day 365 to Day 2,185.</description>
        <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
        <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period). N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL Hemoglobin, Total Protein, and Albumin in the OL Period</title>
          <description>Mean baseline values are those that are reported for each cohort at each time point on Day 365 to Day 2,185.</description>
          <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period). N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.49" spread="1.57"/>
                    <measurement group_id="O2" value="12.70" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.23" spread="0.52"/>
                    <measurement group_id="O2" value="7.35" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.03" spread="0.33"/>
                    <measurement group_id="O2" value="4.13" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.50" spread="1.54"/>
                    <measurement group_id="O2" value="12.72" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.22" spread="0.52"/>
                    <measurement group_id="O2" value="7.34" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.01" spread="0.33"/>
                    <measurement group_id="O2" value="4.12" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.48" spread="1.55"/>
                    <measurement group_id="O2" value="12.75" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.23" spread="0.51"/>
                    <measurement group_id="O2" value="7.34" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.02" spread="0.33"/>
                    <measurement group_id="O2" value="4.11" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.46" spread="1.54"/>
                    <measurement group_id="O2" value="12.74" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.23" spread="0.51"/>
                    <measurement group_id="O2" value="7.35" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.02" spread="0.33"/>
                    <measurement group_id="O2" value="4.12" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.49" spread="1.51"/>
                    <measurement group_id="O2" value="12.79" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.23" spread="0.49"/>
                    <measurement group_id="O2" value="7.37" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.02" spread="0.33"/>
                    <measurement group_id="O2" value="4.13" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.35" spread="1.55"/>
                    <measurement group_id="O2" value="12.88" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.27" spread="0.52"/>
                    <measurement group_id="O2" value="7.35" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.03" spread="0.32"/>
                    <measurement group_id="O2" value="4.13" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.35" spread="1.60"/>
                    <measurement group_id="O2" value="12.98" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.25" spread="0.51"/>
                    <measurement group_id="O2" value="7.38" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.03" spread="0.33"/>
                    <measurement group_id="O2" value="4.12" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.21" spread="1.46"/>
                    <measurement group_id="O2" value="12.84" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.18" spread="0.47"/>
                    <measurement group_id="O2" value="7.27" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.98" spread="0.33"/>
                    <measurement group_id="O2" value="4.08" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.25" spread="1.44"/>
                    <measurement group_id="O2" value="12.82" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.18" spread="0.47"/>
                    <measurement group_id="O2" value="7.28" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.97" spread="0.32"/>
                    <measurement group_id="O2" value="4.08" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From BL in Hemoglobin, Total Protein, and Albumin in the OL Period</title>
        <description>All changes in participant laboratory parameters were monitored on each day of study drug administration.</description>
        <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
        <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period). N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in Hemoglobin, Total Protein, and Albumin in the OL Period</title>
          <description>All changes in participant laboratory parameters were monitored on each day of study drug administration.</description>
          <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period). N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="0.07"/>
                    <measurement group_id="O2" value="-0.09" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="0.02"/>
                    <measurement group_id="O2" value="-0.25" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.02"/>
                    <measurement group_id="O2" value="0.02" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="0.07"/>
                    <measurement group_id="O2" value="0.61" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.03"/>
                    <measurement group_id="O2" value="-0.05" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.02"/>
                    <measurement group_id="O2" value="0.23" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.07"/>
                    <measurement group_id="O2" value="0.40" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.03"/>
                    <measurement group_id="O2" value="-0.26" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.02"/>
                    <measurement group_id="O2" value="0.02" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="0.07"/>
                    <measurement group_id="O2" value="0.52" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.03"/>
                    <measurement group_id="O2" value="-0.35" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.02"/>
                    <measurement group_id="O2" value="-0.02" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="0.08"/>
                    <measurement group_id="O2" value="0.70" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.03"/>
                    <measurement group_id="O2" value="-0.35" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.02"/>
                    <measurement group_id="O2" value="-0.05" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="0.12"/>
                    <measurement group_id="O2" value="0.39" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.05"/>
                    <measurement group_id="O2" value="-0.31" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.03"/>
                    <measurement group_id="O2" value="-0.06" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="0.13"/>
                    <measurement group_id="O2" value="0.41" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.05"/>
                    <measurement group_id="O2" value="-0.33" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.03"/>
                    <measurement group_id="O2" value="0.01" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" spread="0.15"/>
                    <measurement group_id="O2" value="0.23" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.04"/>
                    <measurement group_id="O2" value="-0.24" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.03"/>
                    <measurement group_id="O2" value="0.09" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="0.14"/>
                    <measurement group_id="O2" value="0.40" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.04"/>
                    <measurement group_id="O2" value="-0.12" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.03"/>
                    <measurement group_id="O2" value="0.25" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL by Visit in the Physical Function Component of the SF-36 in the OL Period</title>
        <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the OL period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA + MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL by Visit in the Physical Function Component of the SF-36 in the OL Period</title>
          <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 (n=373, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.61" spread="0.58"/>
                    <measurement group_id="O2" value="6.44" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 (n=367, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.44" spread="0.57"/>
                    <measurement group_id="O2" value="9.13" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 (n=355, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.43" spread="0.59"/>
                    <measurement group_id="O2" value="9.46" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 (n=348, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.43" spread="0.57"/>
                    <measurement group_id="O2" value="9.80" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n=338, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.51" spread="0.61"/>
                    <measurement group_id="O2" value="9.63" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 (n=324, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.17" spread="0.62"/>
                    <measurement group_id="O2" value="9.71" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 (n=320, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.95" spread="0.60"/>
                    <measurement group_id="O2" value="9.39" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.23" spread="0.63"/>
                    <measurement group_id="O2" value="10.45" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,093 (n=310, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.40" spread="0.63"/>
                    <measurement group_id="O2" value="10.35" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,177 (n=275, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.74" spread="0.71"/>
                    <measurement group_id="O2" value="10.57" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,261 (n=292, 135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.95" spread="0.68"/>
                    <measurement group_id="O2" value="9.92" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,345 (n=147, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.18" spread="1.00"/>
                    <measurement group_id="O2" value="10.75" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,457 (n=290, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.55" spread="0.70"/>
                    <measurement group_id="O2" value="10.03" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,625 (n=279, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.80" spread="0.72"/>
                    <measurement group_id="O2" value="9.68" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,821 (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.48" spread="0.75"/>
                    <measurement group_id="O2" value="9.08" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,989 (n=118, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.35" spread="1.17"/>
                    <measurement group_id="O2" value="9.22" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,185 (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.06" spread="1.22"/>
                    <measurement group_id="O2" value="10.90" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL Role-Physical Component of the SF-36 by Visit in the OL Period</title>
        <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the OL period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA + MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL Role-Physical Component of the SF-36 by Visit in the OL Period</title>
          <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 365 Cohort (n=372, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.06" spread="7.78"/>
                    <measurement group_id="O2" value="32.08" spread="7.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 449 Cohort (n=367, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.88" spread="7.64"/>
                    <measurement group_id="O2" value="32.02" spread="7.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 533 Cohort (n=355, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.02" spread="7.78"/>
                    <measurement group_id="O2" value="32.11" spread="7.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 617 Cohort (n=348, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.04" spread="7.81"/>
                    <measurement group_id="O2" value="32.14" spread="7.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 729 Cohort (n=338, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.12" spread="7.86"/>
                    <measurement group_id="O2" value="31.79" spread="6.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 813 Cohort (n=324, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.93" spread="7.65"/>
                    <measurement group_id="O2" value="31.91" spread="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 897 Cohort (n=320, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.91" spread="7.56"/>
                    <measurement group_id="O2" value="32.01" spread="7.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 981 Cohort (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.83" spread="7.52"/>
                    <measurement group_id="O2" value="32.05" spread="7.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,093 Cohort (n=309, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.82" spread="7.52"/>
                    <measurement group_id="O2" value="32.02" spread="7.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,177 Cohort (n=275, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.84" spread="7.55"/>
                    <measurement group_id="O2" value="31.88" spread="7.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,261 Cohort (n=292, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.83" spread="7.56"/>
                    <measurement group_id="O2" value="32.09" spread="7.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,345 Cohort (n=147, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.90" spread="7.13"/>
                    <measurement group_id="O2" value="31.66" spread="6.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,457 Cohort (n=289, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.82" spread="7.57"/>
                    <measurement group_id="O2" value="32.08" spread="7.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,625 Cohort (n=279, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.88" spread="7.60"/>
                    <measurement group_id="O2" value="31.96" spread="7.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,821 Cohort (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.87" spread="7.71"/>
                    <measurement group_id="O2" value="31.71" spread="6.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,989 Cohort (n=118, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.79" spread="7.72"/>
                    <measurement group_id="O2" value="31.43" spread="6.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 2,185 Cohort (n=84, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.98" spread="6.88"/>
                    <measurement group_id="O2" value="30.56" spread="5.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL by Visit in the Role-Physical Component of the SF-36 in the OL Period</title>
        <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the OL period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA + MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL by Visit in the Role-Physical Component of the SF-36 in the OL Period</title>
          <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 (n=372, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.10" spread="0.67"/>
                    <measurement group_id="O2" value="7.59" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 (n=367, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.66" spread="0.70"/>
                    <measurement group_id="O2" value="10.89" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 (n=355, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.18" spread="0.70"/>
                    <measurement group_id="O2" value="10.98" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 (n=348, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.93" spread="0.73"/>
                    <measurement group_id="O2" value="11.61" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n=338, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.33" spread="0.72"/>
                    <measurement group_id="O2" value="11.50" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 (n=324, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.56" spread="0.73"/>
                    <measurement group_id="O2" value="10.57" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 (n=320, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.13" spread="0.74"/>
                    <measurement group_id="O2" value="10.96" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.96" spread="0.76"/>
                    <measurement group_id="O2" value="10.88" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,093 (n=309, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.82" spread="0.76"/>
                    <measurement group_id="O2" value="9.72" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,177 (n=275, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.32" spread="0.82"/>
                    <measurement group_id="O2" value="11.09" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,261 (n=292, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.25" spread="0.82"/>
                    <measurement group_id="O2" value="11.61" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,345 (n=147, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.09" spread="1.13"/>
                    <measurement group_id="O2" value="10.32" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,457 (n=289, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.57" spread="0.79"/>
                    <measurement group_id="O2" value="11.39" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,625 (n=279, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.11" spread="0.80"/>
                    <measurement group_id="O2" value="11.10" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,821 (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.25" spread="0.84"/>
                    <measurement group_id="O2" value="10.62" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,989 (n=118, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.79" spread="1.31"/>
                    <measurement group_id="O2" value="10.42" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,185 (n=84, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.04" spread="1.41"/>
                    <measurement group_id="O2" value="12.84" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL Bodily Pain Component of the SF-36 by Visit in the OL Period</title>
        <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>AlAll treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the OL period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA + MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL Bodily Pain Component of the SF-36 by Visit in the OL Period</title>
          <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
          <population>AlAll treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 365 Cohort (n=373, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.13" spread="7.37"/>
                    <measurement group_id="O2" value="33.43" spread="7.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 449 Cohort (n=367, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.95" spread="7.36"/>
                    <measurement group_id="O2" value="33.47" spread="7.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 533 Cohort (n=355, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.05" spread="7.36"/>
                    <measurement group_id="O2" value="33.27" spread="7.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 617 Cohort (n=348, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.00" spread="7.30"/>
                    <measurement group_id="O2" value="33.49" spread="7.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 729 Cohort (n=338, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.94" spread="7.38"/>
                    <measurement group_id="O2" value="33.44" spread="7.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 813 Cohort (n=324, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.80" spread="7.27"/>
                    <measurement group_id="O2" value="33.53" spread="7.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 897 Cohort (n=320, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.80" spread="7.33"/>
                    <measurement group_id="O2" value="33.29" spread="7.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 981 Cohort (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.79" spread="7.28"/>
                    <measurement group_id="O2" value="33.29" spread="7.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,093 Cohort (n=309, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.88" spread="7.30"/>
                    <measurement group_id="O2" value="33.29" spread="7.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,177 Cohort (n=275, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.84" spread="7.34"/>
                    <measurement group_id="O2" value="33.13" spread="7.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,261 Cohort (n=291, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.81" spread="7.50"/>
                    <measurement group_id="O2" value="33.31" spread="7.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,345 Cohort (n=147, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.57" spread="7.37"/>
                    <measurement group_id="O2" value="31.83" spread="6.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,457 Cohort (n=289, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.73" spread="7.35"/>
                    <measurement group_id="O2" value="33.48" spread="7.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,625 Cohort (n=279, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.78" spread="7.36"/>
                    <measurement group_id="O2" value="33.20" spread="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,821 Cohort (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.85" spread="7.44"/>
                    <measurement group_id="O2" value="33.56" spread="7.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,989 Cohort (n=118, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.98" spread="7.20"/>
                    <measurement group_id="O2" value="32.81" spread="7.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 2,185 Cohort (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.49" spread="6.81"/>
                    <measurement group_id="O2" value="31.40" spread="5.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL by Visit in the Bodily Pain Component of the SF-36 in the OL Period</title>
        <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the OL period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA + MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL by Visit in the Bodily Pain Component of the SF-36 in the OL Period</title>
          <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 (n=373, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.08" spread="0.51"/>
                    <measurement group_id="O2" value="7.98" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 (n=367, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.38" spread="0.53"/>
                    <measurement group_id="O2" value="11.78" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 (n=355, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.94" spread="0.55"/>
                    <measurement group_id="O2" value="12.53" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 (n=348, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.52" spread="0.56"/>
                    <measurement group_id="O2" value="11.97" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n=338, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.84" spread="0.57"/>
                    <measurement group_id="O2" value="12.06" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 (n=324, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.13" spread="0.60"/>
                    <measurement group_id="O2" value="12.25" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 (n=320, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.44" spread="0.59"/>
                    <measurement group_id="O2" value="11.84" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.86" spread="0.63"/>
                    <measurement group_id="O2" value="12.87" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,093 (n=309, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.34" spread="0.60"/>
                    <measurement group_id="O2" value="12.93" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,177 (n=275, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.21" spread="0.67"/>
                    <measurement group_id="O2" value="13.44" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,261 (n=291, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.83" spread="0.68"/>
                    <measurement group_id="O2" value="13.31" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,345 (n=147, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.44" spread="0.98"/>
                    <measurement group_id="O2" value="13.40" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,457 (n=289, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.13" spread="0.60"/>
                    <measurement group_id="O2" value="11.74" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,625 (n=279, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.89" spread="0.63"/>
                    <measurement group_id="O2" value="13.36" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,821 (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.56" spread="0.67"/>
                    <measurement group_id="O2" value="12.65" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,989 (n=118, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.45" spread="0.98"/>
                    <measurement group_id="O2" value="13.19" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,185 (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.44" spread="1.18"/>
                    <measurement group_id="O2" value="14.28" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL General Health Component of the SF-36 by Visit in the OL Period</title>
        <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the OL period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA + MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL General Health Component of the SF-36 by Visit in the OL Period</title>
          <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 365 Cohort (n=373, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.43" spread="8.41"/>
                    <measurement group_id="O2" value="35.27" spread="7.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 449 Cohort (n=367, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.33" spread="8.45"/>
                    <measurement group_id="O2" value="35.28" spread="7.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 533 Cohort (n=355, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.34" spread="8.40"/>
                    <measurement group_id="O2" value="35.17" spread="7.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 617 Cohort (n=348, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.41" spread="8.38"/>
                    <measurement group_id="O2" value="35.21" spread="7.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 729 Cohort (n=338, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.47" spread="8.46"/>
                    <measurement group_id="O2" value="35.16" spread="7.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 813 Cohort (n=324, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.59" spread="8.45"/>
                    <measurement group_id="O2" value="35.19" spread="7.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 897 Cohort (n=320, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.72" spread="8.50"/>
                    <measurement group_id="O2" value="35.22" spread="7.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 981 Cohort (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.67" spread="8.46"/>
                    <measurement group_id="O2" value="35.38" spread="7.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,093 Cohort (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.69" spread="8.52"/>
                    <measurement group_id="O2" value="35.32" spread="7.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,177 Cohort (n=275, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.50" spread="8.38"/>
                    <measurement group_id="O2" value="35.54" spread="7.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,261 Cohort (n=291, 135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.65" spread="8.38"/>
                    <measurement group_id="O2" value="35.31" spread="7.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,345 Cohort (n=147, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.88" spread="8.68"/>
                    <measurement group_id="O2" value="33.78" spread="7.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,457 Cohort (n=290, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.56" spread="8.48"/>
                    <measurement group_id="O2" value="35.43" spread="7.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,625 Cohort (n=280, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.67" spread="8.33"/>
                    <measurement group_id="O2" value="35.23" spread="7.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,821 Cohort (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.61" spread="8.46"/>
                    <measurement group_id="O2" value="35.56" spread="7.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,989 Cohort (n=119, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.87" spread="8.65"/>
                    <measurement group_id="O2" value="34.94" spread="8.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 2,185 Cohort (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.29" spread="9.03"/>
                    <measurement group_id="O2" value="33.71" spread="8.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL by Visit in the General Health Component of the SF-36 in the OL Period</title>
        <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the OL period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA + MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL by Visit in the General Health Component of the SF-36 in the OL Period</title>
          <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 (n=373, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.88" spread="0.46"/>
                    <measurement group_id="O2" value="5.43" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 (n=367, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.94" spread="0.46"/>
                    <measurement group_id="O2" value="7.32" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 (n=355, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.82" spread="0.47"/>
                    <measurement group_id="O2" value="7.88" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 (n=348, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.22" spread="0.45"/>
                    <measurement group_id="O2" value="7.87" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n=338, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.31" spread="0.46"/>
                    <measurement group_id="O2" value="7.90" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 (n=324, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.89" spread="0.49"/>
                    <measurement group_id="O2" value="7.63" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 (n=320, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.86" spread="0.52"/>
                    <measurement group_id="O2" value="8.24" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.31" spread="0.53"/>
                    <measurement group_id="O2" value="8.45" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.24" spread="0.55"/>
                    <measurement group_id="O2" value="8.36" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,177 (n=275, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.48" spread="0.57"/>
                    <measurement group_id="O2" value="8.55" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,261 (n=291, 135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.18" spread="0.58"/>
                    <measurement group_id="O2" value="8.17" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,345 (n=147, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.19" spread="0.73"/>
                    <measurement group_id="O2" value="8.45" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,457 (n=290, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.07" spread="0.57"/>
                    <measurement group_id="O2" value="8.32" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,625 (n=280, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.27" spread="0.57"/>
                    <measurement group_id="O2" value="8.10" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,821 (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.50" spread="0.60"/>
                    <measurement group_id="O2" value="7.53" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,989 (n=119, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.55" spread="0.81"/>
                    <measurement group_id="O2" value="7.05" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,185 (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.93" spread="1.02"/>
                    <measurement group_id="O2" value="8.76" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL Social Functioning Component of the SF-36 by Visit in the OL Period</title>
        <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the OL period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA + MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL Social Functioning Component of the SF-36 by Visit in the OL Period</title>
          <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 365 Cohort (n=373, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.58" spread="10.10"/>
                    <measurement group_id="O2" value="34.98" spread="9.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 449 Cohort (n=368, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.42" spread="10.13"/>
                    <measurement group_id="O2" value="34.91" spread="9.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 533 Cohort (n=355, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.52" spread="10.18"/>
                    <measurement group_id="O2" value="34.94" spread="9.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 617 Cohort (n=348, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.46" spread="10.14"/>
                    <measurement group_id="O2" value="35.01" spread="9.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 729 Cohort (n=338, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.70" spread="10.24"/>
                    <measurement group_id="O2" value="34.51" spread="9.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 813 Cohort (n=324, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.47" spread="10.17"/>
                    <measurement group_id="O2" value="34.57" spread="9.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 897 Cohort (n=320, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.47" spread="10.20"/>
                    <measurement group_id="O2" value="34.65" spread="9.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 981 Cohort (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.46" spread="10.17"/>
                    <measurement group_id="O2" value="34.67" spread="9.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,093 Cohort (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.60" spread="10.07"/>
                    <measurement group_id="O2" value="34.68" spread="9.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,177 Cohort (n=275, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.52" spread="10.10"/>
                    <measurement group_id="O2" value="34.51" spread="9.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,261 Cohort (n=292, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.48" spread="10.24"/>
                    <measurement group_id="O2" value="34.82" spread="9.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,345 Cohort (n=147, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.65" spread="10.53"/>
                    <measurement group_id="O2" value="33.24" spread="9.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,457 Cohort (n=289, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.56" spread="10.28"/>
                    <measurement group_id="O2" value="34.83" spread="9.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,625 Cohort (n=280, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.44" spread="10.45"/>
                    <measurement group_id="O2" value="34.73" spread="9.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,821 Cohort (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.56" spread="10.42"/>
                    <measurement group_id="O2" value="34.86" spread="9.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,989 Cohort (n=118, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.50" spread="10.41"/>
                    <measurement group_id="O2" value="33.75" spread="8.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 2,185 Cohort (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.66" spread="10.43"/>
                    <measurement group_id="O2" value="31.85" spread="8.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL by Visit in the Social Functioning Component of the SF-36 in the OL Period</title>
        <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the OL period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA + MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL by Visit in the Social Functioning Component of the SF-36 in the OL Period</title>
          <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 (n=373, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.01" spread="0.61"/>
                    <measurement group_id="O2" value="7.12" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 (n=368, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.74" spread="0.61"/>
                    <measurement group_id="O2" value="9.47" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 (n=355, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.88" spread="0.62"/>
                    <measurement group_id="O2" value="9.44" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 (n=348, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.48" spread="0.62"/>
                    <measurement group_id="O2" value="8.66" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n=338, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.99" spread="0.63"/>
                    <measurement group_id="O2" value="9.90" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 (n=324, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.80" spread="0.67"/>
                    <measurement group_id="O2" value="8.97" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 (n=320, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.96" spread="0.67"/>
                    <measurement group_id="O2" value="9.81" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.71" spread="0.66"/>
                    <measurement group_id="O2" value="9.51" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.16" spread="0.68"/>
                    <measurement group_id="O2" value="8.61" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,177 (n=275, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.28" spread="0.71"/>
                    <measurement group_id="O2" value="9.64" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,261 (n=292, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.54" spread="0.73"/>
                    <measurement group_id="O2" value="9.92" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,345 (n=147, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.01" spread="1.11"/>
                    <measurement group_id="O2" value="8.84" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,457 (n=289, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.16" spread="0.72"/>
                    <measurement group_id="O2" value="9.26" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,625 (n=280, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.67" spread="0.73"/>
                    <measurement group_id="O2" value="9.05" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,821 (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.93" spread="0.75"/>
                    <measurement group_id="O2" value="8.16" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,989 (n=118, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.34" spread="1.17"/>
                    <measurement group_id="O2" value="10.17" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,185 (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.98" spread="1.31"/>
                    <measurement group_id="O2" value="10.57" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL Role-Emotional Component of the SF-36 by Visit in the OL Period</title>
        <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the OL period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA + MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL Role-Emotional Component of the SF-36 by Visit in the OL Period</title>
          <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 365 Cohort (n= 370, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.78" spread="13.63"/>
                    <measurement group_id="O2" value="33.40" spread="12.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 449 Cohort (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.71" spread="13.61"/>
                    <measurement group_id="O2" value="33.26" spread="12.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 533 Cohort (n=355, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.61" spread="13.57"/>
                    <measurement group_id="O2" value="33.39" spread="12.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 617 Cohort (n=348, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.66" spread="13.55"/>
                    <measurement group_id="O2" value="33.52" spread="12.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 729 Cohort (n=338, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.49" spread="13.49"/>
                    <measurement group_id="O2" value="33.34" spread="12.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 813 Cohort (n=324, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.38" spread="13.42"/>
                    <measurement group_id="O2" value="33.26" spread="12.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 897 Cohort (n=320, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.46" spread="13.40"/>
                    <measurement group_id="O2" value="33.13" spread="12.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 981 Cohort (n=312, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.42" spread="13.36"/>
                    <measurement group_id="O2" value="33.19" spread="12.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,093 Cohort (n=309, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.40" spread="13.36"/>
                    <measurement group_id="O2" value="33.27" spread="12.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,177 Cohort (n=275, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.46" spread="13.34"/>
                    <measurement group_id="O2" value="33.42" spread="12.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,261 Cohort (n=291, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.61" spread="13.44"/>
                    <measurement group_id="O2" value="33.00" spread="12.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,345 Cohort (n=146, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.00" spread="13.78"/>
                    <measurement group_id="O2" value="32.69" spread="12.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,457 Cohort (n=289, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.36" spread="13.44"/>
                    <measurement group_id="O2" value="32.79" spread="12.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,625 Cohort (n=279, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.33" spread="13.39"/>
                    <measurement group_id="O2" value="32.92" spread="12.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,821 Cohort (n=273, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.43" spread="13.50"/>
                    <measurement group_id="O2" value="32.74" spread="12.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,989 Cohort (n=118, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.61" spread="13.67"/>
                    <measurement group_id="O2" value="30.76" spread="11.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 2,185 Cohort (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.26" spread="13.76"/>
                    <measurement group_id="O2" value="29.28" spread="10.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL by Visit in the Role-Emotional Component of the SF-36 in the OL Period</title>
        <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the OL period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA + MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL by Visit in the Role-Emotional Component of the SF-36 in the OL Period</title>
          <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 (n= 370, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.97" spread="0.81"/>
                    <measurement group_id="O2" value="8.60" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.02" spread="0.86"/>
                    <measurement group_id="O2" value="10.80" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 (n=355, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.44" spread="0.88"/>
                    <measurement group_id="O2" value="10.13" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 (n=348, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.60" spread="0.88"/>
                    <measurement group_id="O2" value="10.47" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n=338, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.96" spread="0.86"/>
                    <measurement group_id="O2" value="10.89" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 (n=324, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.71" spread="0.89"/>
                    <measurement group_id="O2" value="11.04" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 (n=320, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.48" spread="0.90"/>
                    <measurement group_id="O2" value="11.67" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 (n=312, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.61" spread="0.92"/>
                    <measurement group_id="O2" value="11.70" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,093 (n=309, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.31" spread="0.94"/>
                    <measurement group_id="O2" value="9.46" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,177 (n=275, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.35" spread="1.01"/>
                    <measurement group_id="O2" value="11.17" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,261 (n=291, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.43" spread="1.00"/>
                    <measurement group_id="O2" value="10.53" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,345 (n=146, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.22" spread="1.35"/>
                    <measurement group_id="O2" value="11.41" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,457 (n=289, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.51" spread="0.98"/>
                    <measurement group_id="O2" value="10.70" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,625 (n=279, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.91" spread="1.02"/>
                    <measurement group_id="O2" value="9.44" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,821 (n=273, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.39" spread="0.71"/>
                    <measurement group_id="O2" value="6.56" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,989 (n=118, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.81" spread="1.60"/>
                    <measurement group_id="O2" value="12.49" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,185 (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.06" spread="1.69"/>
                    <measurement group_id="O2" value="16.08" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL Vitality Component of the SF-36 by Visit in the OL Period</title>
        <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the OL period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA + MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL Vitality Component of the SF-36 by Visit in the OL Period</title>
          <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 365 Cohort (n=373, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.93" spread="9.14"/>
                    <measurement group_id="O2" value="41.29" spread="8.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 449 Cohort (n=368, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.77" spread="9.11"/>
                    <measurement group_id="O2" value="41.21" spread="8.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 533 Cohort (n=355, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.68" spread="8.99"/>
                    <measurement group_id="O2" value="41.21" spread="8.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 617 Cohort (n=348, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.77" spread="9.02"/>
                    <measurement group_id="O2" value="41.40" spread="8.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 729 Cohort (n=338, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.74" spread="9.11"/>
                    <measurement group_id="O2" value="41.19" spread="8.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 813 Cohort (n=323, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.60" spread="9.06"/>
                    <measurement group_id="O2" value="41.27" spread="8.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 897 Cohort (n=320, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.79" spread="9.11"/>
                    <measurement group_id="O2" value="41.34" spread="8.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 981 Cohort (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.85" spread="9.00"/>
                    <measurement group_id="O2" value="41.43" spread="8.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,093 Cohort (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.85" spread="9.07"/>
                    <measurement group_id="O2" value="41.33" spread="8.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,177 Cohort (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.69" spread="9.23"/>
                    <measurement group_id="O2" value="41.23" spread="8.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,261 Cohort (n=292, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.78" spread="9.15"/>
                    <measurement group_id="O2" value="41.31" spread="8.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,345 Cohort (n=147, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.30" spread="9.39"/>
                    <measurement group_id="O2" value="40.64" spread="7.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,457 Cohort (n=290, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.79" spread="9.21"/>
                    <measurement group_id="O2" value="41.47" spread="8.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,625 Cohort (n=280, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.84" spread="9.18"/>
                    <measurement group_id="O2" value="41.23" spread="8.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,821 Cohort (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.82" spread="9.27"/>
                    <measurement group_id="O2" value="41.47" spread="8.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,989 Cohort (n=118, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.19" spread="8.85"/>
                    <measurement group_id="O2" value="41.72" spread="8.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 2,185 Cohort (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.16" spread="9.08"/>
                    <measurement group_id="O2" value="39.88" spread="8.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL by Visit in the Vitality Component of the SF-36 in the OL Period</title>
        <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the OL period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA + MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL by Visit in the Vitality Component of the SF-36 in the OL Period</title>
          <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 (n=373, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.58" spread="0.55"/>
                    <measurement group_id="O2" value="6.04" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 (n=368, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.29" spread="0.55"/>
                    <measurement group_id="O2" value="8.70" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 (n=355, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.68" spread="0.52"/>
                    <measurement group_id="O2" value="8.09" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 (n=348, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.61" spread="0.53"/>
                    <measurement group_id="O2" value="8.46" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n=338, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.69" spread="0.55"/>
                    <measurement group_id="O2" value="8.41" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 (n=323, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.99" spread="0.58"/>
                    <measurement group_id="O2" value="8.22" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 (n=320, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.69" spread="0.57"/>
                    <measurement group_id="O2" value="8.53" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.85" spread="0.58"/>
                    <measurement group_id="O2" value="7.52" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.98" spread="0.56"/>
                    <measurement group_id="O2" value="7.53" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,177 (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.08" spread="0.63"/>
                    <measurement group_id="O2" value="8.08" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,261 (n=292, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.39" spread="0.64"/>
                    <measurement group_id="O2" value="8.14" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,345 (n=147, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.29" spread="0.91"/>
                    <measurement group_id="O2" value="6.39" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,457 (n=290, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.19" spread="0.62"/>
                    <measurement group_id="O2" value="7.57" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,625 (n=280, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.77" spread="0.64"/>
                    <measurement group_id="O2" value="8.20" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,821 (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.96" spread="0.66"/>
                    <measurement group_id="O2" value="7.42" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,989 (n=118, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.60" spread="0.99"/>
                    <measurement group_id="O2" value="7.99" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,185 (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.06" spread="1.11"/>
                    <measurement group_id="O2" value="9.61" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL Mental Health Component of the SF-36 by Visit in the OL Period</title>
        <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the OL period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA + MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL Mental Health Component of the SF-36 by Visit in the OL Period</title>
          <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 365 Cohort (n=373, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.08" spread="11.55"/>
                    <measurement group_id="O2" value="39.43" spread="11.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 449 Cohort (n=368, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.87" spread="11.46"/>
                    <measurement group_id="O2" value="39.33" spread="11.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 533 Cohort (n=355, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.89" spread="11.44"/>
                    <measurement group_id="O2" value="39.40" spread="11.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 617 Cohort (n=348, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.76" spread="11.46"/>
                    <measurement group_id="O2" value="39.49" spread="11.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 729 Cohort (n=338, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.75" spread="11.56"/>
                    <measurement group_id="O2" value="39.05" spread="11.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 813 Cohort (n=323, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.85" spread="11.57"/>
                    <measurement group_id="O2" value="39.01" spread="11.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 897 Cohort (n=320, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.96" spread="11.66"/>
                    <measurement group_id="O2" value="39.03" spread="11.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 981 Cohort (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.06" spread="11.58"/>
                    <measurement group_id="O2" value="39.09" spread="11.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,093 Cohort (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.16" spread="11.47"/>
                    <measurement group_id="O2" value="39.08" spread="11.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,177 Cohort (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.88" spread="11.54"/>
                    <measurement group_id="O2" value="38.67" spread="11.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,261 Cohort (n=292, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.81" spread="11.56"/>
                    <measurement group_id="O2" value="39.15" spread="11.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,345 Cohort (n=147, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.91" spread="11.46"/>
                    <measurement group_id="O2" value="39.33" spread="11.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,457 Cohort (n=290, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.83" spread="11.62"/>
                    <measurement group_id="O2" value="38.93" spread="11.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,625 Cohort (n=280, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.88" spread="11.66"/>
                    <measurement group_id="O2" value="38.97" spread="11.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,821 Cohort (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.06" spread="11.72"/>
                    <measurement group_id="O2" value="38.95" spread="11.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,989 Cohort (n=118, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.95" spread="10.99"/>
                    <measurement group_id="O2" value="39.90" spread="10.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 2,185 Cohort (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.32" spread="12.04"/>
                    <measurement group_id="O2" value="37.40" spread="10.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL by Visit in the Mental Health Component of the SF-36 in the OL Period</title>
        <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the OL period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA + MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL by Visit in the Mental Health Component of the SF-36 in the OL Period</title>
          <description>The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. Improvements of &gt; 3 points were considered clinically meaningful.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 (n=373, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.02" spread="0.59"/>
                    <measurement group_id="O2" value="5.31" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 (n=368, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.27" spread="0.58"/>
                    <measurement group_id="O2" value="6.45" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 (n=355, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.72" spread="0.61"/>
                    <measurement group_id="O2" value="6.49" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 (n=348, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.60" spread="0.61"/>
                    <measurement group_id="O2" value="6.03" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n=338, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.49" spread="0.61"/>
                    <measurement group_id="O2" value="7.38" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 (n=323, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.26" spread="0.66"/>
                    <measurement group_id="O2" value="5.72" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 (n=320, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.65" spread="0.67"/>
                    <measurement group_id="O2" value="7.29" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.13" spread="0.65"/>
                    <measurement group_id="O2" value="6.97" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.85" spread="0.62"/>
                    <measurement group_id="O2" value="5.81" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,177 (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.67" spread="0.68"/>
                    <measurement group_id="O2" value="7.02" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,261 (n=292, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.18" spread="0.70"/>
                    <measurement group_id="O2" value="6.14" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,345 (n=147, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.80" spread="0.93"/>
                    <measurement group_id="O2" value="7.01" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,457 (n=290, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.75" spread="0.70"/>
                    <measurement group_id="O2" value="6.51" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,625 (n=280, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.96" spread="0.70"/>
                    <measurement group_id="O2" value="7.13" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,821 (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.39" spread="0.71"/>
                    <measurement group_id="O2" value="6.56" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,989 (n=118, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.58" spread="1.08"/>
                    <measurement group_id="O2" value="6.65" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,185 (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.92" spread="1.22"/>
                    <measurement group_id="O2" value="7.10" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL Fatigue in the OL Period</title>
        <description>Mean baseline values are reported for each cohort at each time point using the VAS 100 mm where 0= no fatigue to 100 = the worst fatigue imaginable. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL Fatigue in the OL Period</title>
          <description>Mean baseline values are reported for each cohort at each time point using the VAS 100 mm where 0= no fatigue to 100 = the worst fatigue imaginable. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 365 Cohort (n=373, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.52" spread="23.23"/>
                    <measurement group_id="O2" value="65.37" spread="22.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 449 Cohort (n=358, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.59" spread="23.51"/>
                    <measurement group_id="O2" value="65.28" spread="23.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 533 Cohort (n=353, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.25" spread="23.57"/>
                    <measurement group_id="O2" value="65.78" spread="22.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 617 Cohort (n=339, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.19" spread="23.48"/>
                    <measurement group_id="O2" value="64.73" spread="23.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 729 Cohort (n=329, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.53" spread="23.15"/>
                    <measurement group_id="O2" value="64.59" spread="23.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 813 Cohort (n=318, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.77" spread="22.77"/>
                    <measurement group_id="O2" value="64.81" spread="23.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 897 Cohort (n=316, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.61" spread="23.11"/>
                    <measurement group_id="O2" value="65.36" spread="23.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 981 Cohort (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.58" spread="22.99"/>
                    <measurement group_id="O2" value="65.51" spread="23.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,093 Cohort (n=307, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.33" spread="23.18"/>
                    <measurement group_id="O2" value="65.47" spread="23.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,177 Cohort (n=271, 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.05" spread="22.73"/>
                    <measurement group_id="O2" value="65.18" spread="23.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,261 Cohort (n=289, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.38" spread="23.37"/>
                    <measurement group_id="O2" value="65.56" spread="23.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,345 Cohort (n=141, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.64" spread="21.44"/>
                    <measurement group_id="O2" value="69.00" spread="20.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,457 Cohort (n=283, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.66" spread="23.51"/>
                    <measurement group_id="O2" value="65.50" spread="23.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,625 Cohort (n=275, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.18" spread="23.78"/>
                    <measurement group_id="O2" value="66.34" spread="22.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,821 Cohort (n=263, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.48" spread="23.84"/>
                    <measurement group_id="O2" value="65.00" spread="23.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,989 Cohort (n=115, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.36" spread="23.88"/>
                    <measurement group_id="O2" value="67.45" spread="22.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 2,185 Cohort (n=81, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.77" spread="22.45"/>
                    <measurement group_id="O2" value="70.17" spread="19.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in Fatigue in the OL Period</title>
        <description>The mean change from baseline in fatigue was measured on the VAS 100 mm where 0= no fatigue to 100 = the worst fatigue imaginable.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in Fatigue in the OL Period</title>
          <description>The mean change from baseline in fatigue was measured on the VAS 100 mm where 0= no fatigue to 100 = the worst fatigue imaginable.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 (n=373, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.0" spread="1.49"/>
                    <measurement group_id="O2" value="-22.6" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 (n=358, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.5" spread="1.55"/>
                    <measurement group_id="O2" value="-31.1" spread="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 (n=353, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.4" spread="1.51"/>
                    <measurement group_id="O2" value="-31.1" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 (n=339, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.4" spread="1.60"/>
                    <measurement group_id="O2" value="-30.5" spread="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n=329, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.2" spread="1.60"/>
                    <measurement group_id="O2" value="-30.0" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 (n=318, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.9" spread="1.60"/>
                    <measurement group_id="O2" value="-31.0" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 (n=316, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.7" spread="1.66"/>
                    <measurement group_id="O2" value="-30.6" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.5" spread="1.69"/>
                    <measurement group_id="O2" value="-31.1" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,093 (n=307, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.8" spread="1.61"/>
                    <measurement group_id="O2" value="-31.3" spread="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,177 (n=271, 123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.2" spread="1.83"/>
                    <measurement group_id="O2" value="-33.3" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,261 (n=289, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.3" spread="1.70"/>
                    <measurement group_id="O2" value="-31.2" spread="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,345 (n=141, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.9" spread="2.42"/>
                    <measurement group_id="O2" value="-28.2" spread="3.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,457 (n=283, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.2" spread="1.65"/>
                    <measurement group_id="O2" value="-32.6" spread="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,625 (n=275, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.9" spread="1.69"/>
                    <measurement group_id="O2" value="-32.3" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,821 (n=263, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.3" spread="1.82"/>
                    <measurement group_id="O2" value="-32.0" spread="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,989 (n=115, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.6" spread="2.80"/>
                    <measurement group_id="O2" value="-33.7" spread="4.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,185 (n=81, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.4" spread="3.22"/>
                    <measurement group_id="O2" value="-35.0" spread="4.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL Sleep Quality in the OL Period</title>
        <description>Mean baseline values are reported for each cohort at each time point using the Medical Outcomes Study Sleep scale (MOS-sleep [assesses the extent of sleep problems and measures six dimensions of sleep on a 12-item participant-reported measure]). An overall Sleep Problems Index (SPI) was generated as a summary measure of different types of sleep problems (sleep disturbance, sleep quantity, sleep adequacy, etc.). The score ranges from 0 to 100, with 0 = no problems with sleep and 100 = the most severe problems with sleep. The mean score of the SPI in a population with chronic conditions is 29.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL Sleep Quality in the OL Period</title>
          <description>Mean baseline values are reported for each cohort at each time point using the Medical Outcomes Study Sleep scale (MOS-sleep [assesses the extent of sleep problems and measures six dimensions of sleep on a 12-item participant-reported measure]). An overall Sleep Problems Index (SPI) was generated as a summary measure of different types of sleep problems (sleep disturbance, sleep quantity, sleep adequacy, etc.). The score ranges from 0 to 100, with 0 = no problems with sleep and 100 = the most severe problems with sleep. The mean score of the SPI in a population with chronic conditions is 29.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 365 Cohort (n=373, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.42" spread="19.96"/>
                    <measurement group_id="O2" value="43.53" spread="19.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 449 Cohort (n=358, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.77" spread="20.07"/>
                    <measurement group_id="O2" value="43.22" spread="19.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 533 Cohort (n=353, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.62" spread="20.11"/>
                    <measurement group_id="O2" value="43.24" spread="19.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 617 Cohort (n=339, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.51" spread="20.19"/>
                    <measurement group_id="O2" value="43.24" spread="19.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 729 Cohort (n=329, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.28" spread="20.01"/>
                    <measurement group_id="O2" value="43.97" spread="19.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 813 Cohort (n=318, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.63" spread="20.07"/>
                    <measurement group_id="O2" value="43.58" spread="19.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 897 Cohort (n=316, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.60" spread="20.31"/>
                    <measurement group_id="O2" value="43.65" spread="19.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 981 Cohort (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.51" spread="20.25"/>
                    <measurement group_id="O2" value="43.58" spread="19.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,093 Cohort (n=307, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.69" spread="20.36"/>
                    <measurement group_id="O2" value="43.78" spread="19.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,177 Cohort (n=270, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.08" spread="20.28"/>
                    <measurement group_id="O2" value="43.51" spread="19.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,261 Cohort (n=289, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.87" spread="20.40"/>
                    <measurement group_id="O2" value="43.76" spread="19.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,345 Cohort (n=141, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.78" spread="21.79"/>
                    <measurement group_id="O2" value="48.39" spread="20.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,457 Cohort (n=275, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.93" spread="20.82"/>
                    <measurement group_id="O2" value="44.14" spread="19.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,625 Cohort (n=272, 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.70" spread="20.46"/>
                    <measurement group_id="O2" value="44.51" spread="20.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,821 Cohort (n=263, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.04" spread="20.53"/>
                    <measurement group_id="O2" value="43.59" spread="20.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,989 Cohort (n=115, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.15" spread="22.33"/>
                    <measurement group_id="O2" value="47.62" spread="20.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 2,185 Cohort (n=81, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.70" spread="22.06"/>
                    <measurement group_id="O2" value="51.43" spread="19.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in Sleep Quality in the OL Period</title>
        <description>The mean change from baseline in sleep quality was assessed on the Medical Outcomes Study Sleep scale (MOS-sleep [assesses the extent of sleep problems and measures six dimensions of sleep on a 12-item participant-reported measure]). An overall Sleep Problems Index (SPI) was generated as a summary measure of different types of sleep problems (sleep disturbance, sleep quantity, sleep adequacy, etc.). The score ranges from 0 to 100, with 0 = no problems with sleep and 100 = the most severe problems with sleep. The mean score of the SPI in a population with chronic conditions is 29.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 617, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457, Day 1,625, Day 1,821, Day 1,989, Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in Sleep Quality in the OL Period</title>
          <description>The mean change from baseline in sleep quality was assessed on the Medical Outcomes Study Sleep scale (MOS-sleep [assesses the extent of sleep problems and measures six dimensions of sleep on a 12-item participant-reported measure]). An overall Sleep Problems Index (SPI) was generated as a summary measure of different types of sleep problems (sleep disturbance, sleep quantity, sleep adequacy, etc.). The score ranges from 0 to 100, with 0 = no problems with sleep and 100 = the most severe problems with sleep. The mean score of the SPI in a population with chronic conditions is 29.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 (n=373, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.8" spread="0.91"/>
                    <measurement group_id="O2" value="-7.97" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 (n=358, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.0" spread="0.97"/>
                    <measurement group_id="O2" value="-11.4" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 (n=353, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.4" spread="0.92"/>
                    <measurement group_id="O2" value="-10.9" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 (n=339, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.6" spread="0.92"/>
                    <measurement group_id="O2" value="-11.9" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n=329, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" spread="0.99"/>
                    <measurement group_id="O2" value="-11.3" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 (n=318, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" spread="1.07"/>
                    <measurement group_id="O2" value="-10.8" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 (n=316, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.2" spread="1.04"/>
                    <measurement group_id="O2" value="-12.0" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.4" spread="1.05"/>
                    <measurement group_id="O2" value="-10.8" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,093 (n=307, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.9" spread="1.09"/>
                    <measurement group_id="O2" value="-11.3" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,177 (n=270, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.9" spread="1.19"/>
                    <measurement group_id="O2" value="-10.8" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,261 (n=289, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.2" spread="1.16"/>
                    <measurement group_id="O2" value="-10.1" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,345 (n=141, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.6" spread="1.68"/>
                    <measurement group_id="O2" value="-12.5" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,457 (n=275, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.7" spread="1.16"/>
                    <measurement group_id="O2" value="-10.4" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,625 (n=272, 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.2" spread="1.19"/>
                    <measurement group_id="O2" value="-11.6" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,821 (n=263, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.8" spread="1.23"/>
                    <measurement group_id="O2" value="-9.10" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,989 (n=115, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.7" spread="1.98"/>
                    <measurement group_id="O2" value="-11.0" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2,185 (n=81, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.76" spread="2.03"/>
                    <measurement group_id="O2" value="-14.6" spread="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL Limitations on Activities of Daily Living in the OL Period</title>
        <description>Mean baseline values are reported for each cohort at each time point. Activity limitation was measured by the number of days in the past 30 days a participant was unable to perform usual activities due to RA. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL Limitations on Activities of Daily Living in the OL Period</title>
          <description>Mean baseline values are reported for each cohort at each time point. Activity limitation was measured by the number of days in the past 30 days a participant was unable to perform usual activities due to RA. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 365 Cohort (n=360, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.80" spread="10.98"/>
                    <measurement group_id="O2" value="13.21" spread="12.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 449 Cohort (n=348, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.82" spread="10.92"/>
                    <measurement group_id="O2" value="13.19" spread="12.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 533 Cohort (n=338, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.91" spread="11.06"/>
                    <measurement group_id="O2" value="13.55" spread="12.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 617 Cohort (n=332, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.01" spread="11.10"/>
                    <measurement group_id="O2" value="13.23" spread="12.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 729 Cohort (n=316, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.96" spread="11.11"/>
                    <measurement group_id="O2" value="13.52" spread="12.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 813 Cohort (n=306, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.31" spread="11.14"/>
                    <measurement group_id="O2" value="13.38" spread="12.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 897 Cohort (n=302, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.08" spread="11.14"/>
                    <measurement group_id="O2" value="13.81" spread="12.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 981 Cohort (n=300, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.13" spread="11.19"/>
                    <measurement group_id="O2" value="13.70" spread="13.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,093 Cohort (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.34" spread="11.15"/>
                    <measurement group_id="O2" value="13.79" spread="12.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,177 Cohort (n=259, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.53" spread="11.17"/>
                    <measurement group_id="O2" value="13.80" spread="13.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,261 Cohort (n=231, 105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.00" spread="11.01"/>
                    <measurement group_id="O2" value="13.81" spread="13.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,345 Cohort (n=133, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.71" spread="11.20"/>
                    <measurement group_id="O2" value="15.05" spread="11.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 1,457 Cohort (n=196, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.36" spread="11.16"/>
                    <measurement group_id="O2" value="14.87" spread="13.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in Limitations on Activities of Daily Living in the OL Period</title>
        <description>The mean change from baseline in limitations on activities of daily living in the OL period. Activity limitation was measured by the number of days in the past 30 days a participant was unable to perform usual activities due to RA.</description>
        <time_frame>BL (Day 0), Day 365, Day 449, Day 533, Day 729, Day 813, Day 897, Day 981, Day 1,093, Day 1,177, Day 1,261, Day 1,345, Day 1,457</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in Limitations on Activities of Daily Living in the OL Period</title>
          <description>The mean change from baseline in limitations on activities of daily living in the OL period. Activity limitation was measured by the number of days in the past 30 days a participant was unable to perform usual activities due to RA.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 (n=360, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.04" spread="0.60"/>
                    <measurement group_id="O2" value="-6.39" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 (n=348, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.75" spread="0.58"/>
                    <measurement group_id="O2" value="-8.60" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 (n=338, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.21" spread="0.61"/>
                    <measurement group_id="O2" value="-9.00" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 (n=332, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.49" spread="0.63"/>
                    <measurement group_id="O2" value="-8.62" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n=316, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.55" spread="0.62"/>
                    <measurement group_id="O2" value="-8.18" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 813 (n=306, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.87" spread="0.64"/>
                    <measurement group_id="O2" value="-8.67" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 897 (n=302, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.35" spread="0.65"/>
                    <measurement group_id="O2" value="-9.22" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 981 (n=300, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.48" spread="0.66"/>
                    <measurement group_id="O2" value="-8.68" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,093 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.1" spread="0.69"/>
                    <measurement group_id="O2" value="-8.71" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,177 (n=259, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.6" spread="0.68"/>
                    <measurement group_id="O2" value="-8.39" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,261 (n=231, 105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.96" spread="0.73"/>
                    <measurement group_id="O2" value="-8.30" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,345 (n=133, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.1" spread="1.02"/>
                    <measurement group_id="O2" value="-9.18" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1,457 (n=196, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.73" spread="0.94"/>
                    <measurement group_id="O2" value="-10.3" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean BL White Blood Cells in the OL Period</title>
        <description>Mean baseline values are those that are reported for each cohort at each time point on Day 365 to Day 2,185.</description>
        <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
        <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period). N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL White Blood Cells in the OL Period</title>
          <description>Mean baseline values are those that are reported for each cohort at each time point on Day 365 to Day 2,185.</description>
          <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period). N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>10^3 c/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>White Blood Cells Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.78" spread="2.83"/>
                    <measurement group_id="O2" value="8.81" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Neutrophils Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.45" spread="2.63"/>
                    <measurement group_id="O2" value="6.39" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Eosinophils Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.16"/>
                    <measurement group_id="O2" value="0.18" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Monocytes Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.25"/>
                    <measurement group_id="O2" value="0.41" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cells Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.89" spread="2.87"/>
                    <measurement group_id="O2" value="8.73" spread="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Neutrophils Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.50" spread="2.63"/>
                    <measurement group_id="O2" value="6.35" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Eosinophils Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.16"/>
                    <measurement group_id="O2" value="0.18" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Monocytes Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.25"/>
                    <measurement group_id="O2" value="0.40" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cells Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.81" spread="2.83"/>
                    <measurement group_id="O2" value="8.80" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Neutrophils Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.46" spread="2.63"/>
                    <measurement group_id="O2" value="6.37" spread="2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Eosinophils Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.16"/>
                    <measurement group_id="O2" value="0.18" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Monocytes Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.25"/>
                    <measurement group_id="O2" value="0.41" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cells Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.80" spread="2.81"/>
                    <measurement group_id="O2" value="8.74" spread="3.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Neutrophils Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.43" spread="2.59"/>
                    <measurement group_id="O2" value="6.32" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Eosinophils Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.17"/>
                    <measurement group_id="O2" value="0.18" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Monocytes Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.25"/>
                    <measurement group_id="O2" value="0.40" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cells Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.82" spread="2.76"/>
                    <measurement group_id="O2" value="8.70" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Neutrophils Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.45" spread="2.56"/>
                    <measurement group_id="O2" value="6.35" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Eosinophils Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.16"/>
                    <measurement group_id="O2" value="0.18" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Monocytes Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.24"/>
                    <measurement group_id="O2" value="0.39" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cells Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.14" spread="2.83"/>
                    <measurement group_id="O2" value="8.80" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Neutrophils Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.78" spread="2.67"/>
                    <measurement group_id="O2" value="6.56" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Eosinophils Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.16"/>
                    <measurement group_id="O2" value="0.16" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Monocytes Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.21"/>
                    <measurement group_id="O2" value="0.34" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cells Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.16" spread="2.87"/>
                    <measurement group_id="O2" value="8.81" spread="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Neutrophils Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.86" spread="2.77"/>
                    <measurement group_id="O2" value="6.69" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Eosinophils Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.14"/>
                    <measurement group_id="O2" value="0.15" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Monocytes Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.21"/>
                    <measurement group_id="O2" value="0.35" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cells Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.64" spread="3.05"/>
                    <measurement group_id="O2" value="9.22" spread="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Neutrophils Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.25" spread="2.90"/>
                    <measurement group_id="O2" value="6.97" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Eosinophils Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.10"/>
                    <measurement group_id="O2" value="0.13" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Monocytes Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.22"/>
                    <measurement group_id="O2" value="0.38" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cells Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.73" spread="2.98"/>
                    <measurement group_id="O2" value="9.22" spread="3.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Neutrophils Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.35" spread="2.84"/>
                    <measurement group_id="O2" value="6.93" spread="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Eosinophils Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.11"/>
                    <measurement group_id="O2" value="0.13" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Monocytes Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.22"/>
                    <measurement group_id="O2" value="0.38" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From BL in White Blood Cells in the OL Period</title>
        <description>All changes in participant laboratory parameters were monitored on each day of study drug administration.</description>
        <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
        <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period). N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in White Blood Cells in the OL Period</title>
          <description>All changes in participant laboratory parameters were monitored on each day of study drug administration.</description>
          <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period). N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>10^3 c/uL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>White Blood Cells Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.10" spread="0.13"/>
                    <measurement group_id="O2" value="-0.44" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Neutrophils Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.20" spread="0.12"/>
                    <measurement group_id="O2" value="-0.43" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Eosinophils Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.01"/>
                    <measurement group_id="O2" value="-0.01" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Monocytes Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.01"/>
                    <measurement group_id="O2" value="-0.03" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cells Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" spread="0.15"/>
                    <measurement group_id="O2" value="-1.19" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Neutrophils Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.50" spread="0.14"/>
                    <measurement group_id="O2" value="-1.49" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Eosinophils Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.01"/>
                    <measurement group_id="O2" value="-0.04" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Monocytes Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.02"/>
                    <measurement group_id="O2" value="-0.03" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cells Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.50" spread="0.16"/>
                    <measurement group_id="O2" value="-1.55" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Neutrophils Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.57" spread="0.15"/>
                    <measurement group_id="O2" value="-1.66" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Eosinophils Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.01"/>
                    <measurement group_id="O2" value="-0.01" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Monocytes Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.02"/>
                    <measurement group_id="O2" value="-0.08" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cells Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="0.16"/>
                    <measurement group_id="O2" value="-1.62" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Neutrophils Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.44" spread="0.15"/>
                    <measurement group_id="O2" value="-1.68" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Eosinophils Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" spread="0.01"/>
                    <measurement group_id="O2" value="0.01" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Monocytes Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.02"/>
                    <measurement group_id="O2" value="-0.07" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cells Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.56" spread="0.18"/>
                    <measurement group_id="O2" value="-1.71" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Neutrophils Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.72" spread="0.17"/>
                    <measurement group_id="O2" value="-1.92" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Eosinophils Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" spread="0.01"/>
                    <measurement group_id="O2" value="0.01" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Monocytes Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.02"/>
                    <measurement group_id="O2" value="-0.04" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cells Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.38"/>
                    <measurement group_id="O2" value="-1.11" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Neutrophils Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30" spread="0.31"/>
                    <measurement group_id="O2" value="-1.53" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Eosinophils Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" spread="0.02"/>
                    <measurement group_id="O2" value="-0.02" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Monocytes Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.02"/>
                    <measurement group_id="O2" value="0.05" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cells Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.07" spread="0.26"/>
                    <measurement group_id="O2" value="-0.97" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Neutrophils Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.152" spread="0.26"/>
                    <measurement group_id="O2" value="-1.47" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Eosinophils Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.02"/>
                    <measurement group_id="O2" value="-0.00" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Monocytes Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.02"/>
                    <measurement group_id="O2" value="0.03" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cells Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" spread="0.33"/>
                    <measurement group_id="O2" value="-1.54" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Neutrophils Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.57" spread="0.35"/>
                    <measurement group_id="O2" value="-2.17" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Eosinophils Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.01"/>
                    <measurement group_id="O2" value="0.04" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Monocytes Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.03"/>
                    <measurement group_id="O2" value="0.11" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cells Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" spread="0.33"/>
                    <measurement group_id="O2" value="-1.96" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Neutrophils Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.78" spread="0.33"/>
                    <measurement group_id="O2" value="-2.39" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Eosinophils Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.02"/>
                    <measurement group_id="O2" value="-0.01" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Monocytes Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.04"/>
                    <measurement group_id="O2" value="0.08" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean BL Liver Function Parameters in the OL Period</title>
        <description>Mean baseline values are those that are reported for each cohort at each time point on Day 365 to Day 2,185.</description>
        <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
        <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period). N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL Liver Function Parameters in the OL Period</title>
          <description>Mean baseline values are those that are reported for each cohort at each time point on Day 365 to Day 2,185.</description>
          <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period). N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alkaline Phosphatase Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.56" spread="37.11"/>
                    <measurement group_id="O2" value="98.73" spread="41.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.35" spread="22.07"/>
                    <measurement group_id="O2" value="23.40" spread="27.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.53" spread="12.00"/>
                    <measurement group_id="O2" value="22.87" spread="15.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-Glutamyl Transferase Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.89" spread="32.59"/>
                    <measurement group_id="O2" value="30.73" spread="26.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.30" spread="35.22"/>
                    <measurement group_id="O2" value="99.49" spread="41.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.74" spread="22.91"/>
                    <measurement group_id="O2" value="23.21" spread="28.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.62" spread="12.35"/>
                    <measurement group_id="O2" value="22.87" spread="15.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-Glutamyl Transferase Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.37" spread="33.62"/>
                    <measurement group_id="O2" value="28.73" spread="19.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.18" spread="34.95"/>
                    <measurement group_id="O2" value="99.43" spread="40.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.75" spread="23.38"/>
                    <measurement group_id="O2" value="23.01" spread="28.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.60" spread="12.55"/>
                    <measurement group_id="O2" value="22.91" spread="15.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-Glutamyl Transferase Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.34" spread="29.93"/>
                    <measurement group_id="O2" value="28.43" spread="20.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.8" spread="36.04"/>
                    <measurement group_id="O2" value="99.75" spread="41.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.05" spread="23.95"/>
                    <measurement group_id="O2" value="23.43" spread="29.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.88" spread="12.84"/>
                    <measurement group_id="O2" value="23.29" spread="16.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-Glutamyl Transferase Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.80" spread="34.83"/>
                    <measurement group_id="O2" value="28.34" spread="20.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.80" spread="34.22"/>
                    <measurement group_id="O2" value="97.68" spread="33.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.22" spread="24.74"/>
                    <measurement group_id="O2" value="23.55" spread="30.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.63" spread="12.98"/>
                    <measurement group_id="O2" value="23.50" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-Glutamyl Transferase Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.50" spread="34.74"/>
                    <measurement group_id="O2" value="27.76" spread="19.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.33" spread="35.95"/>
                    <measurement group_id="O2" value="92.19" spread="35.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.57" spread="22.33"/>
                    <measurement group_id="O2" value="25.65" spread="39.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.43" spread="12.21"/>
                    <measurement group_id="O2" value="24.60" spread="20.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-Glutamyl Transferase Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.08" spread="31.28"/>
                    <measurement group_id="O2" value="30.01" spread="22.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.46" spread="35.63"/>
                    <measurement group_id="O2" value="95.18" spread="36.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.15" spread="23.24"/>
                    <measurement group_id="O2" value="27.80" spread="42.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.55" spread="12.72"/>
                    <measurement group_id="O2" value="25.82" spread="22.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-Glutamyl Transferase Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.27" spread="32.43"/>
                    <measurement group_id="O2" value="31.39" spread="23.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.87" spread="30.05"/>
                    <measurement group_id="O2" value="78.53" spread="22.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.34" spread="24.62"/>
                    <measurement group_id="O2" value="27.50" spread="50.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.93" spread="12.70"/>
                    <measurement group_id="O2" value="25.37" spread="26.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-Glutamyl Transferase Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.62" spread="37.07"/>
                    <measurement group_id="O2" value="30.47" spread="21.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.33" spread="30.52"/>
                    <measurement group_id="O2" value="78.97" spread="22.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.51" spread="24.78"/>
                    <measurement group_id="O2" value="27.82" spread="51.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.80" spread="12.29"/>
                    <measurement group_id="O2" value="25.81" spread="26.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-Glutamyl Transferase Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.23" spread="37.42"/>
                    <measurement group_id="O2" value="30.46" spread="21.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From BL in Liver Function Parameters in the OL Period</title>
        <description>All changes in participant laboratory parameters were monitored on each day of study drug administration.</description>
        <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
        <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period). N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in Liver Function Parameters in the OL Period</title>
          <description>All changes in participant laboratory parameters were monitored on each day of study drug administration.</description>
          <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period). N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alkaline Phosphatase Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.27" spread="1.60"/>
                    <measurement group_id="O2" value="-10.8" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" spread="1.25"/>
                    <measurement group_id="O2" value="-2.64" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.76"/>
                    <measurement group_id="O2" value="-1.42" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-Glutamyl Transferase Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.42" spread="1.48"/>
                    <measurement group_id="O2" value="-2.83" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.3" spread="1.70"/>
                    <measurement group_id="O2" value="-18.8" spread="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="1.39"/>
                    <measurement group_id="O2" value="-1.69" spread="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="0.83"/>
                    <measurement group_id="O2" value="0.47" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-Glutamyl Transferase Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.96" spread="1.62"/>
                    <measurement group_id="O2" value="-3.98" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="1.69"/>
                    <measurement group_id="O2" value="-13.0" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="1.40"/>
                    <measurement group_id="O2" value="-0.17" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="0.85"/>
                    <measurement group_id="O2" value="0.07" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-Glutamyl Transferase Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.81" spread="1.55"/>
                    <measurement group_id="O2" value="-4.51" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.4" spread="1.73"/>
                    <measurement group_id="O2" value="-12.0" spread="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="2.66"/>
                    <measurement group_id="O2" value="-3.11" spread="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="1.73"/>
                    <measurement group_id="O2" value="-1.82" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-Glutamyl Transferase Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.15" spread="2.35"/>
                    <measurement group_id="O2" value="-3.66" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.6" spread="1.70"/>
                    <measurement group_id="O2" value="-14.7" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" spread="1.49"/>
                    <measurement group_id="O2" value="-0.75" spread="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.85"/>
                    <measurement group_id="O2" value="-0.52" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-Glutamyl Transferase Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.63" spread="2.04"/>
                    <measurement group_id="O2" value="-4.65" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.9" spread="2.82"/>
                    <measurement group_id="O2" value="-10.6" spread="3.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.35" spread="2.03"/>
                    <measurement group_id="O2" value="-5.74" spread="4.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="1.18"/>
                    <measurement group_id="O2" value="-3.00" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-Glutamyl Transferase Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.76" spread="3.16"/>
                    <measurement group_id="O2" value="-3.09" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.4" spread="2.80"/>
                    <measurement group_id="O2" value="-13.0" spread="3.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" spread="2.04"/>
                    <measurement group_id="O2" value="-4.98" spread="5.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="1.24"/>
                    <measurement group_id="O2" value="-1.71" spread="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-Glutamyl Transferase Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.66" spread="3.58"/>
                    <measurement group_id="O2" value="-4.00" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.6" spread="3.40"/>
                    <measurement group_id="O2" value="-4.24" spread="3.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="2.82"/>
                    <measurement group_id="O2" value="-8.08" spread="7.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="1.68"/>
                    <measurement group_id="O2" value="-2.37" spread="4.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-Glutamyl Transferase Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.2" spread="4.23"/>
                    <measurement group_id="O2" value="-4.92" spread="3.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.2" spread="2.79"/>
                    <measurement group_id="O2" value="-7.76" spread="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.56" spread="2.84"/>
                    <measurement group_id="O2" value="-7.43" spread="8.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="1.60"/>
                    <measurement group_id="O2" value="-1.43" spread="4.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-Glutamyl Transferase Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.9" spread="3.81"/>
                    <measurement group_id="O2" value="-4.51" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean BL Select Laboratory Parameters in the OL Period</title>
        <description>Mean baseline values are those that are reported for each cohort at each time point on Day 365 to Day 2,185.</description>
        <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
        <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period). N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL Select Laboratory Parameters in the OL Period</title>
          <description>Mean baseline values are those that are reported for each cohort at each time point on Day 365 to Day 2,185.</description>
          <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period). N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Bilirubin Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.18"/>
                    <measurement group_id="O2" value="0.48" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood Urea Nitrogen (BUN) Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.05" spread="5.19"/>
                    <measurement group_id="O2" value="15.09" spread="4.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="0.17"/>
                    <measurement group_id="O2" value="0.74" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Calcium Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.26" spread="0.44"/>
                    <measurement group_id="O2" value="9.26" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorous Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.48" spread="0.57"/>
                    <measurement group_id="O2" value="3.56" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Glucose Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.63" spread="29.30"/>
                    <measurement group_id="O2" value="98.78" spread="58.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.80" spread="1.45"/>
                    <measurement group_id="O2" value="4.83" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.18"/>
                    <measurement group_id="O2" value="0.48" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.02" spread="5.23"/>
                    <measurement group_id="O2" value="15.03" spread="4.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="0.18"/>
                    <measurement group_id="O2" value="0.73" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Calcium Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.26" spread="0.44"/>
                    <measurement group_id="O2" value="9.24" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorous Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50" spread="0.57"/>
                    <measurement group_id="O2" value="3.55" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Glucose Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.36" spread="30.59"/>
                    <measurement group_id="O2" value="98.56" spread="60.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.79" spread="1.41"/>
                    <measurement group_id="O2" value="4.75" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.18"/>
                    <measurement group_id="O2" value="0.48" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.26"/>
                    <measurement group_id="O2" value="0.00" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="0.17"/>
                    <measurement group_id="O2" value="0.74" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Calcium Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.03"/>
                    <measurement group_id="O2" value="0.02" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorous Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.04"/>
                    <measurement group_id="O2" value="0.10" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Glucose Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.49" spread="29.70"/>
                    <measurement group_id="O2" value="97.65" spread="61.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.06"/>
                    <measurement group_id="O2" value="-0.32" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.18"/>
                    <measurement group_id="O2" value="0.49" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.86" spread="5.28"/>
                    <measurement group_id="O2" value="15.02" spread="4.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="0.17"/>
                    <measurement group_id="O2" value="0.74" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Calcium Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.26" spread="0.45"/>
                    <measurement group_id="O2" value="9.25" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorous Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.49" spread="0.54"/>
                    <measurement group_id="O2" value="3.54" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Glucose Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.81" spread="28.90"/>
                    <measurement group_id="O2" value="95.35" spread="55.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.73" spread="1.40"/>
                    <measurement group_id="O2" value="4.75" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin Day Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.18"/>
                    <measurement group_id="O2" value="0.50" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.93" spread="5.29"/>
                    <measurement group_id="O2" value="14.88" spread="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="0.16"/>
                    <measurement group_id="O2" value="0.74" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Calcium Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.25" spread="0.45"/>
                    <measurement group_id="O2" value="9.25" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorous Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.49" spread="0.53"/>
                    <measurement group_id="O2" value="3.54" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Glucose Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.81" spread="30.21"/>
                    <measurement group_id="O2" value="98.59" spread="64.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.66" spread="1.29"/>
                    <measurement group_id="O2" value="4.68" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.18"/>
                    <measurement group_id="O2" value="0.50" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.15" spread="5.74"/>
                    <measurement group_id="O2" value="14.77" spread="3.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="0.16"/>
                    <measurement group_id="O2" value="0.75" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Calcium Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.30" spread="0.45"/>
                    <measurement group_id="O2" value="9.30" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorous Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50" spread="0.56"/>
                    <measurement group_id="O2" value="3.44" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Glucose Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.82" spread="31.18"/>
                    <measurement group_id="O2" value="101.1" spread="74.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.70" spread="1.25"/>
                    <measurement group_id="O2" value="4.93" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.18"/>
                    <measurement group_id="O2" value="0.52" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.26" spread="5.68"/>
                    <measurement group_id="O2" value="15.18" spread="3.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.14"/>
                    <measurement group_id="O2" value="0.72" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Calcium Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.31" spread="0.44"/>
                    <measurement group_id="O2" value="9.33" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorous Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.51" spread="0.57"/>
                    <measurement group_id="O2" value="3.45" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Glucose Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.59" spread="33.41"/>
                    <measurement group_id="O2" value="104.80" spread="81.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.72" spread="1.25"/>
                    <measurement group_id="O2" value="4.99" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.19"/>
                    <measurement group_id="O2" value="0.52" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.36" spread="5.83"/>
                    <measurement group_id="O2" value="15.27" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.13"/>
                    <measurement group_id="O2" value="0.69" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Calcium Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.41" spread="0.36"/>
                    <measurement group_id="O2" value="9.48" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorous Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.61" spread="0.58"/>
                    <measurement group_id="O2" value="3.52" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Glucose Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.4" spread="31.96"/>
                    <measurement group_id="O2" value="111.1" spread="97.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.58" spread="1.19"/>
                    <measurement group_id="O2" value="4.60" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.18"/>
                    <measurement group_id="O2" value="0.52" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.40" spread="5.86"/>
                    <measurement group_id="O2" value="15.22" spread="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.13"/>
                    <measurement group_id="O2" value="0.69" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Calcium Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.43" spread="0.41"/>
                    <measurement group_id="O2" value="9.48" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorous Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" spread="0.58"/>
                    <measurement group_id="O2" value="3.54" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Glucose Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.29" spread="30.71"/>
                    <measurement group_id="O2" value="111.4" spread="99.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.61" spread="1.22"/>
                    <measurement group_id="O2" value="4.60" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From BL in Select Laboratory Parameters in the OL Period</title>
        <description>All changes in participant laboratory parameters were monitored on each day of study drug administration.</description>
        <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
        <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period). N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in Select Laboratory Parameters in the OL Period</title>
          <description>All changes in participant laboratory parameters were monitored on each day of study drug administration.</description>
          <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period). N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Bilirubin Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.01"/>
                    <measurement group_id="O2" value="0.00" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood Urea Nitrogen (BUN) Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.05" spread="5.19"/>
                    <measurement group_id="O2" value="15.09" spread="4.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="0.17"/>
                    <measurement group_id="O2" value="0.74" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Calcium Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.02"/>
                    <measurement group_id="O2" value="0.22" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorous Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.03"/>
                    <measurement group_id="O2" value="-0.12" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Glucose Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.65" spread="1.26"/>
                    <measurement group_id="O2" value="-4.06" spread="4.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.05"/>
                    <measurement group_id="O2" value="-0.06" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.01"/>
                    <measurement group_id="O2" value="0.05" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.31"/>
                    <measurement group_id="O2" value="-0.06" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.01"/>
                    <measurement group_id="O2" value="0.08" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Calcium Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.03"/>
                    <measurement group_id="O2" value="0.18" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorous Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.03"/>
                    <measurement group_id="O2" value="-0.10" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Glucose Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.77" spread="1.67"/>
                    <measurement group_id="O2" value="-4.74" spread="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.06"/>
                    <measurement group_id="O2" value="0.00" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.01"/>
                    <measurement group_id="O2" value="0.01" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.26"/>
                    <measurement group_id="O2" value="0.00" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" spread="0.01"/>
                    <measurement group_id="O2" value="-0.03" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Calcium Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.03"/>
                    <measurement group_id="O2" value="0.02" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorous Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.04"/>
                    <measurement group_id="O2" value="0.10" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Glucose Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="1.63"/>
                    <measurement group_id="O2" value="-4.95" spread="4.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.06"/>
                    <measurement group_id="O2" value="-0.32" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.01"/>
                    <measurement group_id="O2" value="-0.04" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.27"/>
                    <measurement group_id="O2" value="-0.47" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.01"/>
                    <measurement group_id="O2" value="-0.03" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Calcium Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.03"/>
                    <measurement group_id="O2" value="-0.08" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorous Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" spread="0.04"/>
                    <measurement group_id="O2" value="0.02" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Glucose Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="1.53"/>
                    <measurement group_id="O2" value="-0.12" spread="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.06"/>
                    <measurement group_id="O2" value="-0.43" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin Day Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.01"/>
                    <measurement group_id="O2" value="-0.01" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.28"/>
                    <measurement group_id="O2" value="0.30" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.01"/>
                    <measurement group_id="O2" value="-0.04" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Calcium Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.03"/>
                    <measurement group_id="O2" value="-0.04" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorous Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.04"/>
                    <measurement group_id="O2" value="0.01" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Glucose Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.27" spread="1.86"/>
                    <measurement group_id="O2" value="-0.02" spread="5.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.06"/>
                    <measurement group_id="O2" value="-0.30" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.02"/>
                    <measurement group_id="O2" value="-0.05" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.39"/>
                    <measurement group_id="O2" value="0.56" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.01"/>
                    <measurement group_id="O2" value="-0.03" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Calcium Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.04"/>
                    <measurement group_id="O2" value="-0.11" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorous Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.06"/>
                    <measurement group_id="O2" value="0.11" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Glucose Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="2.96"/>
                    <measurement group_id="O2" value="-0.50" spread="9.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.09"/>
                    <measurement group_id="O2" value="-0.29" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.02"/>
                    <measurement group_id="O2" value="-0.03" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.45"/>
                    <measurement group_id="O2" value="0.09" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.01"/>
                    <measurement group_id="O2" value="-0.02" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Calcium Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.04"/>
                    <measurement group_id="O2" value="-0.08" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorous Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.06"/>
                    <measurement group_id="O2" value="0.08" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Glucose Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.58" spread="2.85"/>
                    <measurement group_id="O2" value="-2.70" spread="11.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.09"/>
                    <measurement group_id="O2" value="-0.38" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.02"/>
                    <measurement group_id="O2" value="-0.100" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.47"/>
                    <measurement group_id="O2" value="0.84" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.01"/>
                    <measurement group_id="O2" value="0.04" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Calcium Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.04"/>
                    <measurement group_id="O2" value="-0.20" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorous Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.07"/>
                    <measurement group_id="O2" value="-0.11" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Glucose Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" spread="3.13"/>
                    <measurement group_id="O2" value="-18.2" spread="16.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.11"/>
                    <measurement group_id="O2" value="-0.15" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.02"/>
                    <measurement group_id="O2" value="0.00" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.53"/>
                    <measurement group_id="O2" value="0.18" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.01"/>
                    <measurement group_id="O2" value="0.04" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Calcium Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.04"/>
                    <measurement group_id="O2" value="-0.19" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorous Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.07"/>
                    <measurement group_id="O2" value="-0.13" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Glucose Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.85" spread="3.81"/>
                    <measurement group_id="O2" value="-8.86" spread="17.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.10"/>
                    <measurement group_id="O2" value="-0.17" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean BL Serum Electrolytes in the OL Period</title>
        <description>Mean baseline values are those that are reported for each cohort at each time point on Day 365 to Day 2,185.</description>
        <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
        <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period). N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL Serum Electrolytes in the OL Period</title>
          <description>Mean baseline values are those that are reported for each cohort at each time point on Day 365 to Day 2,185.</description>
          <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period). N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum Sodium Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.9" spread="2.89"/>
                    <measurement group_id="O2" value="140.7" spread="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Potassium Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.27" spread="0.37"/>
                    <measurement group_id="O2" value="4.29" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Chloride Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.1" spread="3.17"/>
                    <measurement group_id="O2" value="105.0" spread="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Sodium Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.8" spread="2.97"/>
                    <measurement group_id="O2" value="140.7" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Potassium Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.27" spread="0.36"/>
                    <measurement group_id="O2" value="4.30" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Chloride Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.9" spread="3.13"/>
                    <measurement group_id="O2" value="104.9" spread="3.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Sodium Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.9" spread="2.88"/>
                    <measurement group_id="O2" value="140.7" spread="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Potassium Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.27" spread="0.36"/>
                    <measurement group_id="O2" value="4.27" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Chloride Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.0" spread="3.08"/>
                    <measurement group_id="O2" value="104.9" spread="3.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Sodium Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.9" spread="2.83"/>
                    <measurement group_id="O2" value="140.7" spread="3.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Potassium Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.27" spread="0.35"/>
                    <measurement group_id="O2" value="4.27" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Chloride Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.0" spread="3.06"/>
                    <measurement group_id="O2" value="105.0" spread="3.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Sodium Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.0" spread="2.84"/>
                    <measurement group_id="O2" value="140.7" spread="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Potassium Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" spread="0.36"/>
                    <measurement group_id="O2" value="4.28" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Chloride Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.1" spread="3.08"/>
                    <measurement group_id="O2" value="104.8" spread="3.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Sodium Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.6" spread="3.13"/>
                    <measurement group_id="O2" value="140.5" spread="3.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Potassium Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.25" spread="0.37"/>
                    <measurement group_id="O2" value="4.25" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Chloride Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.9" spread="3.44"/>
                    <measurement group_id="O2" value="104.9" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Sodium Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.5" spread="3.14"/>
                    <measurement group_id="O2" value="140.1" spread="3.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Potassium Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.27" spread="0.41"/>
                    <measurement group_id="O2" value="4.24" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Chloride Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.8" spread="3.61"/>
                    <measurement group_id="O2" value="104.8" spread="4.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Sodium Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.2" spread="2.33"/>
                    <measurement group_id="O2" value="139.0" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Potassium Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.31" spread="0.44"/>
                    <measurement group_id="O2" value="4.27" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Chloride Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.3" spread="2.57"/>
                    <measurement group_id="O2" value="103.0" spread="4.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Sodium Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.2" spread="2.31"/>
                    <measurement group_id="O2" value="138.9" spread="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Potassium Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.30" spread="0.43"/>
                    <measurement group_id="O2" value="4.28" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Chloride Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.3" spread="2.51"/>
                    <measurement group_id="O2" value="102.9" spread="4.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From BL in Serum Electrolytes in the OL Period</title>
        <description>All changes in participant laboratory parameters were monitored on each day of study drug administration.</description>
        <time_frame>BL (Day 0), Day 365, Day 729, Day 1,093, Day 1,457, Day 1,821, Day 1,905, Day 1,989, Day 2,073, Day 2,185</time_frame>
        <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period). N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in Serum Electrolytes in the OL Period</title>
          <description>All changes in participant laboratory parameters were monitored on each day of study drug administration.</description>
          <population>All treated participants in the OL period (treatment groups represent treatment received in the double-blind period). N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum Sodium Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.17"/>
                    <measurement group_id="O2" value="-1.37" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Potassium Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.02"/>
                    <measurement group_id="O2" value="-0.06" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Chloride Day 365 (n=365, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.14"/>
                    <measurement group_id="O2" value="-0.21" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Sodium Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.19"/>
                    <measurement group_id="O2" value="-0.29" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Potassium Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.02"/>
                    <measurement group_id="O2" value="-0.12" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Chloride Day 729 (n=328, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.17"/>
                    <measurement group_id="O2" value="0.15" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Sodium Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.21"/>
                    <measurement group_id="O2" value="-1.34" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Potassium Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.02"/>
                    <measurement group_id="O2" value="-0.08" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Chloride Day 1,093 (n=312, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.18"/>
                    <measurement group_id="O2" value="-1.17" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Sodium Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.25"/>
                    <measurement group_id="O2" value="-0.88" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Potassium Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.03"/>
                    <measurement group_id="O2" value="-0.08" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Chloride Day 1,457 (n=292, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.0" spread="3.06"/>
                    <measurement group_id="O2" value="105.0" spread="3.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Sodium Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.24"/>
                    <measurement group_id="O2" value="-1.29" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Potassium Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.02"/>
                    <measurement group_id="O2" value="-0.15" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Chloride Day 1,821 (n=262,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.22"/>
                    <measurement group_id="O2" value="-0.69" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Sodium Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.36"/>
                    <measurement group_id="O2" value="-0.75" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Potassium Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.04"/>
                    <measurement group_id="O2" value="-0.06" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Chloride Day 1,905 (n=134, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.33"/>
                    <measurement group_id="O2" value="-0.15" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Sodium Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.40"/>
                    <measurement group_id="O2" value="-0.25" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Potassium Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.04"/>
                    <measurement group_id="O2" value="-0.12" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Chloride Day 1,989 (n=121,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.38"/>
                    <measurement group_id="O2" value="-0.52" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Sodium Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" spread="0.32"/>
                    <measurement group_id="O2" value="2.05" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Potassium Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.05"/>
                    <measurement group_id="O2" value="-0.14" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Chloride Day 2,073 (n=81,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.27" spread="0.40"/>
                    <measurement group_id="O2" value="1.89" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Sodium Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.76" spread="0.34"/>
                    <measurement group_id="O2" value="2.24" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Potassium Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.05"/>
                    <measurement group_id="O2" value="-0.20" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Chloride Day 2,185 (n=82,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.95" spread="0.40"/>
                    <measurement group_id="O2" value="1.81" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL Interleukin-6 (IL-6), SIL-2R, and Tumor Necrosis Alpha (TNF-Alpha) in the DB Period</title>
        <description>Mean baseline values are reported for each cohort at each time point. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
        <time_frame>BL (Day 0), Day 169, Day 365</time_frame>
        <population>All treated participants in the DB period. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL Interleukin-6 (IL-6), SIL-2R, and Tumor Necrosis Alpha (TNF-Alpha) in the DB Period</title>
          <description>Mean baseline values are reported for each cohort at each time point. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
          <population>All treated participants in the DB period. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>pg / mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) IL-6 for Day 169 Cohort (n=357, 175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.35" spread="43.53"/>
                    <measurement group_id="O2" value="39.90" spread="54.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) SIL-2R for Day 169 Cohort (n=370, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1776" spread="946.5"/>
                    <measurement group_id="O2" value="1603" spread="933.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) TNF-Alpha for D169 Cohort (n=354,172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.94" spread="7.90"/>
                    <measurement group_id="O2" value="7.86" spread="29.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) IL-6 for Day 365 Cohort (n=247, 121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.27" spread="49.06"/>
                    <measurement group_id="O2" value="37.89" spread="49.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) SIL-2R for Day 365 Cohort (n=235, 106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1674" spread="835.1"/>
                    <measurement group_id="O2" value="1601" spread="1076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) TNF-Alpha for D365 Cohort (n=246, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.55" spread="7.84"/>
                    <measurement group_id="O2" value="5.46" spread="8.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in Interleukin-6 (IL-6), SIL-2R, and Tumor Necrosis Alpha (TNF-Alpha) in the DB Period</title>
        <description>The mean change from baseline in potential biomarkers of disease (IL-6, SIL-3R, and TNF-Alpha were determined for all participants.</description>
        <time_frame>BL (Day 0), Day 169, Day 365</time_frame>
        <population>All treated participants in the DB period. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in Interleukin-6 (IL-6), SIL-2R, and Tumor Necrosis Alpha (TNF-Alpha) in the DB Period</title>
          <description>The mean change from baseline in potential biomarkers of disease (IL-6, SIL-3R, and TNF-Alpha were determined for all participants.</description>
          <population>All treated participants in the DB period. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>pg / mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-6 Day 169 (n=357, 175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.0" spread="2.24"/>
                    <measurement group_id="O2" value="-5.81" spread="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SIL-2R Day 169 (n=370, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-519.0" spread="32.72"/>
                    <measurement group_id="O2" value="-85.5" spread="32.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-Alpha Day 169 (n=354, 172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.72"/>
                    <measurement group_id="O2" value="2.27" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6 Day 365 (n=247, 121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.4" spread="3.08"/>
                    <measurement group_id="O2" value="-1.82" spread="5.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SIL-2R Day 365(n=235, 106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-562" spread="40.82"/>
                    <measurement group_id="O2" value="-290" spread="87.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-Alpha Day 365 (n=246, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="1.04"/>
                    <measurement group_id="O2" value="1.22" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in RF in the DB Period</title>
        <description>The mean change from baseline in participant rheumatoid factor was determined after 6 months and 1 year of treatment relative to baseline. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
        <time_frame>BL (Day 0), Day 169, Day 365</time_frame>
        <population>All treated participants in the DB period. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + MTX DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in RF in the DB Period</title>
          <description>The mean change from baseline in participant rheumatoid factor was determined after 6 months and 1 year of treatment relative to baseline. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
          <population>All treated participants in the DB period. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>IU / mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) for Day 169 Cohort (n=308, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.8" spread="10.90"/>
                    <measurement group_id="O2" value="-18.6" spread="10.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) for Day 365 Cohort (n=281, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.5" spread="11.44"/>
                    <measurement group_id="O2" value="-5.83" spread="22.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL E-Selectin, SICAM-1, and MMP3 in the DB Period</title>
        <description>Mean baseline values are reported for each cohort at each time point. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
        <time_frame>BL (Day 0), Day 169, Day 365</time_frame>
        <population>All treated participants in the DB period. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + MTX DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL E-Selectin, SICAM-1, and MMP3 in the DB Period</title>
          <description>Mean baseline values are reported for each cohort at each time point. Time-matched BL(Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.</description>
          <population>All treated participants in the DB period. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>ng / mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL (Day 0) E-Selectin for D169 Cohort (n= 256,126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.89" spread="72.62"/>
                    <measurement group_id="O2" value="85.53" spread="68.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) SICAM-1 for D169 Cohort (n=264, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="444.0" spread="398.1"/>
                    <measurement group_id="O2" value="426.8" spread="323.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) MMP3 for D169 Cohort (n=362, 183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.37" spread="81.53"/>
                    <measurement group_id="O2" value="77.22" spread="73.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) E-Selectin fpr D365 Cohort (n=162, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.91" spread="71.66"/>
                    <measurement group_id="O2" value="88.39" spread="75.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) SICAM-1 for D365 Cohort (n=235, 114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="467.2" spread="578.5"/>
                    <measurement group_id="O2" value="449.5" spread="356.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL (Day 0) MMP3 for D365 Cohort (n=232, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.56" spread="78.35"/>
                    <measurement group_id="O2" value="64.02" spread="59.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in E-Selectin, SICAM-1, and MMP3 in the DB Period</title>
        <description>The mean change from basline in particpant biomarkers of RA disease (E-Selectin, SICAM-1, and MMP3) after 6 months and 1 year of treatment, relative to baseline, were evaluated.</description>
        <time_frame>BL (Day 0), Day 169, Day 365</time_frame>
        <population>All treated participants in the DB period. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + MTX DB</title>
            <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in E-Selectin, SICAM-1, and MMP3 in the DB Period</title>
          <description>The mean change from basline in particpant biomarkers of RA disease (E-Selectin, SICAM-1, and MMP3) after 6 months and 1 year of treatment, relative to baseline, were evaluated.</description>
          <population>All treated participants in the DB period. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>ng / mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>E-Selectin Day 169 (n= 256, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.8" spread="3.28"/>
                    <measurement group_id="O2" value="-6.52" spread="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SICAM-1 Day 169 (n=264, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-65.0" spread="9.87"/>
                    <measurement group_id="O2" value="-42.0" spread="17.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMP3 Day 169 (n=362, 183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.2" spread="2.85"/>
                    <measurement group_id="O2" value="-8.03" spread="3.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>E-Selectin Day 365 (n=162, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.4" spread="4.37"/>
                    <measurement group_id="O2" value="-9.94" spread="5.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SICAM-1 Day 365 (n=235, 114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-80.0" spread="27.20"/>
                    <measurement group_id="O2" value="-43.7" spread="16.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMP3 Day 365 (n=232, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.0" spread="4.09"/>
                    <measurement group_id="O2" value="-12.1" spread="5.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) for the Day 365 Cohort of Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 365</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) for the Day 365 Cohort of Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=369, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="0.63"/>
                    <measurement group_id="O2" value="1.70" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=372, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="0.75"/>
                    <measurement group_id="O2" value="1.49" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=372, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.82"/>
                    <measurement group_id="O2" value="1.46" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=372, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.97"/>
                    <measurement group_id="O2" value="1.68" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=372, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.83"/>
                    <measurement group_id="O2" value="1.37" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=370, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="0.90"/>
                    <measurement group_id="O2" value="1.91" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=370, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.86"/>
                    <measurement group_id="O2" value="1.97" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=371, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="0.76"/>
                    <measurement group_id="O2" value="1.90" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=369, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.79"/>
                    <measurement group_id="O2" value="1.86" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 365 for Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 365</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 365 for Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=369, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.03"/>
                    <measurement group_id="O2" value="-0.51" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=372, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="0.04"/>
                    <measurement group_id="O2" value="-0.62" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=372, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.05"/>
                    <measurement group_id="O2" value="-0.59" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=372, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.05"/>
                    <measurement group_id="O2" value="-0.46" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=372, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="0.04"/>
                    <measurement group_id="O2" value="-0.48" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=370, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.05"/>
                    <measurement group_id="O2" value="-0.36" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=370, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="0.05"/>
                    <measurement group_id="O2" value="-0.60" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=371, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.05"/>
                    <measurement group_id="O2" value="-0.49" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=369, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="0.05"/>
                    <measurement group_id="O2" value="-0.47" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) for the Day 449 Cohort of Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 449</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) for the Day 449 Cohort of Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=366, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.64"/>
                    <measurement group_id="O2" value="1.71" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=367, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="0.75"/>
                    <measurement group_id="O2" value="1.49" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=367, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.83"/>
                    <measurement group_id="O2" value="1.46" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=367, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="0.97"/>
                    <measurement group_id="O2" value="1.67" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=367, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.83"/>
                    <measurement group_id="O2" value="1.37" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=367, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="0.90"/>
                    <measurement group_id="O2" value="1.92" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n= 367, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.86"/>
                    <measurement group_id="O2" value="1.97" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=368, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="0.75"/>
                    <measurement group_id="O2" value="1.90" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=367, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.79"/>
                    <measurement group_id="O2" value="1.87" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 449 for Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 449</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 449 for Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=366, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.03"/>
                    <measurement group_id="O2" value="-0.71" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=367, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="0.04"/>
                    <measurement group_id="O2" value="-0.85" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=367, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="0.05"/>
                    <measurement group_id="O2" value="-0.86" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=367, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.05"/>
                    <measurement group_id="O2" value="-0.63" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=367, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="0.05"/>
                    <measurement group_id="O2" value="-0.61" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=367, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.05"/>
                    <measurement group_id="O2" value="-0.59" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n= 367, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.05"/>
                    <measurement group_id="O2" value="-0.76" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=368, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" spread="0.05"/>
                    <measurement group_id="O2" value="-0.73" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=367, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.05"/>
                    <measurement group_id="O2" value="-0.65" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) for the Day 533 Cohort of Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 533</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) for the Day 533 Cohort of Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=354, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.64"/>
                    <measurement group_id="O2" value="1.71" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=355, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="0.75"/>
                    <measurement group_id="O2" value="1.49" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=355, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.84"/>
                    <measurement group_id="O2" value="1.45" spread=".078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=355, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="0.98"/>
                    <measurement group_id="O2" value="1.67" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=351, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.84"/>
                    <measurement group_id="O2" value="1.37" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=354, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.91"/>
                    <measurement group_id="O2" value="1.92" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=354, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="0.86"/>
                    <measurement group_id="O2" value="1.97" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=354, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="0.76"/>
                    <measurement group_id="O2" value="1.91" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=354, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="0.79"/>
                    <measurement group_id="O2" value="1.87" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 533 for Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 533</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 533 for Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=354, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" spread="0.04"/>
                    <measurement group_id="O2" value="-0.73" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=355, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" spread="0.05"/>
                    <measurement group_id="O2" value="-0.85" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=355, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="0.05"/>
                    <measurement group_id="O2" value="-0.86" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=355, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.05"/>
                    <measurement group_id="O2" value="-0.74" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=351, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" spread="0.05"/>
                    <measurement group_id="O2" value="-0.69" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=354, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" spread="0.05"/>
                    <measurement group_id="O2" value="-0.57" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=354, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="0.05"/>
                    <measurement group_id="O2" value="-0.57" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=354, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.05"/>
                    <measurement group_id="O2" value="-0.74" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=354, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.05"/>
                    <measurement group_id="O2" value="-0.68" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 617 Cohort of Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 617</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 617 Cohort of Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=348, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.64"/>
                    <measurement group_id="O2" value="1.71" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=348, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="0.75"/>
                    <measurement group_id="O2" value="1.50" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=348, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.84"/>
                    <measurement group_id="O2" value="1.46" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=348, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="0.97"/>
                    <measurement group_id="O2" value="1.68" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=348, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.83"/>
                    <measurement group_id="O2" value="1.37" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=348, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="0.90"/>
                    <measurement group_id="O2" value="1.92" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=348, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="0.86"/>
                    <measurement group_id="O2" value="1.97" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=348, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="0.75"/>
                    <measurement group_id="O2" value="1.91" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=348, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="0.79"/>
                    <measurement group_id="O2" value="1.87" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 617 for Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 617</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 617 for Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=348, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" spread="0.04"/>
                    <measurement group_id="O2" value="-0.74" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=348, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="0.05"/>
                    <measurement group_id="O2" value="-0.82" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=348, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" spread="0.05"/>
                    <measurement group_id="O2" value="-0.81" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=348, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.05"/>
                    <measurement group_id="O2" value="-0.75" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=348, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="0.05"/>
                    <measurement group_id="O2" value="-0.67" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=348, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="0.05"/>
                    <measurement group_id="O2" value="-0.66" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=348, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" spread="0.05"/>
                    <measurement group_id="O2" value="-0.80" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=348, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.05"/>
                    <measurement group_id="O2" value="-0.68" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=348, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="0.05"/>
                    <measurement group_id="O2" value="-0.76" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 729 Cohort of Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 729</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 729 Cohort of Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=337, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.64"/>
                    <measurement group_id="O2" value="1.72" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=337, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="0.76"/>
                    <measurement group_id="O2" value="1.51" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=338, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="0.83"/>
                    <measurement group_id="O2" value="1.45" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n= 337, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.98"/>
                    <measurement group_id="O2" value="1.72" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=338, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="0.84"/>
                    <measurement group_id="O2" value="1.37" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=338, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="0.89"/>
                    <measurement group_id="O2" value="1.93" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=336, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="0.87"/>
                    <measurement group_id="O2" value="1.97" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=338, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="0.77"/>
                    <measurement group_id="O2" value="1.92" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=338, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" spread="0.79"/>
                    <measurement group_id="O2" value="1.89" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 729 for Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 729</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 729 for Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=337, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" spread="0.04"/>
                    <measurement group_id="O2" value="-0.72" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=337, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.05"/>
                    <measurement group_id="O2" value="-0.91" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=338, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.05"/>
                    <measurement group_id="O2" value="-0.82" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n= 337, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" spread="0.05"/>
                    <measurement group_id="O2" value="-0.72" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=338, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.05"/>
                    <measurement group_id="O2" value="-0.63" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=338, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.05"/>
                    <measurement group_id="O2" value="-0.62" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=336, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="0.05"/>
                    <measurement group_id="O2" value="-0.73" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=338, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.05"/>
                    <measurement group_id="O2" value="-0.62" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=338, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="0.05"/>
                    <measurement group_id="O2" value="-0.72" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 813 Cohort of Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 813</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 813 Cohort of Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=325, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="0.64"/>
                    <measurement group_id="O2" value="1.72" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=325, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="0.75"/>
                    <measurement group_id="O2" value="1.51" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=325, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.83"/>
                    <measurement group_id="O2" value="1.46" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=325, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="0.98"/>
                    <measurement group_id="O2" value="1.70" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=324, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.83"/>
                    <measurement group_id="O2" value="1.38" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=325, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="0.89"/>
                    <measurement group_id="O2" value="1.94" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=324, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="0.87"/>
                    <measurement group_id="O2" value="1.97" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=325, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="0.77"/>
                    <measurement group_id="O2" value="1.92" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=324, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.79"/>
                    <measurement group_id="O2" value="1.87" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 813 for Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 813</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 813 for Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=325, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="0.04"/>
                    <measurement group_id="O2" value="-0.71" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=325, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.06"/>
                    <measurement group_id="O2" value="-0.87" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=325, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.05"/>
                    <measurement group_id="O2" value="-0.78" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=325, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="0.06"/>
                    <measurement group_id="O2" value="-0.72" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=324, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="0.05"/>
                    <measurement group_id="O2" value="-0.66" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=325, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.06"/>
                    <measurement group_id="O2" value="-0.53" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=324, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.85" spread="0.05"/>
                    <measurement group_id="O2" value="-0.72" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=325, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="0.05"/>
                    <measurement group_id="O2" value="-0.77" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=324, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="0.05"/>
                    <measurement group_id="O2" value="-0.71" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 897 Cohort of Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 897</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 897 Cohort of Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=318, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.64"/>
                    <measurement group_id="O2" value="1.72" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=319, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="0.76"/>
                    <measurement group_id="O2" value="1.52" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=319, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="0.84"/>
                    <measurement group_id="O2" value="1.46" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=319, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.99"/>
                    <measurement group_id="O2" value="1.71" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=319, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="0.84"/>
                    <measurement group_id="O2" value="1.38" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=319, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="0.90"/>
                    <measurement group_id="O2" value="1.94" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=319, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="0.87"/>
                    <measurement group_id="O2" value="2.01" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=319, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="0.76"/>
                    <measurement group_id="O2" value="1.92" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=319, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.79"/>
                    <measurement group_id="O2" value="1.87" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 897 for Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 897</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 897 for Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=318, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="0.04"/>
                    <measurement group_id="O2" value="-0.74" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=319, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="0.05"/>
                    <measurement group_id="O2" value="-0.90" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=319, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" spread="0.05"/>
                    <measurement group_id="O2" value="-0.87" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=319, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="0.05"/>
                    <measurement group_id="O2" value="-0.78" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=319, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="0.05"/>
                    <measurement group_id="O2" value="-0.67" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=319, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="0.06"/>
                    <measurement group_id="O2" value="-0.54" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=319, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.06"/>
                    <measurement group_id="O2" value="-0.74" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=319, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" spread="0.06"/>
                    <measurement group_id="O2" value="-0.74" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=319, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="0.05"/>
                    <measurement group_id="O2" value="-0.71" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 981 Cohort of Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 981</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 981 Cohort of Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.65"/>
                    <measurement group_id="O2" value="1.72" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="0.76"/>
                    <measurement group_id="O2" value="1.52" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.84"/>
                    <measurement group_id="O2" value="1.45" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.99"/>
                    <measurement group_id="O2" value="1.70" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=308, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="0.84"/>
                    <measurement group_id="O2" value="1.37" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.89"/>
                    <measurement group_id="O2" value="1.93" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="0.86"/>
                    <measurement group_id="O2" value="1.99" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="0.78"/>
                    <measurement group_id="O2" value="1.92" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.79"/>
                    <measurement group_id="O2" value="1.85" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 981 for Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 981</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 981 for Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" spread="0.04"/>
                    <measurement group_id="O2" value="-0.69" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.05"/>
                    <measurement group_id="O2" value="-0.86" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.05"/>
                    <measurement group_id="O2" value="-0.77" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" spread="0.06"/>
                    <measurement group_id="O2" value="-0.64" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=308, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="0.05"/>
                    <measurement group_id="O2" value="-0.63" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.06"/>
                    <measurement group_id="O2" value="-0.49" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.05"/>
                    <measurement group_id="O2" value="-0.75" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.06"/>
                    <measurement group_id="O2" value="-0.74" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=312, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" spread="0.05"/>
                    <measurement group_id="O2" value="-0.64" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 1,093 Cohort of Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 1,093</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 1,093 Cohort of Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=308, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.64"/>
                    <measurement group_id="O2" value="1.72" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=310, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="0.75"/>
                    <measurement group_id="O2" value="1.51" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=309, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="0.84"/>
                    <measurement group_id="O2" value="1.45" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=309, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.98"/>
                    <measurement group_id="O2" value="1.69" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=308, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="0.83"/>
                    <measurement group_id="O2" value="1.36" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=310, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.89"/>
                    <measurement group_id="O2" value="1.92" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=310, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="0.87"/>
                    <measurement group_id="O2" value="1.99" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=310, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" spread="0.77"/>
                    <measurement group_id="O2" value="1.92" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=310, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.79"/>
                    <measurement group_id="O2" value="1.85" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 1,093 for Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 1,093</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 1,093 for Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=308, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" spread="0.04"/>
                    <measurement group_id="O2" value="-0.76" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=310, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.05"/>
                    <measurement group_id="O2" value="-0.91" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=309, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.05"/>
                    <measurement group_id="O2" value="-0.87" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=309, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" spread="0.06"/>
                    <measurement group_id="O2" value="-0.70" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=308, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.05"/>
                    <measurement group_id="O2" value="-0.69" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=310, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.05"/>
                    <measurement group_id="O2" value="-0.59" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=310, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="0.05"/>
                    <measurement group_id="O2" value="-0.81" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=310, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="0.06"/>
                    <measurement group_id="O2" value="-0.74" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=310, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="0.05"/>
                    <measurement group_id="O2" value="-0.73" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 1,177 Cohort of Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 1,177</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 1,177 Cohort of Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=274, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.63"/>
                    <measurement group_id="O2" value="1.71" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=274, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="0.76"/>
                    <measurement group_id="O2" value="1.53" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=274, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="0.81"/>
                    <measurement group_id="O2" value="1.45" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=274, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="0.97"/>
                    <measurement group_id="O2" value="1.70" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=272, 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread="0.83"/>
                    <measurement group_id="O2" value="1.37" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=275, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.89"/>
                    <measurement group_id="O2" value="1.90" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=275, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="0.85"/>
                    <measurement group_id="O2" value="1.99" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=275, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="0.75"/>
                    <measurement group_id="O2" value="1.91" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=275, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.80"/>
                    <measurement group_id="O2" value="1.85" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 1,177 for Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 1,177</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 1,177 for Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=274, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="0.04"/>
                    <measurement group_id="O2" value="-0.74" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=274, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.05"/>
                    <measurement group_id="O2" value="-0.86" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=274, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" spread="0.06"/>
                    <measurement group_id="O2" value="-0.79" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=274, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" spread="0.06"/>
                    <measurement group_id="O2" value="-0.74" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=272, 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.06"/>
                    <measurement group_id="O2" value="-0.66" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=275, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.06"/>
                    <measurement group_id="O2" value="-0.48" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=275, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.06"/>
                    <measurement group_id="O2" value="-0.84" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=275, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.06"/>
                    <measurement group_id="O2" value="-0.80" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=275, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.06"/>
                    <measurement group_id="O2" value="-0.76" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 1,261 Cohort of Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 1,261</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 1,261 Cohort of Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=292, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.65"/>
                    <measurement group_id="O2" value="1.70" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=292, 135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="0.77"/>
                    <measurement group_id="O2" value="1.51" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=292, 135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.85"/>
                    <measurement group_id="O2" value="1.44" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=292, 135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="1.00"/>
                    <measurement group_id="O2" value="1.69" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=290, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.83"/>
                    <measurement group_id="O2" value="1.36" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=292, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="0.90"/>
                    <measurement group_id="O2" value="1.92" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=292, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="0.87"/>
                    <measurement group_id="O2" value="1.97" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=292, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" spread="0.77"/>
                    <measurement group_id="O2" value="1.91" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=292, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.81"/>
                    <measurement group_id="O2" value="1.83" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 1,261 for Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 1,261</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 1,261 for Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=292, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" spread="0.04"/>
                    <measurement group_id="O2" value="-0.73" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=292, 135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" spread="0.05"/>
                    <measurement group_id="O2" value="-0.91" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=292, 135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.05"/>
                    <measurement group_id="O2" value="-0.82" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=292, 135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.85" spread="0.06"/>
                    <measurement group_id="O2" value="-0.73" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=290, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="0.06"/>
                    <measurement group_id="O2" value="-0.63" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=292, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.06"/>
                    <measurement group_id="O2" value="-0.54" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=292, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.06"/>
                    <measurement group_id="O2" value="-0.80" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=292, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.06"/>
                    <measurement group_id="O2" value="-0.70" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=292, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.05"/>
                    <measurement group_id="O2" value="-0.68" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 1,345 Cohort of Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 1,345</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 1,345 Cohort of Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=152, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="0.63"/>
                    <measurement group_id="O2" value="1.73" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=152, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="0.73"/>
                    <measurement group_id="O2" value="1.50" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=152, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread="0.79"/>
                    <measurement group_id="O2" value="1.44" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=152, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.97"/>
                    <measurement group_id="O2" value="1.69" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=151, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="0.80"/>
                    <measurement group_id="O2" value="1.35" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=152, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="0.89"/>
                    <measurement group_id="O2" value="2.05" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=152, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="0.82"/>
                    <measurement group_id="O2" value="2.06" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=152, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="0.74"/>
                    <measurement group_id="O2" value="1.94" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=152, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="0.79"/>
                    <measurement group_id="O2" value="1.79" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 1,345 for Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 1,345</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 1,345 for Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=152, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="0.06"/>
                    <measurement group_id="O2" value="-0.73" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=152, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" spread="0.07"/>
                    <measurement group_id="O2" value="-0.81" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=152, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.08"/>
                    <measurement group_id="O2" value="-0.84" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=152, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" spread="0.08"/>
                    <measurement group_id="O2" value="-0.68" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=151, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" spread="0.07"/>
                    <measurement group_id="O2" value="-0.60" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=152, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="0.09"/>
                    <measurement group_id="O2" value="-0.71" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=152, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" spread="0.08"/>
                    <measurement group_id="O2" value="-0.76" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=152, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.08"/>
                    <measurement group_id="O2" value="-0.82" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=152, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" spread="0.08"/>
                    <measurement group_id="O2" value="-0.60" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 1,457 Cohort of Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 1,457</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 1,457 Cohort of Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=289, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="0.65"/>
                    <measurement group_id="O2" value="1.71" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=289, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="0.76"/>
                    <measurement group_id="O2" value="1.51" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=289, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="0.85"/>
                    <measurement group_id="O2" value="1.44" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=289, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="1.00"/>
                    <measurement group_id="O2" value="1.70" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=287, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.83"/>
                    <measurement group_id="O2" value="1.37" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=289, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="0.89"/>
                    <measurement group_id="O2" value="1.91" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=289, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="0.86"/>
                    <measurement group_id="O2" value="1.99" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=289, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="0.77"/>
                    <measurement group_id="O2" value="1.91" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=289, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="0.80"/>
                    <measurement group_id="O2" value="1.84" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 1,457 for Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 1,457</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 1,457 for Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=289, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="0.04"/>
                    <measurement group_id="O2" value="-0.74" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=289, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.85" spread="0.06"/>
                    <measurement group_id="O2" value="-0.91" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=289, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.05"/>
                    <measurement group_id="O2" value="-0.82" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=289, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.89" spread="0.06"/>
                    <measurement group_id="O2" value="-0.81" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=287, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.05"/>
                    <measurement group_id="O2" value="-0.63" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=289, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.06"/>
                    <measurement group_id="O2" value="-0.59" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=289, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" spread="0.06"/>
                    <measurement group_id="O2" value="-0.76" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=289, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="0.06"/>
                    <measurement group_id="O2" value="-0.71" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=289, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="0.06"/>
                    <measurement group_id="O2" value="-0.74" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 1,625 Cohort of Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 1,625</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 1,625 Cohort of Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=280, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.65"/>
                    <measurement group_id="O2" value="1.72" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=280, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" spread="0.77"/>
                    <measurement group_id="O2" value="1.52" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=280, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.85"/>
                    <measurement group_id="O2" value="1.45" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=280, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.99"/>
                    <measurement group_id="O2" value="1.69" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=279, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="0.84"/>
                    <measurement group_id="O2" value="1.37" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=280, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.90"/>
                    <measurement group_id="O2" value="1.93" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=280, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="0.85"/>
                    <measurement group_id="O2" value="2.00" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=280, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="0.77"/>
                    <measurement group_id="O2" value="1.93" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=280, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="0.80"/>
                    <measurement group_id="O2" value="1.87" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 1,625 for Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 1,625</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 1,625 for Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=280, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="0.04"/>
                    <measurement group_id="O2" value="-0.78" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=280, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" spread="0.06"/>
                    <measurement group_id="O2" value="-0.98" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=280, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="0.06"/>
                    <measurement group_id="O2" value="-0.84" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=280, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.06"/>
                    <measurement group_id="O2" value="-0.79" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=279, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.06"/>
                    <measurement group_id="O2" value="-0.74" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=280, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="0.06"/>
                    <measurement group_id="O2" value="-0.57" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=280, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.06"/>
                    <measurement group_id="O2" value="-0.81" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=280, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.06"/>
                    <measurement group_id="O2" value="-0.76" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=280, 126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="0.06"/>
                    <measurement group_id="O2" value="-0.76" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 1,821 Cohort of Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 1,821</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 1,821 Cohort of Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.65"/>
                    <measurement group_id="O2" value="1.69" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="0.77"/>
                    <measurement group_id="O2" value="1.49" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="0.83"/>
                    <measurement group_id="O2" value="1.42" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=273, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="1.00"/>
                    <measurement group_id="O2" value="1.67" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=271, 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="0.84"/>
                    <measurement group_id="O2" value="1.34" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="0.90"/>
                    <measurement group_id="O2" value="1.88" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="0.86"/>
                    <measurement group_id="O2" value="1.97" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" spread="0.78"/>
                    <measurement group_id="O2" value="1.90" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="0.81"/>
                    <measurement group_id="O2" value="1.82" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 1,821 for Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 1,821</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 1,821 for Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="0.44"/>
                    <measurement group_id="O2" value="-0.72" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.06"/>
                    <measurement group_id="O2" value="-0.86" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.06"/>
                    <measurement group_id="O2" value="-0.90" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=273, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="0.07"/>
                    <measurement group_id="O2" value="-0.78" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=271, 122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.06"/>
                    <measurement group_id="O2" value="-0.61" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="0.07"/>
                    <measurement group_id="O2" value="-0.53" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.06"/>
                    <measurement group_id="O2" value="-0.74" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="0.06"/>
                    <measurement group_id="O2" value="-0.80" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=273, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="0.06"/>
                    <measurement group_id="O2" value="-0.61" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 1,989 Cohort of Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 1,989</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 1,989 Cohort of Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=119, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="0.61"/>
                    <measurement group_id="O2" value="1.67" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=119, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="0.72"/>
                    <measurement group_id="O2" value="1.49" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=119, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="0.78"/>
                    <measurement group_id="O2" value="1.38" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=119, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" spread="0.99"/>
                    <measurement group_id="O2" value="1.62" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=117, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="0.79"/>
                    <measurement group_id="O2" value="1.30" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=119, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.94"/>
                    <measurement group_id="O2" value="1.89" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=119, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" spread="0.81"/>
                    <measurement group_id="O2" value="1.98" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=119, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" spread="0.74"/>
                    <measurement group_id="O2" value="1.87" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=119, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="0.81"/>
                    <measurement group_id="O2" value="1.84" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 1,989 for Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 1,989</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 1,989 for Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=119, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" spread="0.07"/>
                    <measurement group_id="O2" value="-0.70" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=119, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" spread="0.09"/>
                    <measurement group_id="O2" value="-0.76" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=119, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="0.08"/>
                    <measurement group_id="O2" value="-0.84" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=119, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.10"/>
                    <measurement group_id="O2" value="-0.62" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=117, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="0.09"/>
                    <measurement group_id="O2" value="-0.67" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=119, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="0.11"/>
                    <measurement group_id="O2" value="-0.58" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=119, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.89" spread="0.10"/>
                    <measurement group_id="O2" value="-0.75" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=119, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="0.10"/>
                    <measurement group_id="O2" value="-0.67" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=119, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" spread="0.10"/>
                    <measurement group_id="O2" value="-0.71" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 2,185 Cohort of Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BL HAQ-DI Score and HAQ-DI Individual Component Scores at BL (Day 0) of the Day 2,185 Cohort of Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="0.55"/>
                    <measurement group_id="O2" value="1.69" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=85, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="0.70"/>
                    <measurement group_id="O2" value="1.54" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="0.72"/>
                    <measurement group_id="O2" value="1.37" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="0.96"/>
                    <measurement group_id="O2" value="1.58" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=84, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="0.73"/>
                    <measurement group_id="O2" value="1.37" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" spread="0.91"/>
                    <measurement group_id="O2" value="1.97" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="0.79"/>
                    <measurement group_id="O2" value="2.03" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" spread="0.73"/>
                    <measurement group_id="O2" value="1.84" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" spread="0.70"/>
                    <measurement group_id="O2" value="1.84" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 2,185 for Participants Continuing in the OL Period</title>
        <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
        <time_frame>BL (Day 0), Day 2,185</time_frame>
        <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX DB</title>
            <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
          <group group_id="O2">
            <title>MTX + Placebo DB</title>
            <description>Participants that received MTX + placebo in the DB treatment period (Day 1 to Day 365) but are currently receiving treatment with ABA +MTX in the OL period. Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From BL in HAQ-DI Score and HAQ-DI Individual Component Scores at Day 2,185 for Participants Continuing in the OL Period</title>
          <description>The HAQ-DI includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. HAQ-DI=sum of worst scores in each domain dividied by the number of domains answered. HAQ-DI ranges from 0 to a maximum overall score of 3.0. Clinically meaningful HAQ response was defined as an improvement of at least 0.3 units from baseline in HAQ DI.</description>
          <population>All treated participants in the OL period (Treatment groups represent treatment received in the DB period). Due to the non-compliance of a single site, 3 participants were not included in this analysis. N = number of participants analyzed and n = the number of participants with measurements for that time point.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ DI (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.08"/>
                    <measurement group_id="O2" value="-0.68" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dressing and Grooming (n=85, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.10"/>
                    <measurement group_id="O2" value="-0.78" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arising (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="0.11"/>
                    <measurement group_id="O2" value="-0.82" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.11"/>
                    <measurement group_id="O2" value="-0.74" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (n=84, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" spread="0.11"/>
                    <measurement group_id="O2" value="-0.58" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hygiene (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.13"/>
                    <measurement group_id="O2" value="-0.68" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reaching (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="0.12"/>
                    <measurement group_id="O2" value="-0.66" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gripping (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" spread="0.11"/>
                    <measurement group_id="O2" value="-0.47" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (n=85, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.10"/>
                    <measurement group_id="O2" value="-0.68" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ABA + MTX OL</title>
          <description>Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing &lt; 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants &gt; 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.</description>
        </group>
        <group group_id="E2">
          <title>ABA + MTX DB</title>
          <description>Abatacept was dosed intravenously by weight with participants weighing &lt; 60 kg received 500 mg, participants weighing 60 kg to 100 kg received 750 mg, and participants weighing &gt; 100 kg received 1 gram. Study medication was administered on Days 1, 15, 29, and every 28 days thereafter for a total of 14 doses. Each dose was infused intravenously over approximately 30 minutes on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337. Participants also received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity.</description>
        </group>
        <group group_id="E3">
          <title>MTX + Placebo DB</title>
          <description>Control group receiving MTX treatment in combination with placebo. Participants received MTX at a minimum dose of 10-30 mg/wk, although doses of &lt; 10 mg/wk were acceptable if due to toxicity. Placebo and MTX were administered IV on Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="215" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>DISSEMINATED INTRAVASCULAR COAGULATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA PAROXYSMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>STRABISMUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>VITREOUS DETACHMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PEPTIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>RECTAL POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ABDOMINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ANAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>GASTRODUODENITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>COLITIS ULCERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ABDOMINAL HERNIA OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ABDOMINAL STRANGULATED HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>MESENTERIC VASCULAR INSUFFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>IMPAIRED HEALING</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>HERNIA OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PARONYCHIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ABSCESS JAW</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>DACRYOCYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>DOUGLAS' ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>HERPES DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PERIRECTAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ARTHRITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>LOCALISED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PERINEPHRIC ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>TUBERCULOUS PLEURISY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>SOFT TISSUE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ABDOMINAL WALL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>HERPES VIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PULMONARY TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>INCISION SITE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SKIN INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>BRONCHOPULMONARY ASPERGILLOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>EYE INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>FOOT FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ULNA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>GUN SHOT WOUND</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>MENISCUS LESION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>SPINAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>WOUND DEHISCENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ALCOHOL POISONING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>FAILURE OF IMPLANT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>TRAUMATIC FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ACCIDENTAL OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PROCEDURAL VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>VASCULAR PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>INCORRECT DOSE ADMINISTERED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>MEDICAL DEVICE COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>DISLOCATION OF JOINT PROSTHESIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ARTERIOGRAM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>LABORATORY TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM ST SEGMENT ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>OBESITY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>BURSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>BONE CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>SYNOVITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>MONARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>METATARSALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>OSTEONECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>SYNOVIAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>FOOT DEFORMITY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>RHEUMATOID NODULE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>SPONDYLOLISTHESIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>MUSCLE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>SOFT TISSUE NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>OSTEOPOROTIC FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>SPINAL COLUMN STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>SYSTEMIC LUPUS ERYTHEMATOSUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>LEIOMYOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CARDIAC MYXOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>THYROID NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>UTERINE LEIOMYOMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>METASTATIC NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>BENIGN BREAST NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>FIBROADENOMA OF BREAST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>MYELODYSPLASTIC SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>NEUROENDOCRINE CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA IN SITU</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ACUTE LYMPHOCYTIC LEUKAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>BRONCHIOLOALVEOLAR CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>LYMPHOPROLIFERATIVE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>METASTATIC MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF SKIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT TYPE)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>APHASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>OPTIC NEURITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>POLYNEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>TENSION HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>NERVE COMPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CERVICAL MYELOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CARPAL TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>COMPLEX REGIONAL PAIN SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL COLIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CALCULUS BLADDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>CYSTOCELE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>RECTOCELE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>METRORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>OVARIAN CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ENDOMETRIOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>UTERINE POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>UTERINE PROLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>BREAST CALCIFICATIONS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>TONSILLAR INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>INGROWING NAIL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>DERMATOMYOSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>VARICOSE VEIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>AORTIC ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ARTERIAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>AORTIC ANEURYSM RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ARTERIAL THROMBOSIS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="466" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="320" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="144" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>TENDONITIS</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>RHINITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="539"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="433"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>BMS Study Director</name_or_title>
      <organization>Bristol Myers-Squibb</organization>
      <email>clinical.trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

